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Abstract 
Radiopharmaceuticals are the fundamental tool for nuclear medicine procedures, 
enabling imaging and therapy of cancer after administration of a radioligand. Imaging 
or therapy are performed with radionuclides that are bound to a ligand, which 
selectively accumulates into cancer tissues. The discovery of new radionuclides on one 
side and the optimization of ligands on the other are fundamental parts of the research in 
the radiopharmaceutical field.  
In the first part of this thesis work we aimed at the development of a new technique for 
the production of pure radionuclides. The study was born from the collaboration 
between the Department of Pharmaceutical and Pharmacological Sciences (DSF) of the 
University of Padua (UniPD) and the Legnaro National Laboratories (LNL) of the 
National Institute for Nuclear Physics (INFN), where the Selective Production of Exotic 
Species (SPES) project is under development. This project aims at the production of 
Radioactive Ion Beams (RIBs) by means of the Isotope Separation On-Line technique 
(ISOL), which can be exploited for radionuclides production. Thanks to mass 
separation, a feature of the ISOL technique, radionuclides can be produced at high 
purity because isotopic contaminants can be cleared away easily. Suitable secondary 
targets (chapter 2) were developed to allow ion beams collection, depending on the 
accelerated ions. To verify the suitability of the method for radionuclides production, 
tests with accelerated stable ion beams were carried out and are described in chapter 3. 
The SPES test bench was used for the elements ionization and acceleration. The beams 
were collected on the produced secondary targets and quantified. The tests were carried 
out for yttrium, iodine and copper, elements interesting for the production of 90Y, 
125/127/131I and 64/67Cu. The ISOL method guarantees the purification of the radionuclides 
from the isotopic contaminants, but isobaric and pseudo-isobaric contaminants can be 
present in the beam and thus in the final solution. For this reason, chemical purification 
methods have to be developed for radionuclides purification. In chapter 4 the synthesis 
of an inorganic material (sodium nonatitanate) and its use for strontium and yttrium 
purification is described.  
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The second part of this thesis, chapters 5 and 6, was developed in collaboration with the 
group of PD Dr. Cristina Müller at the Center for Radiopharmaceutical Sciences (CRS) 
of Paul Scherrer Institute (PSI).  
Targeted radionuclide therapy (TRT) represents one of the most promising therapeutic 
strategies for cancer therapy ; it is based on the use of energetic particles (, - or Auger 
electrons) selectively delivered in proximity of tumors thanks to specific biologic 
features. Small molecules are an attractive strategy for active targeted delivery because 
they are amenable for chemical synthesis and have some advantages if compared with 
high molecular weight vehicles, such as antibodies. 
A potential challenge of small molecular radiotherapeutics is their fast elimination from 
the body preventing sufficient accumulation of radioactivity in the malignancies due to 
glomerular filtration and fast renal clearance; high accumulation of radioactivity in the 
kidneys increases at the same time the risk of nephrotoxicity. For this reason, new 
strategies to allow a higher translation from preclinical to clinical phase of small 
molecule-based radiopharmaceuticals should be developed.  
In this thesis project two strategies to improve TRT with small molecules were 
developed. The first relies on the development of radioligands with a serum protein-
binding domain. This strategy is based on the consideration that serum proteins have 
high molecular weight, and for this reason do not undergo glomerular filtration 
(filtration cut-off 30-50 kDa). In particular, three serum proteins-binding compounds 
were radiolabeled and characterized in vitro and in vivo (chapter 5). 
Another strategy to improve TRT efficacy while decreasing side effects is the use of 
combined-modality regimens. This approach is very popular in cancer therapy since 
targeting the cancer cell on diverse molecular path mechanisms makes the cell less 
prone to developing resistance to the therapy. At the same time, the use of 
multimodality therapies allows to decrease the dosage of single therapies, thus reducing 
side-effects. In the last chapter of this thesis (chapter 6) a preliminary study combining 
radionuclide therapy (177Lu-cm10) with two tyrosine kinases inhibitors is described, 
based on the assumptions of a possible synergistic effect of the two agents. 
 
  
Riassunto 
I radiofarmaci rappresentano uno strumento fondamentale per la medicina nucleare, 
rendendo possibile, grazie alla somministrazione di un radioligando, procedure 
diagnostiche e terapeutiche in ambito oncologico. I radiofarmaci sono costituiti da un 
radionuclide e da un ligando; quest’ultimo permette la localizzazione della radioattività 
solamente nei tessuti bersaglio. La ricerca in ambito radiofarmaceutico è dedicata sia 
alla scoperta di nuovi radionuclidi, sia all’ottimizzazione dei ligandi.  
Scopo della prima parte di questo lavoro di tesi è stato lo studio e lo sviluppo di una 
tecnica innovativa per la produzione di radionuclidi ad alta purezza per la medicina 
nucleare. Lo studio è nato dalla collaborazione presente tra il Dipartimento di Scienze 
del Farmaco (DSF) dell’Università di Padova (UniPD) e i Laboratori Nazionali di 
Legnaro (LNL) dell’Istituto Nazionale di Fisica Nucleare (INFN). Presso questi ultimi, 
infatti, è in fase di costruzione il progetto Selective Production of Exotic Species 
(SPES), che prevede la produzione di fasci di ioni radioattivi (RIBs), prodotti tramite la 
tecnologia Isotope Separation On Line (ISOL). La separazione in massa prevista dalla 
tecnica ISOL, la rende un’ottima via di produzione di radionuclidi, perché permette di 
eliminare tutti i contaminanti isotopici del radionuclide d’interesse.  
Per la deposizione dei fasci sono stati sviluppati e costruiti dei bersagli secondari; questi 
oggetti, posizionati alla fine della linea di fascio, sono utilizzati per depositare e 
recuperare gli ioni accelerati. La progettazione e realizzazione di tali bersagli è descritta 
nel capitolo 2. In seguito, con lo scopo di verificare la possibilità di utilizzare l’apparato 
sperimentale di SPES per la produzione di radionuclidi per la medicina nucleare, sono 
stati condotti dei test utilizzando fasci di ioni stabili degli elementi di interesse, in 
particolare sono stati studiati fasci di ittrio, iodio e rame, ai fini della produzione futura 
di 90Y, 125/127/131I e 64/67Cu.  
Il metodo ISOL consente grazie alla separazione in massa di purificare i radionuclidi dai 
contaminanti isotopici, ma contaminanti isobarici e pseudo-isobarici devono essere 
rimossi tramite altri metodi, in particolare tramite metodi chimici. Per questo motivo nel 
capitolo 4 vengono descritti la sintesi e l’uso di una resina inorganica a scambio ionico 
per la purificazione di ittrio e stronzio.  
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La seconda parte di questa tesi è stata sviluppata in collaborazione con il Center 
forRadiopharmaceutcal Sciences (CRS) presso il Paul Scherrer Institute (PSI), Villigen 
(CH), in particolare nel gruppo della Dott.ssa PD Cristina Müller. 
La targeted radionuclide therapy (TRT) è un strategia terapeutica molto promettente in 
campo oncologico e si basa sull’uso radionuclidi che emottono particelle ad energia 
medio-alta (, - o elettroni di Auger) che vengono selettivamente direzionati nel 
tessuto canceroso in seguito al riconoscimento di una particolare caratteristica della 
cellula tumorale. L’utilizzo di piccole molecole per il direzionamento dei radionuclidi 
rappresenta una strategia vantaggiosa rispetto all’uso di veicoli ad alto peso molecolare 
(come gli anticorpi monoclonali) ed inoltre possono essere prodotte tramite sintesi 
chimica. Tuttavia, nonostante il successo di alcune small molecules in clinica, molte 
volte questa tipologia di radiofarmaci va incontro ad una veloce eliminazione ematica a 
causa della loro filtrazione glomerulare. In questo modo l’acccumulo della radioattivià 
nel tumore è diminuito, mentre può esserci un accumulo indesiderato nei reni con 
aumentato rischio di nefrotossicità.  
In questa tesi vengono descritte due strategie per il miglioramento della TRT basata 
sull’uso di piccole molecole. La prima prevede la modifica della struttura chimica dei 
ligandi con un dominio di legame alle proteine plasmatiche. Questa strategia permette, 
infatti, di evitare la filtrazione glomerulare del radioligando. Questo, se dopo la 
somministrazione si lega in modo reversibile ad una proteina plasmatica, viene ad 
assumere un peso molecolare >30 kDa, valore del cut-off della filtrazione nel glomerulo 
ed aumenta per questo motivo la sua emivita plasmatica. Nel capitolo 5 vengono 
descritte la radiomarcatura e la caratterizzazione in vitro ed in vivo di tre radioligandi  
con affinità per le proteine plasmatiche.  
La seconda strategia è quella dello sviluppo di terapie combinate con altri agenti 
chemioterapeutici. Questo approccio è molto popolare in quanto permette da una parte 
di ridurre le dosi dei singoli agenti e ridurre così gli effetti collaterali, dall’altra di 
ridurre la resistenza alla terapia. Nel capitolo 6 della tesi, è descritto lo studio 
preliminare dell’associazione di un radioligando per la terapia (177Lu-cm10) con due 
inibitori tirosin chinasici.  
 
 
  
Chapter 1 
Production of radionuclides and challenges 
of targeted radionuclide therapy 
1.1 Introduction 
Nuclear medicine is a fundamental branch of medicine for tumor diagnosis and therapy. 
Its development in the 20th century was due to and boosted by the discovery of 
radioactivity and the possibility of producing radionuclides suitable for human 
administration. Radiopharmaceuticals are the essential tool for nuclear medicine 
procedures, enabling imaging and therapy of disseminated diseases after administration 
of a radioligand. Imaging or diagnostic radionuclides are bound to a ligand, which 
selectively accumulates into a target tissue. The discovery of new radionuclides on one 
side and of new ligands on the other are pivotal parts of the research in the 
radiopharmaceutical field. 
The ISOLPHARM project aims to study a new and unconventional technique for the 
production of pure radionuclides for nuclear medicine, exploiting the Radioactive Ion 
Beams (RIBs) produced in the framework of the SPES (Selective Production of Exotic 
Species) project at the Legnaro National Laboratories (LNL) of the National Institute 
for Nuclear Physics (INFN)  [1.1,1.2]. 
At SPES, RIBs are produced by means of the Isotope Separation On-Line (ISOL) 
technique. Briefly, the ISOL method guarantees the ionization of radioisotopes, 
produced inside a primary target, that are afterwards accelerated and, thanks to mass 
separation, purified to produce an isobaric beam [1.3]. Isobaric beams which contain a 
radionuclide useful for nuclear medicine, can be exploited for the production of 
radiopharmaceutical precursors [1.4,1.5]. This should be regarded as particularly 
relevant because with mass separation all isotopic contaminants are easily and 
inexpensively cleared away from the final product and carrier-free radionuclides can be 
produced [1.6].  
Production of radionuclides and challenges of targeted radionuclide therapy 
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Radionuclides at a “carrier-free quality” are tremendously researched as 
radiopharmaceuticals precursors. This is due to the fact that during the last decades a 
big part of the research in radiopharmacy has been dedicated to the development of new 
receptor targeting radiometal labeled pharmaceuticals [1.7]. These radiopharmaceuticals 
are made of a biomolecule and a radiometal. The biomolecule can also be called vector, 
because, thanks to the molecular recognition with a protein that is overexpressed on the 
surface of cancer cells, it allows the accumulation of the radiation in the target tissue. 
Since the binding is easily saturable it is necessary that no cold compound dilute the 
radiopharmaceutical. If carrier-free radionuclides are used for the radiolabeling the 
accumulation to target organs is optimized [1.6,1.8]. 
The number of radionuclides produced with the ISOL technique at LNL that can be 
considered as promising radiopharmaceutical precursors is huge. Depending on the 
primary target and, consequently on the induced nuclear reaction, different radioactive 
species can be originated: radionuclides already used in the clinics as 89Sr, 125/131I, 90Y, 
and 177Lu, but also innovative radionuclides, as 111Ag, 43/44/47Sc, 64/67Cu and 152/155Tb.    
The ISOLPHARM project is outlined as a multidisciplinary study where many 
competences are involved. Nuclear physics studies on the expected nuclear reactions, 
materials engineering development of the desired production targets and mechanical 
implementation of the accelerator for the RIBs production. Afterwards chemical and 
pharmaceutical development of the secondary target to collect the accelerated ions and 
their chemical purification from isobaric contaminants. Finally, pharmaceutical studies 
for the radiolabeling of biological vectors for the production of a radiopharmaceutical.  
Together with the radionuclides production development, the optimization of the 
ligands characteristics to improve the diagnostic and therapeutic features is 
fundamental. Receptor-affinity, cell internalization, pharmacokinetic properties and 
minimization of side effects are part of the development of a radiopharmaceutical.  
In this thesis the potential use of the ISOL facility under construction at LNL for the 
production of radionuclides was tested:  the secondary targets for the ions deposition 
were developed (chapter 2), the RIBs of the desired element were produced in off-line 
modality, i.e. with stable isotopes (chapter 3), a new material for the chemical 
purification of Sr/Y was developed and tested (chapter 4). Moreover, a study for the 
optimization of the ligand properties was carried out at the Center for 
Radiopharmaceutical Sciences (CRS) of Paul Scherrer Institute (PSI). In particular, 
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three serum proteins-binding compounds were radiolabeled and characterized in vitro 
and in vivo (chapter 5). Finally, a preliminary study for the combination therapy of 
tyrosine kinases inhibitors with targeted radionuclide therapy in folate receptor positive 
cancer cell lines was carried out (chapter 6).  
In this chapter the main conventional routes for radionuclides’ production and the 
principles and challenges of targeted radionuclide therapy are described. Finally, the 
SPES project and the ISOL method for RIBs production are described into detail. 
1.2 Conventional production routes for radionuclides [1.6] 
The production of radioisotopes, which are the radioactive “core” of 
radiopharmaceuticals, is a very crucial step. In this paragraph the main production 
routes are described to allow a comparison with the new production method proposed 
within the ISOLPHARM project. 
When considering the production of radionuclides for nuclear medicine, not only the 
producible amount should be considered. Two additional properties have to be kept in 
mind: the specific activity and the radionuclidic purity.  
The specific activity of a radioisotope is the ratio between the activity of the 
radioisotope (MBq) and the mass of the element (mg). This is an important concept 
because often, due to the production methods, the radionuclide is diluted by mixtures of 
other “cold” isotopes of the same element, which do not exert any effect. Radioisotopes 
with high specific activities are required for radiolabeling of ligands that target tumor 
markers on cells (like receptors), which are easily saturable. Radioisotopes which are 
pure are called “carrier-free”, differently from those diluted by cold mixtures of the 
same element, which are defined as “carrier-added”.  
The second feature that has to be considered is radioisotopic (defined also as 
radionuclidic) purity. This other property measures the presence of unwanted 
radioisotopes.   
The main reactions used for radioisotopes production are neutron capture and proton 
induced reactions. Generators can be considered as a third way for radioisotopes 
production, particularly used and advantageous for short-lived isotopes. 
Production of radionuclides and challenges of targeted radionuclide therapy 
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1.2.1 Neutron capture [1.6] 
Nuclear reactors are the main facilities used for this kind of reactions, which are 
normally used to produce --emitting radionuclides. Stable targets are irradiated with 
neutrons and neutron-rich isotopes, close to the stability valley, are produced.  
The specific activity (S) of the produced radionuclides, if we consider a one-step 
transmutation reaction, is given by equation 1.1: 
𝑆 =
𝑁𝐴
𝐴
∙ 𝜎 ∙ 𝜑 ∙ (1 − exp (−
ln(2)∙𝑡𝑖𝑟𝑟
𝑇1
2⁄
))  (1.1), 
where NA is the Avogadro constant, A is the atomic mass, is the reaction cross-section, 
φ is the neutron flux density and tirr is the irradiation time. Thus it is evident that to have 
high specific activities values, high neutron flux (φ) and high cross sections (are 
essential. This way a high fraction of the stable target is converted into the desired 
radioisotope. Few radionuclides are produced with appreciable levels of specific 
activities with this reaction (60Co, 153Sm, 169Yb, and 177Lu). Although the target 
enrichment1 can be a strategy to improve specific activity, this method is very expensive 
and complex, causing an increase in the production costs.  
Carrier-free radionuclides can be produced by neutron capture reactions if the 
radioisotope produced with this reaction is the “mother” of the wanted radioisotope. 
This way the desired radioisotope is chemically different from the target material and 
can be more easily purified. If the “mother” isotope is short-lived, then a single 
purification step is performed because it quickly decays. If the intermediate isotope is 
longer-lived, then a generator is produced. Generators will be described in 1.2.3. 
1.2.2 Accelerator-based 
The most diffused accelerators used for nuclear medicine are cyclotrons, essential tools 
for nuclear medicine isotopes production, in particular imaging ones (PET and SPECT). 
The most common reactions are proton-induced and depend on the projectile energy. 
~5-15 MeV cyclotrons are used to induce (p,n) and (p,) for most common PET-
radionuclides production; higher protons energies are required for (p,2n) and (p,4n), 30 
and 70 MeV, respectively. Very high protons energies (GeV) can induce spallation, 
                                                 
1 Increasing the amount of the isotope necessary for the nuclear reaction 
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inducing this way the production of radioisotopes far from the elements of the target 
material.   
1.2.3 Generator-based 
Generators are efficient solutions to match the need of short-living radioisotopes for 
imaging with the logistic. They are loaded with a long-lived radionuclide, called 
“mother”, that decays to the daughter radionuclide, which is eluted just before the use. 
A successful example is the 99Mo/99mTc generator, which enabled the use of 99mTc, 
probably the most successful SPECT radioisotope.  
The only disadvantage of generators is that the mother nuclide is often a more exotic 
radionuclide, whose production could require more efforts. 
1.3 Targeted radionuclide therapy (TRT) 
According to the World Health Organization, cancer is the second leading cause of 
death worldwide, with 8.2 million cases every year and an estimated incidence of 14.1 
million new cases every year. The development of improved diagnostic and therapeutic 
strategies for the management of cancer is, therefore, urgently needed. Targeted 
radionuclide therapy (TRT) represents one of the most promising therapeutic strategies 
[1.9]; it is based on the use of energetic particles (, - or Auger electrons) selectively 
delivered in proximity of tumors thanks to specific biologic features. Ideally TRT 
delivers a high amount of radioacitivty to cancer cells, sparing healthy tissues (see 
Figure 1.1). 
 
Figure 1.1. Scheme of Targeted Radionuclides Therapy. The molecule is made of a 
targeting agent that recognizes a molecular target overexpressed on cancer cells, a 
linker and a radionuclide with suitable decay properties. Picture taken from: 
http://www.telixpharma.com/theranostics/ , last access 26th Otboter 2017, 11.45. 
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Moreover, TRT can be used  when external radiation can not be used, like in systemic 
malignancies, and the treatments are usually shorter than chemotherapy [1.9]. The first 
example of TRT dates back to 75 years ago, when radioiodine was used for thyroid 
disorders including cancer. After that many other examples of successful terapies 
followed, such as the treatment of painful bone metasteses with the --emitting 89Sr and 
153Sm, and more recently with the -emitter 223Ra. 90Y found application when 
conjugated with anti-CD20 monoclonal antibodies for relapsed or refractory low-grade, 
follicular, or transformed B-cell non-Hodgkin lymphoma [1.10]. New approaches are 
nowadays used in the clinics and in preclinical reasearch thanks to the new challenges 
introduced with radiotheranostics, that couples imaging of tumor lesions with therapy. 
In this regard one of the biggest issues is the development of chemically similar or 
identical radioligands for imaging first and therapy second. Successful examples in this 
regard are the analogues of somatostatin (e.g. DOTATATE) labeled with either 
diagnostic radionuclides such as 68Ga (for PET) and 111In (for SPECT) or therapeutic 
radionuclides including 90Y or 177Lu allowing the management of patients suffering 
from neuroendocrine tumors [1.11,1.12]. More recently the prostate-specific membrane 
antigen (PSMA)-targeting ligands (e.g. 68Ga-PSMA-11 and 177Lu-PSMA-617), have 
been used for clinical studies resulting in clear visualization of prostate cancer lesions 
via PET and remission in treated patients with metastatic prostate cancer [1.13–1.15]. 
1.4 Challenges of targeted radionuclide therapy  
In targeted radionuclide therapy a radiopharmaceutical is made of two main entities: a 
targeting ligand, which binds specifically to tumor-associated marker (e.g. receptor) and 
a payload, which is a therapeutic radiometal [1.16]. In this paragraph we will describe 
the main challenges related to TRT, talking first about the choice of the radiometal and, 
second, about the challenges related to the development of an ideal small molecule-
based targeting ligand. 
14.1. The choice and availability of suitable radionuclides 
In TRT the choice of the proper radionuclide plays an important role. Several physical 
properties should be considered to select suitable radionuclides for therapy. First of all, 
the nuclear decay properties [1.6]: - and --emitting radionuclides are used in therapy 
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because high-energy particles are able to induce cell death. Alpha particles are 
positively charged and have energies ranging from 5 to 9 MeV. Their range of 
penetration is of ~5 mammalian-cell diameters and their linear energy transfer (LET) is 
in a very high range: 80-100 keV/m [1.17]. The recent successful introduction in the 
clinics of 223RaCl2 for the treatment of bone metastases, renewed the interest for -
emitting radionuclides [1.18]. - radionuclides emit negatively charged particles that 
lose their energy while traversing matter following a contorted path. The LET of these 
radionuclides is ~0.2 keV/m, which is very low compared to  particles. On the 
contrary their penetration range in tissues is higher (up to 12 mm), thus also allowing 
the bombardment of the cells not directly targeted by the radiopharmaceutical, due to 
the cross-fire effect. Thanks to this phenomenon not all the cells within the tumor 
require to be targeted. On the other hand, due to the low LET, a high concentration of 
radionuclides has to be produced in proximity of the tumor [1.17]. 90Y and 177Lu are two 
successful examples of --emitting radionuclides applied in the clinics. The first with - 
particles emission at higher energies and the second with a lower energy and 
accompanied by  radiation useful for dosimetry [1.19]. Lately Auger-emitting 
radionuclides attracted the attention, due to their high therapeutic potential. Auger 
electrons (namely X ray photons, Coster-Kronig or super Coster-Kronig monoenergetic 
electrons) are emitted due to the vacancies produced in the shell of atoms (usually in the 
K shell) after electron capture and/or internal conversion. Vacancies are filled thanks to 
the transition of electrons from outer to inner shells, resulting in the emission of Auger 
electrons. Usually ~5-30 Auger electrons are emitted per decaying atom with an 
energetic range from few eV to 1 keV [1.20]. Auger electrons travel in contorted path 
with a very short range in water (from few nanometers to ~0.5 m) and with multiple 
ionizations in the proximity of the decay site with LET ~4-26 keV/m [1.21]. Due to 
their short range, Auger-emitters need to reach the very proximity of cell DNA to 
induce cell death. 161Tb has very similar characteristics to 177Lu considering the physical 
half-life and the - energy, but coemits a high number of Auger electrons. Its therapeutic 
effect has been compared to that of 177Lu in two independent preclinical studies and 
161Tb proved to be more effective [1.22–1.24].  
One more fundamental property for radioisotopes selection is their physical half-life 
[1.6]. Suitable radionuclides for therapy should range from 6 h to 7 d [1.25]. The half-
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life of radionuclides should match clinical indications and logistics [1.19]. Very short 
living radionuclides, indeed, limits the flexibility of use, due to the impossibility of 
delivering the radiometal to the nuclear medicine centers. On the other hand, too long-
living radionuclides impact in a negative way on the radiation dose to the patients, 
exposing the surrounding people for a longer period.  The half-life should also match 
the biological half-life of the tracer [1.9].  
Furthermore, one should also consider the chemical characteristics of the radiometal. It 
is necessary, indeed, that the radiometal could be stably bound to the bioconjugate. 
Radiometals are normally conjugated thanks to a chelator that guarantees 
thermodynamic and kinetic stability. The aforementioned chelator is most likely a 
bifunctional chelator (BFC), able to complex the radiometal and possessing a functional 
group for covalent attachment of the biomolecule [1.7]. The requirements that a BFC 
has to address are several. First of all, it has to guarantee thermodynamic and kinetic 
inertness in a pH range of 5-7.5, in order to avoid undesired release of the radiometal 
after administration, which can accumulate into not targeted tissues. The BFC has to 
compete with natural chelators present in the blood circulation, like transferrin and 
albumin for example. To face these requirements acyclic and macrocyclic chelators 
have been developed. Acyclic chelators are more advantageous for radiolabeling of 
thermosensitive molecules, such as monoclonal antibodies, because they do not require 
harsh radiolabeling conditions. On the other hand, their kinetic inertness is lower. 
Macrocyclic chelators, instead, are usually more stable; if not it means that they do not 
have the proper denticity for the specific radiometal. In case of this latter kind of 
chelators high temperatures are required to guarantee high radiolabeling yields. The 
BFC also has to be radiostable, to avoid the radiolytic effect [1.7]. 
Last but not least, is the possibility to produce the radionuclides in a large scale and to 
develop a method that is safe and affordable in order to guarantee supply of the 
radionuclides for clinical use [1.6,1.19]. Several of the therapeutic radionuclides (90Y, 
131I, 153Sm, 166Ho, 177Lu and 188Re) are produced by nuclear reactors, whose role have 
yet to be completely replaced [1.26,1.27]. Replacement projects should be encouraged 
in order to be able to provide radionuclides for therapy with alternative routes. The 
research in the field of radionuclidic production should be developed also in order to 
produce new radionuclides whose production is not feasible with nuclear reactors or 
conventional cyclotrons. One example is 67Cu, a very promising radionuclide from the 
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point of view of its physical characteristics (low energy -, coemitted ray for SPECT, 
t1/2 61.9 h) and for the possibility of having a theranostic match with 
64Cu [1.28]. 
Carrier-free 67Cu cannot be produced in sufficient amounts up to now.   
1.4.2 Small molecules-based radioligands for TRT 
In this subparagraph we describe the challenges related to the use of small molecules as 
targeting ligands in TRT. Small molecules are an attractive strategy for active targeted 
delivery because they are amenable for chemical synthesis and have some advantages if 
compared with high molecular weight vehicles, such as antibodies. Antibodies are 
limited in their efficacy, mostly due to their inability to reach cells within the tumor 
mass [1.29]. This is due to the fact that tumor cells are not identical and they can 
undergo loss of antigen expression [1.30] and to the “antigen barrier” effect, an 
hypothesis which predicates that the few antibodies molecules able to extravasate and 
reach the abluminal side of blood vessels are trapped by the antigens located on 
perivascular tumor cells [1.29]. Furthermore, antibodies can be immunogenic, even if 
humanized or fully human, leading to hypersensitivity in patients and neutralization of 
the therapeutic effect [1.31]. In contrast to antibodies, low-molecular-weight 
compounds can easily diffuse out of blood vessels and afterwards penetrate deeply into 
tissues. For these reasons, the use of disease-homing small molecules, coupled to 
cytotoxic payloads, such as radiotherapeutic nuclides, is a good strategy for active 
targeting of tumors overcoming antibodies problems. Beside their ability of penetrating 
into tissues, they are also not immunogenic and they are amenable for chemical 
synthesis. These compounds, after binding to their molecular targets on the cells, e.g. 
receptors, rapidly undergo mediated endocytosis, resulting in the folding of the ligand-
receptor complex into a vesicle, that afterwards fuses with the early endosome, see 
figure 1.2, carrying the radioactive payload into the cancer cell [1.29]. 
Successful examples of the use of this strategy in clinics is the use of radiolabeled small 
peptides, like the somatostatin analog DOTATATE, coupled with 68Ga or 111In for 
diagnosis (PET and SPECT, respectively) and 177Lu or 90Y for therapy for the 
management of patients suffering from neuroendocrine tumor [1.11,1.32]. Recently, the 
use of analogues of the natural substrate of prostate-specific membrane antigen 
(PSMA), namely 68Ga-PSMA-11 and 177Lu-PSMA-617, have been used for clinical 
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studies resulting in clear visualization of prostate cancer lesions via PET and remission 
in treated patients with metastatic prostate cancer [1.14,1.15,1.33].  
 
Figure 1.2. Mechanism of radioconjugate internalization after receptor binding 
[1.29]. 
The folate receptor (FR) is expressed on a variety of tumor types (e.g. ovarian, 
endometrial, lung cancer etc.) [1.34], but restricted to only a few sites in normal tissues, 
the most problematic being the kidneys [1.35]. The vitamin folic acid has been used as a 
tumor targeting ligand due to the possibility for derivatization and its high affinity to the 
FR even after conjugation to a diagnostic/therapeutic probe [1.36]. Over the last ten 
years, a large number of folate radioconjugates has been developed for nuclear imaging 
and therapy of FR-positive tumors. These compounds were extensively studied 
preclinically in preclinical in in vitro and in vivo experiments [1.37]. 
A potential challenge of small molecular radiotherapeutics is their fast elimination from 
the body preventing sufficient accumulation of radioactivity in the malignancies due to 
glomerular filtration and fast renal clearance; high accumulation of radioactivity in the 
kidneys increases at the same time the risk of nephrotoxicity [1.38,1.39]. This drawback 
makes the therapy more expensive and riskier for the patients because repeated 
administration and larger doses are required. For this reason, new strategies to allow a 
higher translation from preclinical to clinical phase of small molecule-based 
radiopharmaceuticals should be developed.  
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1.5 The SPES project and the RIBs production with the ISOL 
method 
The aim of the SPES project [1.40] is to provide high intensity and high-quality beams 
of neutron-reach nuclei to perform forefront research in nuclear structure, reaction 
dynamics and interdisciplinary fields like medical, biological and material sciences. It 
can be considered as composed of four phases (see figure 1.3): 
 SPES-: at the heart of SPES: the cyclotron and ISOL target.  
This phase, now almost completed, foresaw the acquisition, installation and 
commissioning of a high performance cyclotron with high output current (0.7 
mA) and high energy (up to 70 MeV), together with the related infrastructure 
for the accelerator and experimental stations. The cyclotron is provided with 
two exit ports, a configuration well suited for the double mission of the 
laboratory: basic research and technological applications. One of the two beams 
will be dedicated to the nuclear physics facility (producing mainly neutron-rich 
ions by collisions of protons onto a UCx target); the second will be dedicated to 
applied physics; 
 SPES-: the acceleration of neutron-rich unstable nuclei. 
Neutron-rich species will be accelerated against suitable targets. In the 
collisions, new, extremely neutron-rich nuclei will be produced, which are 
similar to those generated in advanced stellar stages and are not present on 
Earth due to their short lifetime. The investigation on such systems is a new 
frontier of physics, for extending our knowledge of nuclei at extreme conditions 
and for providing basic information in the study of stellar evolution; 
 SPES-: production of radionuclides for applications. 
It concerns the production of radionuclides of medical interest by using the 
SPES- cyclotron. The goal is the production of innovative 
radiopharmaceutical both for ISOLPHARM and LARAMED (LAboratory for 
the production of RAdioisotopes of MEDical interest) as well as the production 
of conventional radionuclides with new accelerator-based approaches; 
 SPES-: multidisciplinary neutron sources. 
It foresees the development of an intense neutron source, from the cyclotron 
and/or from a high intensity linear accelerator based on radio-frequency quadri 
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pole (RFQ) technology. Applications of the neutron source range from nuclear 
astrophysics to test of electronics in space, characterization of nuclear waste or 
experimental tumor treatments. 
 
Figure 1.3. SPES project logo. 
SPES-, in particular, aims at producing radioactive ion beams of high purity neutron 
rich nuclei, with mass ranging between 80 and 160 amu [1.1]. The main aim of SPES is 
to become a user facility for physics researchers who will make use of the produced 
radioactive ion beams to perform nuclear physics, materials science and astrophysics 
studies and experiments. The facility layout is outlined in figure 1.4. 
 
Figure 1.4. SPES facility layout. 
Today, the ISOL technique is established as one of the main techniques for the on-line 
production of high intensity and high quality radioactive ion beams [1.41].  
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The production of the radioactive isotopes is obtained by nuclear reactions induced by 
40 MeV protons, accelerated by a cyclotron, that will collide on a target composed of 7 
discs of carbon dispersed uranium carbide (UCx) [1.3], properly spaced in order to 
dissipate the heat (8 kW) generated by the reaction. The uranium contained in the target 
material will be 238U, this ensures that the produced radioactive isotopes will belong to a 
group of elements having atomic numbers between 28 and 57 (elements placed between 
nickel and lanthanum in the periodic table). In particular, most of the produced nuclides 
will be neutron-rich, so we can expect an excess of neutrons with respect to the element 
stable nuclear configuration. Among the radionuclides produced with UCx fission, 
relevant radionuclides already used in nuclear medicine are produced: 89Sr, a 
radionuclide used for treatment of painful bone metastases secondary to prostate cancer 
[1.42], 90Y, successfully used in radioimmunotherapy [1.9], and 125/131I, the first used in 
brachytherapy in several cancer types, e.g. the localized prostatic cancer, [1.43,1.44], 
the second used for thyroid diseases [1.45] and in Non-Hodgkin lymphomas [1.9]. 
Other innovative, not fissile, target materials are under development at LNL for the 
ISOLPHARM project. Firstly, titanium carbide (TiC), a material which is very 
promising for the production of scandium isotopes. In figure 1.5 the produced 
radionuclides foreseen are presented. 
 
Figure 1.5. Isotopes production from TiC target provided by the FLUKA simulation. 
Primary proton beam energy= 40 MeV, current= 200 A, working 
temperature=2200 °C (Unpublished data). 
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43/44/47Sc can be produced with good yields, and as carrier-free, without the need of 
target enrichment. The medical potential of these radionuclides was demonstrated [1.46] 
and for this reason it is worth investigating their production with the ISOL method. 
Moreover, scandium is an ideal element for radiotheranostics, because 43/44Sc are PET 
radionuclides, while 47Sc is a - emitter with suitable decay characteristics for therapy 
[1.19]. 
Another target material under investigation is zirconium germanide. This target can 
produce the radioisotopes reported in figure 1.6. Among these, the two radionuclides of 
mass 64 and 67 of copper are relevant for diagnostic and therapeutic purposes, 
respectively. They also are a perfect matched pair for radiotheranostics, and 67Cu 
production is nowadays very limited [1.19]. 
 
Figure 1.6. Isotopes production from ZrGe target provided by the FLUKA 
simulation. Primary protonbeam energy= 40 MeV, current= 200 A, working 
temperature=2200 °C (Unpublished data). 
 
Independently on the target and on the reaction, the reaction products will be extracted 
from the target by evaporation at high temperature (about 2000 °C), and then forced to 
pass through a transfer tube towards an ionization cavity, where they will be ionized to 
the 1+ state [1.47–1.50]. Once ionized, these isotopes will be accelerated through an 
electrode at high potential (up to 40 kV). The formed beam will be subsequently 
directed and focalized using different electromagnetic systems, and then finally purified 
(mass separated) in order to have a pure isobaric beam without any isotopic 
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contaminants. It will therefore be possible to collect the radionuclides of interest using a 
proper substrate placed at the end of the experimental line, see figure 1.7. 
 
Figure 1.7. ISOLPHARM scheme. 
Thanks to mass separation it is therefore possible to produce in a simple and 
straightforward manner carrier-free radionuclides, ideal for radiolabeling. With the 
ISOLPHARM project we want, to suggest the ISOL technique as new and 
unconventional method for radionuclides production with very high purity, to match the 
necessity of radionuclides, often not available with traditional techniques. 
1.6 New strategies in TRT 
The use of small molecule-based radioconjugates for therapy is hindered by the very 
rapid blood clearance of these compounds. Due to their low molecular weight they 
rapidly undergo glomerular filtration, thus making their biological half-life very short. 
This scenario prevents a high accumulation of the radioconjugate in the tumor and 
makes the repeated administration of high quantities of radioactivity necessary. This is 
not an ideal situation, because side-effects to healthy tissues are increased together with 
the radionuclides costs. Moreover, the high degree of renal clearance can increase the 
risk of nephrotoxicity [1.34,1.39]. In this thesis project two strategies to improve TRT 
with small molecules were developed. The first relies on the development of 
radioligands with a serum protein-binding domain (chapter 5). This strategy is based on 
the consideration that serum proteins have high molecular weight, and for this reason do 
not undergo glomerular filtration (filtration cut-off 30-50 kDa [1.51]). The 
radioconjugate half-life is in this way increased and its tumor accumulation facilitated. 
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The development of a folic acid radioconjugate functionalized with an albumin-binding 
domain enabled the first preclinical therapy study with radiofolate in mice [1.52].  This 
strategy was also recently used for PSMA inhibitors, to improve the biodistribution and 
therapeutic efficacy in prostate tumor-bearing mice [1.33].  
In both these studies an albumin binder was used to decorate the radioconjugate. The 
albumin binder was previously developed by Dumelin et al., and is based on a p-
iodophenyl group [1.53]. Recently another serum protein, transthyretin, was proposed 
as a possible transporter to increase biological half-life of peptides. In this study, 
Penchala et al. developed a binding motif for L-thyroxine binding pocket on 
transthyretin [1.54].  
Another strategy to improve TRT efficacy while decreasing side effects [1.55] is the use 
of combined-modality regimens. This approach is very popular in cancer therapy due to 
the necessity to overcome the emergence of resistance to therapy [1.56]. Targeting the 
cancer cell on diverse molecular path mechanisms makes the cell less prone to 
developing resistance to the therapy. At the same time, the use of multimodality 
therapies allows to decrease the dosage of single therapies, thus reducing side-effects. In 
the last chapter of this thesis (chapter 6) a preliminary study combining radionuclide 
therapy (177Lu-cm10, [1.52]) with tyrosine kinases inhibitors is described, based on the 
assumptions of a possible synergistic effect of the two agents [1.55,1.57–1.59]. 
1.7 Conclusions 
Considering the potential of TRT, in this thesis project a new method for the production 
of carrier-free radionuclides was studied in order to make the production of 
radionuclides for medical use possible at the ISOL facility under construction at LNL-
INFN. As suggested in the NuPECC report [1.6], the use of nuclear physics facilities for 
the production of radionuclides for medicine is very important.  
On the second part of this thesis, two different strategies to improve TRT were studied: 
firstly, a set of serum protein binders were radiolabeled and characterized in vitro and in 
vivo, secondly a preliminary study for the combination therapy of TKIs with TRT was 
carried out. 
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Chapter 2  
Secondary targets production and 
characterization 
2.1 Introduction 
The first part of this work was devoted to the design, production and characterization of 
solid secondary targets suitable for the implantation and recovery of the accelerated 
ions, each one having peculiar characteristics. The main requirements to be addressed 
for the choice of the target material were: the mechanical stability, the easiness in 
recovering the ions from the target and the lack of chemical incompatibilities and of 
isotopic contaminants. 
For the deposition of metals with a high boiling point, such as Sr2+, Y3+ and Cu2+, 
sodium chloride was used as a target [2.1]; for the deposition of iodine, an element that 
is at the gaseous state in high vacuum [2.2], activated carbon mixed with a binder was 
chosen. 
Sodium chloride (NaCl) is an inorganic salt, commonly used in the parenteral 
formulation of drugs [2.3]. It is biocompatible and used to guarantee the proper 
osmolarity to the solutions. The use of a defined amount of NaCl for the preparation of 
a fixed number of radiopharmaceutical doses by direct dissolution of the target material 
after irradiation allows the obtainment of the drug by a direct and straightforward 
method. This is useful for the obtainment of 89SrCl2 for the treatment of bone metastases 
[2.4]. On the other hand, if the implanted radionuclides are intended for the 
radiolabeling of biomolecules, the NaCl should be considered a suitable material 
because Na+ ions are usually present in the radiolabeling solutions, so they are not 
competitors of the radionuclide for the chelator, e.g. DOTA.  It should be noted anyway 
that in most cases the ISOL method will lead to the presence of isobaric contaminants 
on the secondary target, requiring a purification step (see chapter 4). The capacity of 
NaCl to form compact substrates was tested without the use of any binder and the 
properties of the obtained pellets were studied. 
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Activated Carbon (AC) is an organic material in the form of a very thin powder 
(nanoscale) and high flowability. It was considered as a suitable material for the 
development of the secondary target for iodine, since iodide (I-) is a contaminant of 
NaCl. Moreover, AC is not toxic and it is an adsorbent material for iodine, commonly 
used at the industrial level for the recovery of radioactive iodine [2.5]. The aim of this 
second part of the chapter was the development of a suitable method for the 
compression of AC by means of a biocompatible binder. For the use of AC as food 
supplement, it is commonly mixed with several binders: sorbitol, polyvinylpyrrolidone, 
arabic gum, starch and cellulose derivatives. In this work an effort was made to reduce 
the number of ligands to only one binder in order to minimize the number of possible 
chemical incompatibilities with iodine. Among all of them polyvinylalcol (PVA) was 
chosen. PVA is a water-soluble synthetic polymer in the crystalline form, described by 
the general formula [CH2CH(OH)]n. It is a hot binder used in the industrial and in the 
pharmaceutical field. In the latter in particular it is useful in the 3D printing processes, 
in the formulation of tablets coating and in the production of medical device. PVA was 
studied for the production of AC monoliths by Lozano-Castelló et al. [2.6]. The 
possible formation of the complex I2-PVA was reported by Moulay, [2.7]; this 
possibility was verified in our working conditions.  
2.2 Materials and Methods 
2.2.1 Materials 
Sodium Chloride, Metal Free (Sigma Aldrich), Stearic Acid (Vegetable) (A.C.E.F.); 
Caolino USP, Argilla Bianca USP (A.C.E.F.); Activated Carbon, Carbo Activatus USP 
(A.C.E.F.); Mycrocellulose Crystalline, T1 Ph.Eur. (A.C.E.F.); Veegum Pure (Eico 
Novachem); Magnesium stearate (Farmalabor); Liquid paraffin BFR070 FU (A.C.E.F.); 
Poly(vinyl alcohol), PVA, AMw 31000-50000, 98-99% hydrolyzed (Sigma-Aldrich); 
Aerosil 200 (A.C.E.F.); Sorbitolum PLV. FU-Ph.Eur. (A.C.E.F.); Talco Pharma USP-
Ph.Eur.(A.C.E.F.). 
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2.2.2 Sodium Chloride preparation and compression 
For the preparation of the NaCl secondary targets, sodium chloride (Fluka Analytical, 
TraceSelect) or Sodium Chloride (Sigma Aldrich) were used for the deposition of 
copper and yttrium beams, respectively. In both cases, NaCl was previously ground in a 
ceramic mortar for 5 minutes and subsequently sieved. The fraction with a particle size 
> 63 m and < 300 m was used for the preparation of the targets. The powders were 
then compressed into thin discs using cylindrical molds of 13 mm and 40 mm diameter. 
For the smaller diameter mold NaCl amounts ranging from ~0.05 to ~1.00 g were 
pressed applying a strength of 10 tons for 10 minutes in a manual hydraulic press. For 
the bigger mold, from ~1.50 up to ~3.50 g of NaCl were pressed in an industrial 
hydraulic press with a strength of 30 tons for 10 minutes. 
2.2.3 Sodium Chloride discs characterization 
The discs obtained with the previously described method were characterized in terms of 
mechanical resistance, behavior in vacuum conditions and solubility properties.  
To test the mechanical resistance a Texture Analyzer (TA-HDi - Stable Micro System) 
was used. The measurements were carried out by setting the lowering of the probe to 
40% of the disc thickness. Three independent discs were tested for every NaCl weight, a 
p <0.05 was considered statistically significant. 
To verify the behavior of the discs under high vacuum, that is one of the conditions 
which the secondary targets have to survive to, three discs were placed inside a high 
vacuum chamber (10-6 mbar) at room temperature (RT) overnight. The discs were 
weighed before and after the treatment and the weight loss [%] was calculated.  
To verify the capacity of the discs to disaggregate in a short period of time, the ~1.00 g 
13 mm discs and the ~3.60 g 40 mm discs were placed inside a glass vessel filled with 
40 and 400 mL deionized water at RT, respectively. The solutions were continuously 
mixed with a rotating palette (rotating speed = 100 rpm) and the disaggregation of the 
discs was considered completed when no more residual was visible.   
The total porosity (P) of the discs was calculated with the equation 2.1: 
          𝑃 = (1 +
𝜌𝑐
𝜌𝑡ℎ
) ∙ 100                                                                                          (2.1), 
where ρc is the bulk density calculated experimentally by the mass over volume ratio 
and ρth is the theoretical density, a tabulated ideal density that the material would have if 
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it was completely dense, without any porosity. The ρth for NaCl is 2.16 g/cm3. Images of 
the discs surface were taken with an optical microscope.  
2.2.4 Activated Carbon discs preparation 
Activated carbon powder was mixed with different ligands in order to evaluate the best 
ligand to produce a solid AC matrix. AC, indeed, could not be transformed into a 
compact form by direct compression of the powder. Four different ligands were taken 
into consideration: microcrystalline cellulose (MC), sorbitol, stearic acid and PVA 
[2.3,2.6]. 
AC was mixed with MC in two different ratios: AC 85% : MC 15% and AC 70% : MC 
30%. After mixing ~0.80 g of the blend were transferred to a 40 mm diameter mold and 
pressed applying a strength of 30 tons for 30 min. 
AC/sorbitol blends were prepared with a granulation process. Sorbitol was dissolved in 
deionized water at the concentration of 10 and 30% (g/100 mL). The solution was added 
dropwise to a known amount of AC powder (~1 g) under continuous mixing in a 
ceramic mortar until the following AC/sorbitol ratios (w/w) were obtained: ~ 80%/20%; 
~ 60%/40%; ~ 50%/50%; ~ 30%/70%. The granules were then dried overnight at 50°C. 
~0.8 g of the granules were pressed as previously described for the AC/MC blends. 
The lipophilic ligand stearic acid was used at the maximum concentration of 3% (w/w). 
It was first reduced to smaller pieces manually in a mortar and then mixed with the AC 
powder. Also in this case ~0.80 g of the mixture were pressed as previously described in 
the 40 mm mold.  
The last tested ligand was polyvinylalcol (PVA). PVA (Mw 31,000-50,000, 98-99% 
hydrolyzed, Tg 85 °C, Tm 230 °C) was dissolved in distilled boiling water (5%, g/100 
mL) and added to the AC powder until an over wetting of the powder was reached. The 
wet mixture was then dried overnight at 50 °C. The wetting with the PVA solution and 
the drying was repeated more than once to reach an AC/PVA ratio of 50:50 (w/w). The 
obtained granules were then grounded and sieved. ~1.30 g (particle size > 300 m) of 
the granules were transferred to a preheated mold (~ 170 °C) and pressed for 10 minutes 
with a strength of 2 tons.  
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2.2.5 Activated Carbon/PVA discs characterization 
The discs that were resistant enough to be handled where characterized in terms of 
mechanical resistance, loss of weight under high vacuum, superficial structure analysis, 
total porosity and specific surface area. The discs that were characterized were those 
with PVA as a binder. 
One disc was stored in a Petri dish at RT in normal atmosphere for 24 hours, another 
disc was stored inside a closed bag filled with argon. The two discs were then 
transferred into a high vacuum chamber (~10-6 mbar) overnight and the weight loss was 
measured. The same discs, plus one more that was stored in argon atmosphere after 
pressing, were then measured for the mechanical resistance with a Texture Analyzer as 
previously described.  
Some fragments of one of the discs tested for the mechanical resistance were analyzed 
by Scanning Electron Microscopy (SEM) analysis using a Vega3 Tescan microscope. 
Images of the surface and of the internal section of the discs were taken at magnitude of 
100 and 1000 x, high voltage 15.0 kV and working distance ~15.00 mm. SEM pictures 
of the AC and of the granules before compression were also taken at 100 x of 
magnitude with the same instrumental setup. 
The total porosity was calculated with the formula 2.1, previously described. The 
theoretical density (ρth) of the mixture was extrapolated with the formula 2.2: 
          𝜌𝑡ℎ =  𝜌𝑡ℎ,𝐴𝐶 ∙ 𝜈𝐴𝐶 + 𝜌𝑡ℎ,𝑃𝑉𝐴 ∙ 𝜈𝑃𝑉𝐴                                                                  (2.2), 
where ρth,AC = 2.00 g/cm3, ρth, PVA = 1.27 g/cm3 and νAC and νPVA are the volumetric 
fractions of the two phases in the mixture, easily calculated being their masses and 
densities known. 
The samples were characterized also in terms of specific surface area. The AC raw 
powder, the granules before compression and a compressed disc underwent 
physisorption analysis, with ASAPTM2020 Micrometrics. ~0.03 g of AC, ~0.22 g of 
granules and a fragment of a disc of ~0.49 g were independently analyzed. All the 
samples underwent a degassing preparatory phase at 100 °C, 60 °C and 100 °C, 
respectively, for 720 min. The temperature was lower for the granules to avoid a change 
in the structure during the degassing (Tg, PVA = 85 °C). The discs had already been kept 
at higher temperatures during compression (~170 °C) so a temperature of 100 °C was 
not considered a problem. After the degassing, the samples were weighed and analyzed. 
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The analysis gas was N2, the specific surface area was calculated with the BET method 
and the pore size distribution in the mesopore region (2nm < pore size < 50 nm) with 
the BJH method. 
2.2.6 Interaction between I2 and PVA 
The formation of  complexes between PVA and Iodine was reported in the literature 
[2.7]. To evaluate if this was the case also in our working conditions, ~0.65 g of PVA 
were soaked in a solution of NaOH (1 M, 2 mL) and I2 (0.05 M, 2 mL). The mixture 
was shaken and centrifuged at 5000 rpm at RT for 5 minutes. The supernatant was 
analyzed at the UV-Vis spectrophotometry (baseline NaOH 1 M). As reported in 
literature, the PVA-I2 complex is colored with max in the visible range [2.7]. 
2.3 Results and discussion 
2.3.1 Sodium chloride discs preparation 
The direct compression of the sieved NaCl powder allowed to produce solid discs 
without the addition of any ligand both using the 13 and the 40 mm mold (picture in 
figure 2.1), with minimum amounts of 0.70 and 1.50 g of NaCl, respectively. The discs 
presented homogeneous surfaces and no visible crack were present (figure 2.1). 
 
Figure 2.1. The Sodium Chloride disks (13 and 40 mm of diameter). 
2.3.2 Sodium chloride discs characterization 
The strength necessary to break the discs was measured with the texture analyzer. All 
the produced discs showed a good resistance. For the 13 mm discs those of mass >0.40 
13 mm 40 mm 
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g a strength >50.0 N was necessary to break them. For those of masses ranging from 
0.07 to 0.20 g no significant difference was measured (~15 N). The resistance increased 
with the mass to a maximum strength of ~150 N. The average strength with the SD are 
reported in figure 2.2 A and B. No weight loss was measured after the permanence in 
high vacuum. 
 
Figure 2.2. Results of the mechanical tests performed on the 13 mm discs (A) and on 
the 400 mm ones (B).  
The calculation of the total porosity (P) applying formula 2.1 on the ~1.8 g discs 
highlighted a low degree of total porosity (6.86% ± 2.30), see table 2.1, meaning a high 
degree of fusion of the NaCl grains. This is also visible from the pictures taken with the 
optical microscope on the discs surface (Figure 2.3A and B) where the fusion of NaCl 
granules is clearly visible. 
Table 2.1. Calculation of the total porosity (P) on three discs of 1.8 g, 
diameter 40 mm. 
Disc Mass Volume Bulk density (c) Total porosity (P)* 
 
[g] [cm3] [g/cm3] [%] 
1 1.80 0.89 2.02 6.40 
2 1.82 0.93 1.96 9.34 
3 1.81 0.88 2.06 4.85 
   
Average 6.86 
   
SD 2.30 
*Calculated with formula 2.1 and a th,NaCl=2.16 g/cm3 
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Figure 2.3. Pictures of the surface of NaCl discs. 
2.3.3 Activated Carbon discs preparation 
Using the AC/MC mixtures it was not possible to obtain solid discs: after the 
compression time, when the mold was opened the blend was still in the powder form. 
When sorbitol was used as a ligand a slight compression was reached when the sorbitol 
[%] was >70%. Nevertheless, a solid matrix could not be achieved. The AC/stearic acid 
powder gave the same result: no compression could be achieved. The compression of 
the AC/PVA blend, performed by hot pressing, instead lead to a good mechanical 
stability of the pressed discs, which were consequently characterized.  
2.3.4 Activated Carbon/PVA discs characterization 
The disc that was stored in normal atmosphere after compression, had a weight loss of 
~4.13% after staying in high vacuum overnight, while the disc that was immediately 
transferred into a bag filled with argon had a much lower weight loss (~0.90%). These 
two discs tested at the texture analyzer had a breaking strength of 9.53 N and 95.04 N. 
A third disc, conserved in argon, was broken applying a strength of 104.15 N (see figure 
2.4).  
 
Figure 2.4. Graphs of the mechanical tests performed on the AC/PVA discs. 
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The specific surface area of the powder calculated with the BET method showed a 
significant decrease from the pure AC powders to the AC/PVA granules and AC/PVA 
discs. The firsts have, indeed, a specific surface area of 1602 m2/g, while the seconds 
two had values of 169 and 188 m2/g, respectively. The three isotherm curves could be 
classified according to the IUPAC classification (figure 2.5) [2.8].  
 
Fig.2.5. IUPAC classification of Isotherm curves. 
The pure AC isotherm (fig. 2.6A) could be classified as type I for the first region. The 
sharp increase at low p/p0 ratios was typical of the presence of micropores (<2 nm). The 
hysteresis was due to the presence of mesopores: moreover the mesopores shape could 
be predicted since the hysteresis was of the H4 type (Fig. 2.5b), suggesting the presence 
of narrow and long pores. The curve did not reach the saturation, probably due to the 
presence of macropores as well. AC/PVA granules and discs both had a H4 
typehysteresis and lack the saturation step as well (fig 2.6 B and C). 
The high degree of porosity of the AC/PVA discs is confirmed from the calculated total 
porosity (P) that was 44.57% ± 1.60. In table 2.2 the parameters used for the 
determination of the theoretical porosity of the AC/PVA blend is reported. Table 2.3 
reports the calculated total porosity (P). 
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Table 2.2. Parameters used for the total porosity calculations for 
AC/PVA discs. 
th,AC th,PVA Volume AC Volume PVA AC PVA Theorical Density thAC/PVA 
[g/cm3] [g/cm3] [cm3] [cm3]   [g/cm3] 
2.00 1.27 0.03 0.47 0.39 0.61 1.55 
 
Table 2.3. Calculation of total porosity (P) for AC/PVA discs. 
Disc Mass Volume Bulk density (c) Total porosity (P)* 
 [g] [cm3] [g/cm3] [%] 
1 1.269 1.487 0.85 45.05 
2 1.256 1.421 0.88 43.08 
3 1.251 1.508 0.83 46.58 
4 1.256 1.512 0.83 46.51 
5 1.259 1.421 0.89 42.95 
6 1.259 1.458 0.86 44.40 
7 1.256 1.458 0.86 44.53 
8 1.255 1.396 0.90 42.11 
9 1.204 1.433 0.84 45.90 
   
Average 44.57 
   
SD 1.6 
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Figure 2.6. Isotherm curves (on the left) and pore distribution profiles (on the right) 
for pure AC powder (A), AC/PVA granules (B) and AC/PVA discs (C). 
The pore distribution (Figure 2.6 A, B and C, right side) confirmed the presence of 
micro and mesopores in the AC powder, and mesopores only in the AC/PVA granules 
and disc.   
With the SEM analysis we observed the distribution of PVA around the AC powder 
(figure 2.7A and B) and confirmed the good success of the compression process (figure 
2.7 C-F). The surface showed a good homogeneity with the presence of bigger and 
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smaller granules kept together by PVA (figure 2.7C and 2.7D). The presence of 
macropores is confirmed from the SEM pictures. 
A 
 
B 
 
C 
 
D 
 
E 
 
F 
 
Figure 2.7. SEM images at 100 x (left) and 1.0 kx (right) of AC/PVA granules (A) 
and (B), AC/PVA discs surface (C) and (D) and AC/PVA discs section (E) and (F). 
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2.3.5 Interaction between I2 and PVA 
After the addition of PVA to the NaOH solution, the polymer started to swell due to 
water adsorption and accumulated at the bottom of the tube. The I2 gave a reddish color 
to the solution that vanished fast due to iodine dismutation to I- and IO3
- in basic 
conditions. No colored I2-PVA complex was visible and no typical UV spectrum could 
be observed. 
2.4 Discussion 
This study was fundamental for the design and development of solid substrates useful 
for the deposition of accelerated ion beams. These substrates were used for the 
experiments described in chapter 3.  
Sodium chloride could be easily pressed in the form of a disc without the addition of 
any binder. Its ability to form compact matrixes is probably due to its hygroscopicity. 
Thanks to the absence of binders no compatibility issues had to be taken into account. 
Nevertheless, it was important to establish the smaller quantity necessary to have a 
substrate with acceptable mechanical characteristics (1.8 g for the 40 mm discs and 0.5 
g for the 13 mm) because a too large amount of NaCl can be a problem for: (i) 
interference with the chemical analysis of the deposed elements; (ii) osmotic pressure of 
the solution prepared after the disc dissolution. The produced discs were, indeed, used 
for the deposition and quantification of stable elements, for this reason different 
analytical techniques were used depending on the element, as described in chapter 3. 
These techniques foresee the dissolution of the elements (for their quantification) and of 
sodium chloride simultaneously. Reducing its amount was necessary to have accurate 
and precise analyses.  
The compression of activated carbon represented a bigger challenge because different 
ligands were taken into consideration. PVA was the only one that could be used 
efficiently to produce solid AC discs. High temperature pressing (160 °C) had to be 
used to allow the transition of the polymer to its glass phase, without melting it (Tg 85 
°C, Tm 230 °C). A granulation process of the AC powder using a solution of the 
polymer was done before the compression, the final blend had AC and PVA in a ratio of 
1:1. The produced discs had a good mechanical resistance if stored in argon 
atmosphere; the absorption of water was, indeed, cause of a decrease in the mechanical 
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resistance of the 1st disc (~9 N vs.  >90 N for the disc kept under argon) and underwent 
a weight loss after vacuum treatment (~5% of the initial weight). The discs had a good 
total porosity (~45%) and high specific surface area (~170 m2/g), meaning a high 
surface available for the I2 adsorption. The chemical compatibility between the ligand 
PVA and I2 was verified and no complex was formed.  
2.5 Conclusions 
With this study it was possible to produce the secondary targets for the ion beams 
deposition. These targets could be produced after compression of the materials with the 
addition of PVA as a binder in the case of activated carbon and without any binder in 
the case of sodium chloride. As described in chapter 3 these substrates could be used for 
the deposition of stable accelerated yttrium, copper and iodine.  
The discs were characterized and proved to have good mechanical and superficial 
properties. The use of the discs as secondary targets and their installation in the beam 
line is described in chapter number 3. 
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Chapter 3   
Stable Ion Beams tests 
The results regarding iodine and yttrium reported in this chapter were recently 
published in the journal Applied Radiation and Isotopes (DOI: 
10.1016/j.apradiso.2017.06.022). 
3.1 Introduction 
To study the feasibility of the use of SPES, a Front-End (FE) was built in recent years 
and used in this work in off-line mode (not connected to the proton beam line) to ionize, 
accelerate and collect stable beams of elements of interest. More details on the FE 
architecture and operation will be given in 3.2.2. 
Like already reported in Chapter 1, SPES is a second generation ISOL facility [3.1]; the 
ISOL method guarantees the production of high intensity Radioactive Ion Beams (RIBs) 
that can be purified On Line thanks to a mass separator [3.2]. The use of the ISOL 
method for the production of radionuclides for nuclear medicine relies on the possibility 
to perform mass separation, thus getting rid of all isotopic impurities eventually present 
after the desired nuclear reaction [3.3,3.4]. High purity coupled with high intensities 
guarantees the production of carrier-free radionuclides, ready for the radiolabeling of 
diagnostic or therapeutic agents. A step of chemical purification from isobaric 
contaminants has to be considered in case of long-lived radioisotopes of the same mass 
chain co-produced with the desired radionuclide (See Chapter 4). 
In this study yttrium, copper and iodine were ionized and accelerated with the FE and 
collected on the secondary targets described in chapter 2. The elements collected on the 
substrates were analyzed and quantified. The process developed with stable ion beams 
will be the same that will be performed with the radioactive ones. Their chemical 
behavior, indeed, is the same. These tests thus represented a proof of principle of the 
validity of the separation and collection methodologies that will be used in 
ISOLPHARM. 
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Yttrium beams were produced because 90Y is a radionuclide used in therapy [3.5], that 
can be produced with the ISOL method from 238U fission (primary proton beam 40 
MeV, 200 A) in a uranium carbide target [3.6]. The UCx target is the main target 
currently under development for the SPES project [3.7,3.8].  
64Cu and 67Cu are ISOLPHARM radionuclides that will be produced from targets 
alternative to UCx. Nickel based targets are currently under development for the 
production of 64Cu, and germanium based targets (such as zirconium germanide) for the 
production of both 64Cu and 67Cu, as explained in chapter 1. The couple 64Cu/67Cu is a 
perfect matched pair because the two radionuclides can be used to perform diagnosis 
(64Cu) and therapy (67Cu) of a patient using the same element, having this way the same 
chemical behavior [3.9].  
Iodine was studied since 131I and 125I are radionuclides already used in nuclear medicine 
[3.10–3.13]  and are produced inside the SPES uranium carbide fission target . 
Moreover, other interesting iodine radionuclides are produced from this target, like 127I. 
3.2 Materials and Methods 
3.2.1 Materials 
Copper Standard for AAS TraceCERT (Fluka Analytical), Yttrium Standard for AAS 
TraceCERT (Fluka Analytical) and Yttrium Chloride hexahydrate 99.99% trace metal 
basis (Sigma Aldrich) were used for copper and yttrium beams production and sodium 
chloride (Sigma Aldrich) was used to develop substrates for yttrium deposition. Nitric 
acid 69.0% TraceSELECT (Fluka Analytical) was used for sample preparation in 
copper and yttrium analysis. Active charcoal Carbo Activatus USP (A.C.E.F.) and 
Poly(vinyl alcohol) AMw 31000-50000, 98-99% hydrolyzed (Sigma Aldrich) were used 
for the production of the substrate to collect iodine beams. 
Formic acid 99-100% AnalaR Normapur Analytical reagent (Prolabo), Sulfuric Acid 
95-97% for analysis or manufacturing use (J.T. Baker), Bromine reagent grade (Sigma 
Aldrich), Potassium iodate 99.5% for analysis (ACROS Organics), Potassium Iodide 
puriss p.a. reag. ISO, reag. Ph. Eur. 99.5% (Sigma Aldrich) and Sodium Thiosulphate 
solution 0.1mol/L (Scharlab S.L.) were used for Iodine analysis. Sodium Hydroxide 
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reagent grade 98%, pellets (anhydrous) (Sigma-Aldrich) was used for iodine extraction 
from the substrate prior to analysis. 
3.2.2 Front End description 
The experimental apparatus installed at LNL allowed the performance of some 
preliminary tests to verify the production of radionuclides of pharmaceutical grade with 
the ISOL technique. For this purpose, the SPES Front End off-line was used. This 
apparatus, schematically represented in figure 3.1, has been designed and developed for 
the SPES project and is aimed at the production of (1+) ion beams. It is currently used in 
off-line mode, i.e. for the acceleration of stable ion beams; it is not connected to the 
proton beam line. Once the set up will be completed, it will be moved to a dedicated 
bunker in the final SPES building and coupled to the cyclotron line.  
 
 
Figure 3.1. Scheme of the SPES FE. 
To study the production of a radionuclide with the ISOL technique to obtain 
radiopharmaceutical products, stable isotopes of the same element can be a good 
alternative, since they have the same chemical behavior. For this reason, the FE was 
used to produce stable ion beams to carry out the feasibility tests here reported.  
The FE has been extensively described in previous papers [3.14]. Briefly, it is made of 
five main functional subsystems: the ion source complex, the beam optics subsystem, 
the Wien filter, the diagnostic boxes 1 and 2. The ion source complex is placed inside a 
vacuum chamber that enables the use of the ion source at high temperatures with 
pressure levels between 10-5 and 10-6 mbar. In off-line mode, no fissile target is installed 
inside the chamber but different methodologies are used to introduce the stable isotopes 
to be ionized and accelerated depending on the physical state of the element. In the case 
of gases, they are introduced through a controlled gas flow and injected in the ion 
source by means of a calibrated leak; in case of solid materials, they are usually soluble 
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salts, dissolved in acidic media and quantitatively deposed and solvent evaporated on a 
tantalum foil, called mass marker (MM). The MM is then carefully folded [3.15] and 
inserted into a heated tantalum tube, called oven, that allows the element atomization 
and injection into the ion source. More details on this technique will be given in the next 
paragraph.  
The ion sources  developed for the SPES project are of two kinds, depending on the first 
ionization potential of the element [3.14,3.16]. For elements of the 1st and 2nd group, the 
Surface Ion Source (SIS) is adopted; for those with higher electronegativity, the Plasma 
Ion Source (PIS) is required. 
The SPES SIS is a hot-cavity ion source and its components are mainly made of 
tantalum [3.15]. Geometric specifications of the SIS ion source used to perform the tests 
are reported by Manzolaro et al. [3.15]. Surface ionization occurs following the 
interaction of the atoms with a heated surface; the interaction causes the loss of an 
electron and the production of a positive singly charged ion. This mechanism [3.17] is 
good only for elements with a first ionization potential smaller than 7 eV and with a 
hot-cavity made of materials with high work function values (like tantalum) [3.18]. The 
operating temperature of the source is a crucial parameter to achieve an effective 
ionization. 
The ion source used in these tests is the SPES PIS, which is a forced electron beam 
induced arc discharge ion source [3.14,3.16]. It is a non-selective device capable of 
ionizing a large spectrum of elements, mainly composed of two parts: the tantalum 
cathode and the molybdenum anode. The former is heated at 2200 °C by the Joule 
effect, generating an intense thermionic emission of electrons (free electrons) on the 
cathode surface facing the anode. The anode, at 150 V with respect to the rest of the ion 
source, attracts the ionizing electrons, in this way allowing the creation of a plasma 
inside its cylindrical cavity. PIS is also suitable for ionization of elements with high first 
ionization potential.        
The ion source (SIS or PIS) is placed on a 25 kV platform with respect to the extraction 
electrode at ground potential. The high voltage can however be increased to 40 kV. The 
beam optics subsystem is made of a set of electrostatic deflectors and a quadrupole 
triplet which allow beam alignment and focusing, respectively. In diagnostic box 1 there 
is a Faraday Cup (FC) for beam intensity monitoring and a grid-based beam profile 
(BP) detector.   
Stable Ion Beams tests 
 
 
49 
The beam mass selection is performed by a Wien Filter (WF) [3.19] a device which is 
able to select a specific ion due to mutually perpendicular electric and magnetic fields 
orthogonal to the ion velocity. The undeflected particles have speed equal to the ratio 
between electric and magnetic field. The deflected ions are then stopped by a slits 
subsystem. Since the various masses have approximately the same energy (25 keV), this 
device can be used in the FE as a mass selector. For this reason, the Wien Filter is 
composed by a vacuum chamber where two electrodes, maintained at a certain 
potential, provide the desired electric field and by a magnet excited by two coils, that 
supplies the magnetic field. 
Following mass separation, a second diagnostic box is installed, constituted by a FC, a 
grid-based BP detector and an emittance meter device. 
For the simulation of the radionuclide production for the development of 
radiopharmaceuticals precursors, a substrate of pharmaceutical grade is positioned at the 
end of the line, immediately after the emittance meter in order to collect the desired 
accelerated stable ions. 
3.2.3 The Mass Marker technique 
The Mass Marker capillary technique [3.20] is a useful method for the introduction of 
atoms into the front end. It is used to simulate the process of diffusion of radioactive 
isotopes towards the ionization source in the off line tests. It consists of a small 
tantalum foil (mass marker) on which a calibrated volume of the solution containing the 
element is placed. The solution is allowed to evaporate, leaving on the marker only the 
salt [3.21]; then it is accurately folded and introduced inside the oven. The diffusion 
process is regulated by the temperature and by the vapour pressure of the introduced 
molecule, that is why the oven is heated by means of Joule effect, a well-established 
method to heat components of that kind [3.22] and the temperature can be regulated so 
as to control the diffusion process [3.15]. 
Depending on the element, different calibrated amounts of standard solutions were 
loaded on the MM and are reported in the following paragraphs. The most important 
experimental parameters, used for the ionization and deposition of each element, are 
summarized in table 3.1.  
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Table 3.1. Experimental conditions used for copper, yttrium and 
iodine ionization and depositions. 
 Copper Yttrium Iodine 
Ionization source Plasma Ion Source Plasma Ion Source Plasma Ion Source 
Starting chemical 
form 
Copper nitrate Yttrium chloride Potassium iodide 
Mass marker 
placement 
Oven Transfer line Oven 
Solution loaded in 
the mass marker 
Copper nitrate 
solution (1 g/L), 
200 L 
Yttrium chloride (1 
g/L), 900 L 
Potassium iodide (1 
g/L), 150 L 
Secondary target Sodium chloride 
1.8 g 
Sodium chloride 
1.8 g 
Activated carbon 
50% (w/w) 
PVA 50% (w/w) 
1.3 g 
Analytical 
technique 
GF-AAS 
(=327.4 nm) 
ICP-OES 
(=371.03 nm) 
Titration 
 
The setup of the FE was optimized depending on the boiling temperature, mass and first 
ionization potential of the element under study. In the following, the experimental 
conditions for yttrium, copper and iodine are reported.  
3.2.4 Yttrium Beams [3.1]  
3.2.4.1 Yttrium beams production 
For yttrium ionization two different salts were used for the preparation of the mass 
marker: Yttrium Nitrate (Yttrium Standard for AAS, Standard solution, 1000 mg/L) and 
Yttrium Chloride (Yttrium (III) chloride hexahydrate, Sigma Aldrich, 1000 mg/L 
dissolved in deionized water). Different volumes (40-900 L) of the yttrium salts 
solutions, as per testing, were dropped onto a tantalum foil (10 mm x 15 mm, width 
0.025 mm) and the solvent was allowed to evaporate by mild heating. The foil was later 
folded and connected to the ionization source. To successfully ionize yttrium, the MM 
was placed in two different positions of the ion source unit: (i) inside the oven or (ii) 
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directly into the transfer line. The oven is a thin tantalum tube, that is connected to the 
transfer line and that, thanks to the passage of electric current, is heated up and allows 
atoms evaporation and migration to the transfer line. The placement of the MM directly 
into the transfer line, instead, was regarded as unconventional and due to the high 
yttrium boiling point (~3337 °C), which lead to unsuccessful trials with the 
conventional method.  
The transfer line was heated up with the help of current passage, until a maximum of 
420 A which corresponds to about 2200 °C. The line heating allowed yttrium 
evaporation and atomization. The heating guaranteed also the generation of anode 
current, as described in paragraph 3.2.2. The extractor was placed at 50% of the 
distance and at -25 kV from the ionization source. The WF, to separate yttrium 
(A=89.9) from the other ionized species, was set as follow: electric field 1500 V and 
current inducing magnetic field 89.8 A. To focus yttrium beam onto the final NaCl 
target, triplets and deflectors were set to the value reported in table 3.2. 
 
Table 3.2. Triplets and deflectors value for beam focusing. 
Deflector 1- S1 1792 V 
Deflector 2- S2 0 V 
Deflector 3- S3 974 V 
Deflector 4- S4 0 V 
Triplet 1- Q1 1368 V 
Triplet 2- Q2 703 V 
Triplet 3- Q3 1276 V 
 
 
EM allowed the definition of beam dimension and position. It gave as output couples of 
values xmax-x’max, xmin-x’min and ymax-y’max and ymin-y’min, every couple having a value of 
position (x) and divergence (x’) of the beam.  
The coordinates of the beam at the NaCl disk were calculated with the following 
formulas:  
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𝑟𝑥
+ =  𝑥𝑚𝑎𝑥 + 𝑥′𝑚𝑎𝑥 ∙ 𝑠 (3.1), 
𝑟𝑥
− =  𝑥𝑚𝑖𝑛 + 𝑥′𝑚𝑖𝑛 ∙ 𝑠 (3.2), 
𝑟𝑦
+ =  𝑦𝑚𝑎𝑥 + 𝑦′𝑚𝑎𝑥 ∙ 𝑠 (3.3), 
𝑟𝑦
− =  𝑦𝑚𝑖𝑛 + 𝑦′𝑚𝑖𝑛 ∙ 𝑠 (3.4), 
where s is the distance between EM collimator and the disk and had a fixed value of 336 
mm. 
To verify the composition of the beam (not only yttrium was ionized) several mass 
scans were carried out. The mass scans were performed thanks to the use of the WF: the 
electric field was kept constant and the magnetic field was increased in order to deviate 
the ions depending on their m/q values. A system of slits after the WF was used to allow 
only the selected mass to pass. Slits were at a distance of 2 or 4 mm depending on beam 
intensity. The mass scans were performed at each line current, from 350 A to 420 A. 
3.2.4.2 Tests preliminary to yttrium beam deposition on NaCl disk 
Before performing deposition, some tests were carried out using the same conditions of 
the deposition to monitor the trend of the beam and predict the number of yttrium atoms 
impinging the secondary target ad thus develop a suitable analytical method. The data 
points were then imported with the Software Origin (Version Pro 2015 9.2) and the 
values of current integrated in time to obtain the value of charge. With the assumption 
that the charge carried by one single atom is known, i.e. 1.60217662 × 10-19 coulombs, 
the number of deposed atoms were calculated dividing the total charge for the value of 
charge of one single particle.  
3.2.4.3 Yttrium quantification 
The analysis method for yttrium was set on the ground of the foreseen yttrium atoms on 
the secondary substrate. It was assumed that after the deposition the disc was dissolved 
in 10 mL of HNO3 0.1 M and analyzed with ICP-OES. 
The analytical method was assessed so as to be linear in the concentration range, 
sensible, accurate and precise. Standards were prepared at 2, 7, 10 e 70 ng/mL using 
HNO3 0.1 M + NaCl 18% to obtain the same matrix of the sample. For each 
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concentration three measures were taken and data fit to obtain calibration curves 
considering the three wavelengths  = 371.030 nm, 360.073 nm and 377.433 nm. 
In order to find out the best  for the measurement in terms of precision, accuracy and 
limit of detection (LD), the following considerations were taken into account [3.23]. 
LD is the lowest Y3+ concentration value satisfying the following equation: 
|𝛼| + |𝜎| ≤
𝑓%
100
∙ 𝜇 (3.5), 
where andare accuracy and precision and 𝑓% is the percentage of indetermination 
admitted in the analysis of the true value concentration . Accuracy is calculated 
through the equation 3.6: 
|𝛼| = |?̅? − 𝜇| (3.6), 
where ?̅? is the mean value of the concentration measurements. To evaluate the 
quantification method, the equations 3.7 and 3.8 were also considered:  
𝐷𝑆% =
𝜎
?̅?
∙ 100 (3.7), 
𝑊% =
?̅?
𝜇
∙ 100 (3.8), 
where DS% is the standard deviation (%) and W% represents the percentage of 
observed value on the true one. By substitution of equations 3.6, 3.7 and 3.8 into 
equation 3.5, we obtain: 
|𝑊% − 100| + |
𝐷𝑆%×𝑊%
100
| ≤ 𝑓% (3.9), 
which, assuming that f% = 7.5% [3.23], allows the determination of the LD values. The 
counts measured for the standards at 7, 10 and 70 ng/mL by the instrument at the three 
wavelength were used to determine ?̅?, W%, DS% and f% and thus determine the best . 
3.2.4.4 Yttrium deposition 
900 L of yttrium chloride (1000 mg/mL) were loaded onto the MM, evaporated by 
mild heating and introduced into the transfer line of the SPES PIS. The latter was heated 
up to ~2000 °C (420 A), the extractor placed at -25 kV, 50% of the distance, the 
deflectors and triplets set according to the values reported in table 3.2, the WF was 
switched on (EF 1500 V and current inducing magnetic field 89.8 A) and the slits were 
left open. A sodium chloride disk (1.8 g) was placed at the end of the line and the 
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ionized yttrium was collected on it, by leaving all the diagnostic devices out of the beam 
channel. The FC2 was periodically inserted into the channel to monitor the beam trend 
and calculate, as described above, the quantity of yttrium atoms impinging the NaCl 
substrate. The disc was removed after deposition and dissolved in 10 mL of HNO3 0.1 
M. The solution was finally analyzed via ICP-AES (see above). 
3.2.5 Iodine Beams [3.1]  
3.2.5.1 Iodine beams production and efficiency determination 
For ionizing iodine, the FE was used in the same conditions as for yttrium, with the 
difference that the MM loaded with iodine was inserted in the conventional way, i.e. in 
the oven, connected to the transfer line of the ion source.  
For the ionization efficiency determination 40 L of KI (1.0 g/L in water) were dropped 
onto the MM and the solvent evaporated. The MM accurately folded was inserted into 
the oven and assembled in the ion source. The transfer line was heated to 400 A (~ 2000 
°C) and the extraction set at 25 kV. The beam focalization devices were set as follow: 
S1, S2, S3 and S4 0 V and Q1, Q2 and Q3 1893, 891 and 2010 V, respectively. The 
Wien Filter was switched on to allow mass separation and isolate the mass 127. To 
allow iodine evaporation in a controlled manner, the oven was slowly switched on. 
When the oven was between 5 and 10 A, the iodine was evaporated and consequently 
ionized. 
The secondary target used for Iodine was AC/PVA. Being this kind of target 
conductive, it was used itself as a faraday cup (called FC3). This allowed to monitor 
during the depositions tests the quantity of I+ ions impinging the target. Since this 
“home-made” FC was not suppressed2, one test was carried out to calculate the 
correction factor to apply to eliminate any alteration in the current reading. A 
comparison of the current was made with FC2 (suppressed), being the closest one to 
FC3. The integrated charge of FC2 and FC3 over 1000 seconds was compared, when 
the beam current was constant. Comparison of the two integrated charges allowed to 
determine the correction factor to apply to the detected current in FC3.  
                                                 
2 The electron suppressor is a device fed at high voltage and coupled to the faraday cup which provides low error in 
the beam current measurement. It reduces losses due to the backscattering of incident ions and the emission of 
secondary electrons due to the beam impact. 
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3.2.5.2 Iodine beams deposition 
Three deposition tests were carried out. Each time 150 L of KI 1.0 g/L (~1 mole) 
were loaded on the MM and introduced in the FE.  The deflectors and triplets were set 
as follow: S1, S2, S3 and S4 = 175, 100, 20 and 30 V and Q1, Q2 and Q3 = 1775, 881 
and 2493 V, respectively. The slits were left open. The ionization source, WF and the 
oven were switched on as described above. After the deposition the disc was removed 
and iodine extracted. 
 3.2.5.3 Iodine recovery 
The extraction of iodine from the AC/PVA disks was carried out by means of a water 
solution at basic pH. The addition of NaOH induces iodine dismutation according to 
reactions: 
𝐼2 + 2𝑂𝐻
− → 𝐼− +  𝐼𝑂− + 𝐻2𝑂                                                             (3.10), 
3𝐼𝑂−  → 2𝐼− + 𝐼𝑂3
−                                                                                (3.11), 
These iodine species are water-soluble and for this reason they pass to the water phase 
and are extracted. 
The discs were minced, transferred to a glass tube and 5 mL of NaOH 0.5 M were 
added. The tube was centrifuged for 5 minutes at 5,000 rpm for 30 min, RT. The 
supernatant was removed and kept for analysis. The procedure was repeated twice more 
adding every time 5 mL of NaOH (0.5 M). The second and third part of the extract were 
added to the first one and analyzed all together. For the third deposition the sample was 
treated equally, but the procedure was carried out at 55 °C to improve the extraction 
efficiency. 
3.2.5.4 Iodine analysis 
The titration method was used. The extracted samples were taken to an acidic pH 
adding few drops of H2SO4 3M (final pH between 4.3 and 5.5). The pH had to be 
strictly monitored in order to avoid the dismutation of iodine at basic pH (reaction 3.10 
and 3.11) and the acidic decomposition of Na2S2O3 used for the titration according to 
the undesired reaction 3.12: 
𝑆2𝑂3
2− + 𝐻+ ↔ 𝐻𝑆2𝑂3
2− → 𝐻𝑆𝑂3
− + 𝑆 ↓                                                (3.12). 
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After the H2SO4 addition, the sample was treated with bromine water (Br2). The acidic 
environment was also necessary to avoid bromine dismutation, reaction 3.13: 
𝐵𝑟2 + 2𝑂𝐻
− → 𝐵𝑟− + 𝐵𝑟𝑂− + 𝐻2𝑂                                                       (3.13), 
that would consume the reagent necessary for the conversion of all iodine species to 
iodate (reactions 3.14 and 3.15): 
𝐼− + 3𝐵𝑟2 + 3𝐻2𝑂 → 𝐼𝑂3
− + 6 𝐻+ + 6𝐵𝑟−                                            (3.14), 
𝐼2 + 5𝐵𝑟2 + 6𝐻2𝑂 → 2𝐼𝑂3
− + 12𝐻+ + 10𝐵𝑟−                                       (3.15), 
For these reactions 1 mL of Br2 water was added and the solution was stirred for 15 
minutes. The unreacted bromine was eliminated by addition of few drops of 
concentrated formic acid until the solution was completely decolored. To finally convert 
iodate to iodine for titration, 1 mL of KI (10%) was added to the solution: 
𝐼𝑂3
− + 5𝐼− + 6𝐻+ → 3𝐼2 + 3𝐻2𝑂                                                            (3.16). 
Iodine was then quickly titrated with Na2S2O3 10
-4 M (reaction 3.17): 
2𝑆2𝑂3
2− + 𝐼2 → 𝑆4𝑂6
2− + 2𝐼−                                                                   (3.17). 
For the determination of the equivalent point, 848 Titrino Plus Metrohm was used. The 
instrument measures the change in the redox potential of the solution after the addition 
of the titrant. It has a redox electrode made of a Pt ring and based on the internal 
standard Ag/AgCl.  The titration was carried out with the Dynamic Equivalence Point 
Titration (DET), where the thyosulphate was added in a volume depending on the slope 
of the curve. Smaller volumes were added when the end of the titration was close. This 
allowed to have more accurate results.   
3.2.6 Copper beams 
Copper beams were produced using the aforementioned apparatus. The plasma ion 
source was used and sodium chloride, TraceSelect, was chosen for the secondary target 
production.  
3.2.6.1 Copper beams production and ionization efficiency determination 
For copper beams production and ionization efficiency determination, the MM and oven 
systems were used coupled to the SPES PIS. 40 L of copper standard solution (1 g/L, 
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Fluka Analytics) were dropped on a 10x10 mm tantalum foil and the MM, after being 
folded, was inserted into the oven at 80 mm distance from the opening. The oven was 
then closed on one side and connected to the transfer line on the other one. The 
following parameters were set for the FE operation: transfer line current 415 A, oven 
maximum current 80 A, extractor position 50%, S1, S2, S3 and S4 0 V and Q1, Q2 and 
Q3 1395, 695 and 1398 V. Natural copper is an isotopic mixture: 63Cu (69.17%) and 
65Cu (30.83%). For all the tests the most abundant isotope was considered. For the 
isolation of mass 63, the WF was used (Vp 2579, Vpe 590 V
3 and IWF 111 A) and the 
slits were open (18 mm). The 63Cu beam current was measured until no more current 
could be detected. The current was integrated and the value of charge calculated.  
3.2.6.2 Copper beams deposition and copper analysis 
Copper deposition tests were carried out placing the secondary target in a different 
position of the beam line, due to the upgrades of the FE. A second triplet system was, 
indeed, installed after the second FC, which allowed a better beam focalization. A third 
diagnostic unit, equipped with a FC3 and a BP3, was installed at the end of the line. The 
sodium chloride discs (1.8 g) used for copper deposition were installed inside the new 
FC. This way the target could be moved in and out from the channel, using the motors 
of the FC.  
Prior to each deposition, one MM loaded with 200 L of copper nitrate (1 g/L) was 
inserted into the oven (from 4 to 8 cm from the oven closure) and connected to the PIS 
transfer line. The slits were open at 18 mm, and the triplets and steerers set as follow: 
Q1, Q3 and Q3 875, 695 and 1398 V and S1, S2, S3 and S4 0 V. The WF was switched 
on Vp 2579, Vpe 590 V and IWF ~111 A. The IWF was checked prior to each test, closing 
the slits at 2 mm in order to allow the best mass selection (63Cu). The second triplets 
subsystem was set as follow: QT1, QT2 and QT3 1760, 850 and 1775 V, respectively. 
The best focalization was possible thanks to the use of the BP3.  
The oven was then switched on, the FC3 with the NaCl disk built on it was put into the 
channel, while the FC2 and all the other interceptive devices were removed from the 
channel, to allow the copper beam to impinge on the secondary target. The oven was 
heated up to a maximum of 65 A, and the deposition carried out for 4-5 hours. The FC2 
                                                 
3 This parameter Vpe was used only for copper beams, after an upgrade of the FE. 
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was used to detect the 63Cu current every 20-30 minutes. The values of current were 
integrated in time using the software Origin Pro (2015) in order to estimate the total 
copper atoms reaching the NaCl target. 
After the deposition, the target was removed and dissolved for analysis. Prior to 
dissolution, since the beam spot was very clear and to reduce the sodium chloride 
amount, the portion of the disk were the copper was visible was separated from the rest, 
breaking the substrate. Two different procedures were followed for copper extraction 
from the disc. In the first 2 depositions, the disk was dissolved in 20 mL of HNO3 0.5 
M, under stirring and mild heating. After 20 minutes the solution was quantitatively 
transferred to a 100 mL flask and the volume adjusted with HNO3 0.5 M. The 3
rd and 4th 
disks were treated differently; after weighing, they were transferred to a Teflon vessel, 
and 6 mL of concentrated HNO3 were added. The vessels were then closed and heated 
up thanks to a microwave oven to 180 °C for 20 minutes. After cooling down, the 
solutions were transferred to two 50 mL-flasks and the volume adjusted to 50 mL. In 
both cases standards at 100 g/L were prepared for Graphite Furnace Atomic 
Absorption Spectroscopy (GF-AAS, Varian ©, lamp current = 4 mA, = 327.4 nm). 
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3.3 Results  
The results of ionization and deposition for yttrium, iodine and copper are here reported. 
3.3.1 Yttrium ionization 
Yttrium beam production was plagued by difficult atom evaporation. Yttrium has a very 
high boiling temperature. At atmospheric pressure its boiling point is 3370 °C; this 
value decreases when operating in vacuum conditions (5∙10-6 mbar), reaching the value 
of 1600 °C [3.24]. To overcome this limiting factor two different possibilities where 
studied: (i) the choice of the most volatile yttrium salt and (ii) the positioning of the 
MM in the hottest region of the ion source without folding it as in the case of iodine and 
copper.  
Preliminary tests with the conventional MM system were not successful; very low beam 
currents were produced. For this reason, tests were later performed positioning the MM 
in the transfer line (40 mm from the gas injection and very close to the hot cavity), after 
folding the MM only once. With this set-up the observed yttrium currents were higher, 
up to a value of ~30 nA, when the temperature was ~2200 °C, see figure 3.2. 
As already mentioned, the Plasma Ion Source (PIS) was used to ionize yttrium. The 
crucial parameters for this kind of apparatus are described here. Firstly, the transfer line 
(later only line) temperature, which was responsible for yttrium evaporation; the heating 
of the line influenced the cathode temperature as well. The electron current was 
influenced also by the anode potential, which was fixed at 150 V. Moreover, a constant 
argon flux was used for plasma formation. To increase the ionization efficiency a small 
axial magnetic field (current 5 A, max voltage 30 V) was produced in the anode region, 
with a coil surrounding the ion source. The magnetic field improved the ion source 
performances by means of a plasma confinement effect. Since the oven was not used 
(MM placed directly in the transfer line), the only way to control yttrium evaporation 
was the transfer line heating, which also controlled the electron current, and so yttrium 
ionization. As can be observed from picture 3.2, sharp peaks were present in the trend 
of the yttrium beam current throughout the ionization test, corresponding to the imposed 
increases in the cathode temperature. The cathode was heated up by 420 A in order to 
obtain yttrium evaporation and ionization; at 380 A, the temperature had been proved to 
be above 2000 °C [3.16]. The use of the same numerical method allowed the calculation 
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of the temperature of the transfer line at 420 A which turned out to be higher than 2200 
°C. 
 
Figure 3.2. Trend of yttrium beams during tests. Sharp peaks correspond to to the 
increase in the cathode temperature. 
From 350 A, electron current was detected and a consistent ion beam was produced. A 
representative mass scan is presented in figure 3.3A. As can be observed many peaks 
can be observed at low mass values (N2 mass 28 for example), but no peak was detected 
corresponding to mass 89. Figure 3.3B, instead, shows a mass scan obtained after the 
introduction of YCl3 in the MM.  
 
Figure 3.3 (A) Mass scan prior to yttrium introduction. (B) Mass scan evidencing 
yttrium mass, after yttrium introduction. 
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Tests were performed to compare yttrium nitrate and chloride as possible species to 
introduce in the mass marker. As can be observed from the graph of figure 3.4, yttrium 
chloride gave beam currents higher than those obtained with the nitrate at similar anode 
currents, i.e. cathode temperatures. For this reason, YCl3 was chosen for the deposition 
tests.  
 
Figure 3.4. Comparison between the yttrium currents in the chloride vs the nitrate 
form is made. To make a meaningful comparison, the yttrium currents were 
evaluated at similar anode currents. For each value the chloride gives always 
higher currents. 
We observed that the MMs loaded with Y(NO3)3, after the heating, had a white fine 
powder on them. For this reason, we hypothesized the formation of yttrium oxide, a 
highly refractory material, on the MM. 
Before performing deposition, some tests were performed to monitor the trend of the 
beam current with increasing cathode temperatures, as reported in figure 3.2. The 
integration of the curve made it possible to calculate the number of atoms in the beam, 
Nt = 1.62∙1015. This was important to estimate the yttrium quantity on the secondary 
target. Assuming that the sodium chloride disc would be dissolved in a volume of 10 
mL, a concentration of about 24 g/L was expected in the solution. ICP-OES turned out 
to be a precise and accurate technique in this concentration range (see paragraph 3.3.2). 
3.3.2 Yttrium quantification 
In figure 3.5 the three calibration ICP-OES curves at = 371.030, 360.073 and 377.433 
nm are reported. The experimental data were fitted with a straight line, f(x)=ax+b, 
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where a and b turned out to be, respectively: 2393 and 179 for = 371.030 nm, 1251 
and -1210 for = 360.730 nm, 1200 and 447 for = 377.433 nm.    
The one at = 371.030 nm turned out to be the best one in terms of sensitivity of the 
analysis (slope 371.030 = 2394 >> 360.073 ~ 377.433).  
 
 
Figure 3.5. Calibration curves for yttrium at three different wavelengths. 
In table 3.3 and figures 3.6, 3.7 and 3.8 the observed values, the W% and the DS% are 
reported for each wavelength. The observed values were calculated from the equation of 
the straight lines, while W% was calculated according to equation 3.8.  
Table 3.3. Results of ICP-OES for yttrium. Comparison of wavelength. 

[ng/mL] 
?̅? W% DS% f% 
371 
nm 
360 
nm 
377 
nm 
371 nm 360 nm 377 nm 
371 
nm 
360 
nm 
377 
nm 
371 
nm 
360 
nm 
377 
nm 
0 0.4 0.7 0.5 - - - 17.5 20 12.8 - - - 
7 6.8 6.6 6.7 97.3 95.0 96.2 7.0 4.0 3.4 9.5 8.8 7.1 
10 9.7 9.6 9.7 96.9 95.7 97.0 1.3 4.3 1.2 4.3 8.4 4.2 
70 70.1 70.1 70.1 100.1 100.1 100.1 3.6 6.0 5.7 3.7 6.1 5.8 
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The f% values calculated from equation 3.9 indicated that the LD values were 10 ng/mL 
for =371 and 377 nm and 70 ng/mL for =360 nm, since the percentage of 
indetermination (f%) allowed for the analysis was 7.5 [3.23].  
 
 
Figure 3.6. Accuracy (blue line) and precision (red line) of the method for the 
analysis of Y3+ at 371.030 nm 
 
 
 Figura 3.7.  Accuracy (blue line) and precision (red line) of the method for the analysis of Y3+ 
at 360.073 nm 
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Figura 3.8. Accuracy (blue line) and precision (red line) of the method for the 
analysis of Y3+ at 377.433 nm 
Due to the higher sensitivity, accuracy and precision, the analysis were carried out 
considering the =371.03 nm.  
3.3.3 Yttrium deposition 
The trend of the first deposition test is reported in figure 3.9; the curve was integrated 
obtaining the values reported in table 3.4 (Test 1). The same was done for test number 
2. During the first deposition 1.3x10-4 C, corresponding to 8.0x1014 yttrium atoms, 
reached the NaCl target. A second deposition test was carried out, where the yttrium 
charge impinging the NaCl disk was 10.0x10-5 C, corresponding to 6.2x1014 atoms. 
After irradiation, the substrates were dissolved in 10 mL of HNO3 0.1 M and analyzed 
by means of ICP-OES. The solution of the first disc had a concentration of 12.96 ±1.4 
ng/mL, the second one 5.00 ±0.1 ng/mL, corresponding to 8.78x1014 and 3.39x1014 
yttrium atoms, respectively. The results are summarized in table 3.4. 
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Figure 3.9. Yttrium beam trend during a deposition test. The FC2 was inserted at 
certain times (blue dots) to monitor the beam.  Integration of the curve gives the 
number of ionized atoms that reach the deposition substrate. 
 Table 3.4. Results for yttrium depositions. 
Test 
Integrated 
charge [C] 
Yttrium atoms 
impinging the 
target [N] 
Yttrium atoms 
detected with 
ICP-OES [N] 
Atoms recovered 
from the substrate  
[%] 
1 1.3∙10-4 8.0∙1014 8.8∙1014 100.0 
2 1.0∙10-4 6.2∙1014 3.4∙1014 54.8 
 
3.3.4 Iodine 
Iodine beams were produced by the SPES FE for the first time. The ionization 
efficiency of iodine with the SPES PIS was not known so three tests were performed to 
evaluate it. Efficiency turned out to be 19.34 % (SD=0.34) when operating with the 
cathode at 400 A. Iodine evaporation was efficiently controlled by means of the oven 
heating. No close interfering masses were observed as shown in figure 3.10. Iodine 
evaporation and consequently its ionization started at oven currents of 10 A.  
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Figure 3.10. (A) Mass scan prior to iodine introduction. (B) Mass scan after iodine 
introduction and oven heating. 
Analytical methods and the iodine recovery process from the AC/PVA matrix were set. 
The Limit of Quantification (LOQ) for iodine analysis was 3·10-8 moles of I-. 
In contrast to the previous deposition tests, the beam current was continuously 
monitored on the activated carbon substrate (FC3) during the test. Carbon is, indeed, a 
conductive material so the substrate was used as a homemade FC. The home-made FC 
had no suppression electrode, so a correcting factor for the count of the exact iodine 
current had to be applied. The AC/PVA substrate turned out to register 12.9% more 
current than the suppressed FC. This was kept under consideration for the following 
calculations. 
Three deposition tests for iodine were carried out; the beam trend for the first test is 
outlined in figure 3.11 and data reported in table 3.5. The number of atoms loaded in the 
MM was calculated on the ground of iodine ionization efficiency, which was calculated 
and was ~19%, and the detection limit of the analytical technique, in order to be able to 
quantify iodine after extraction form the AC/PVA disc. The number of iodine atoms 
reaching the AC/PVA target was calculated from the integration of the FC3 signal over 
time, applying the aforementioned suppression correction. Following extraction, iodine 
was titrated and the final quantification and efficiency data are reported in table 3.5. 
After the first two depositions we could titrate 2.16·1016 and 1.7·1016 atoms of iodine, 
which are 22.7 and 17.2% of the total number of iodine atoms impinging the AC/PVA 
target. In the third deposition, we measured 1.2·1017 atoms of iodine, 63.7% of the 
atoms impinging the target. 
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Figure 3.11. Iodine currents during deposition test on the AC/PVA matrix. Large 
fluctuations are due to the fact that the signal read on the substrate is unstable, 
because there is no electron suppression electrode. 
Table 3.5.  Results of iodine depositions tests.NMM is the number of 
iodine atoms loaded on the MM; Nt is the number of iodine ions 
impinging on the AC/PVA target, calculated from integration of the 
current. The third column reports the number of iodine atoms 
measured the titration. 
 
Test 
Integrated 
charge 
[C] 
Iodine 
atoms 
impinging 
the target 
[N] 
Iodine atoms extracted 
from the target 
Chemical 
recovery from the 
target 
1 5.5·1017 9.4·1016 2.1·1016 22.7 % 
2 5.5·1017 9.9·1016 1.7·1016 17.2 % 
3 7.5·1017 1.9·1017 1.2·1017 63.7 % 
 
3.3.5 Copper ionization  
Copper was ionized for the first time using the SPES PIS. It was introduced in the FE 
by means of the MM technique, so ionization occurred after the oven was heated up, 
using currents of ~30 A up to 80 A. Several mass scans were performed to prove copper 
ionization using the WF.  
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A typical mass scan for copper is reported in figure 3.12A. Copper is clearly identified 
thanks to the two peaks of masses 63 and 65. The isotopic abundance ratio was checked 
by the comparison of the peaks heights, which gave a value of 68.7/31.3, very close to 
expected values of 69.1/30.8. 
The ionization efficiency was calculated repeating the assay every time with a new MM 
until all the copper was evaporated and no more copper current could be detected. The 
time necessary was around 4 hours keeping the Cu+ current at about 200 nA, giving an 
efficiency of about10%. In figure 3.12B we report the copper beam current trend. 
 
 
Figure 3.12. (A) Mass scan of copper beams and (B) trend of copper beam in time 
during ionization tests. 
3.3.6 Copper beams deposition and copper analysis 
All the targets irradiated during the copper depositions, resulted in clear brownish spots 
of the beam. The first 2 depositions, carried out with the FE at the upgrade level of July 
2017, had a spot like that reported in figure 3.13A, while the latest, performed in 
September 2017 had a smaller spot (figure 3.13B).  
 
Fiugre 3.13. The copper beam spots on the sodium chloride discs after the July 
deposition tests (A) and September (B). 
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The quantities of expected copper on the substrate, calculated thanks to the integration 
of the beam current in time, and the real detected ones are reported in table 3.6. The first 
two depositions were carried out for a longer time period and at higher heating currents, 
for this reason the expected copper was 9.94 and 5.21 g, while the measured ones, 
after dissolution in HNO3 0.5 M, were 1.46 and 1.09 g, respectively. During 
depositions 3 and 4, 1.12 and 0.94 g was deposed, while the measured ones were 0.54 
and 0.50 mg, respectively.  
Table 3.6. Results of copper deposition. 
 
Copper (current) 
measured in FC2 and 
integrated in time  
[g] 
Copper 
measured via 
GF-AAS  
[g] 
 
1st 
deposition 
9.94 1.46 
Target dissolved in HNO3 
0.5 M,  
mild heating 
2nd 
deposition 
5.21 1.09 
Target dissolved in HNO3 
0.5 M,  
mild heating 
3rd 
deposition 
1.12 0.54 
Target dissolved in 
concentrated HNO3,  
180 °C for 20 min 
4th 
deposition 
0.94 0.50 
Target dissolved in 
concentrated HNO3,  
180 °C for 20 min 
3.4 Discussion 
To test the possibility of using RIBs produced at the SPES facility in Legnaro for 
radionuclides production, the SPES test bench, named Front End, was used in off-line 
mode and tests were performed by means of the Mass Marker technique. It was possible 
to produce iodine and copper ion beams with good ionization efficiencies > 19% and 
~10%, respectively. It was also possible to ionize and detect yttrium ions, but the 
ionization efficiency for yttrium was very low. 
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The ionization of yttrium was greatly affected by its poor volatility (3300 °C 
atmospheric pressure, 1500 °C 10-6 mbar [3.24]). To observe appreciable yttrium 
currents (> 10 nA) the quantity of yttrium solution loaded on the MM had to be 
increased (900 L), and the MM was not placed inside the oven, but directly into the 
transfer line of the ion source to facilitate the evaporation. Also the yttrium salt seemed 
to have an influence on the ionization, the use of YCl3 was, indeed, more effective than 
Y(NO3)3. We hypothesized the possible formation of yttrium oxide, a highly refractory 
material, when using the nitrate, after heating. The presence of a fine white powder on 
the MM after the ionization test was considered another evidence of the occurrence of 
this phenomenon. 
Although yttrium currents, and consequently yttrium quantities, were very low (~100 
ng), thanks to a very sensible analytical method, yttrium could be detected after 
implantation on the secondary target. The recovery of yttrium from the secondary 
targets were high (100 and 53%). The results of the ionization of yttrium are not 
encouraging if one considers the possible production of 90Y with the ISOL method. 
Nevertheless, 90Y remains one the radionuclides considered for the production within 
the ISOLPHARM project, because 90Sr, the mother radionuclide of 90Y is also produced 
inside UCx target and can be ionized and recovered more efficiently using the SPES 
Surface Ion Source [3.15,3.1,3.6]. For this reason, we can consider its production via a 
very pure 90Sr/90Y generator. 
Iodine on the contrary is highly volatile, for this reason the MM was placed inside the 
oven. The ionization efficiency was good (>19%) and high currents could be detected at 
low oven temperatures (~10 A). The biggest problem for iodine was related to its 
chemical recovery from the AC/PVA secondary target. The first two depositions discs, 
indeed, were treated without heating, and this way the recovery efficiency was low 
(~20%). A great improvement (>60%) was possible for the third deposition target, that 
was heated up to 55 °C during iodine extraction. 
The studies performed with copper are useful for the future production both of 64Cu and 
67Cu with the ISOL method. The ionization efficiency was good (10%). In this case the 
recovery process was improved with the dissolution of the secondary target in 
concentrated nitric acid if compared to the use of 0.5 M HNO3, 50% and 20%, 
respectively. The discrepancy between the expected copper deposition and the amount 
analysed via AAS (see table 3.6) can be due to the fact that the beam current was 
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measured from time to time during the deposition and fluctuation in the beam current 
are not detected, to losses during the beam transport, as the deposition target is quite far 
from the FC2, where the beam current for integration was read, or to a problem in the 
chemical dissolution. 
3.5 Conclusions 
In this chapter the experiments using the Front End, the test bench of the SPES project, 
were described. All three elements under test, yttrium, iodine and copper, could be 
ionized, collected on the secondary targets, and detected after dissolution, even if with 
difficult repeatability caused by instability of the FE. These results however represent a 
very positive starting point for the validation of the “ISOL” part of the ISOLPHARM 
project, making available secondary targets in which desired isotopes are collected. 
Further improvements in the recovery processes of the collected atoms need to be 
developed, together with the consolidation of the experimental apparatus, in order to 
make the production and recovery of the radionuclides a reliable and reproducible 
process.  
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Chapter 4  
Chemical purification from isobaric 
contaminants 
4.1 Introduction 
In this chapter the purification method developed for the separation of Sr2+ and Y3+ is 
described. As previously discussed, the isotopic contaminants of the radionuclides can 
be purified thanks to the ISOL technique by means of mass separation [4.1,4.2]. 
However, not only the isotopic contaminants can decrease the quality of a radionuclide, 
also isobaric and pseudo-isobaric contaminants can affect the purity of the final 
radiopharmaceutical precursors. This is true when long-lived radioisotopes of the same 
mass are produced inside the primary target and have a sufficiently low boiling 
temperature, so they can escape from the target together with the radionuclide of 
interest [4.2]. 
89Sr is a radionuclide used in the clinics as a chloride (SrCl2) for painful bone 
metastases secondary to prostate cancer [4.3]. It is one of the radioisotopes which can 
be produced thanks to uranium fission inside the SPES UCx target [4.2]. For this reason 
its production with ISOL method was previously studied [4.2]. Uranium-fission 
products of mass 89 are neutron-rich radionuclides which quickly decays to 89Sr. For 
this reason, after waiting for a short time all the parents radionuclides of mass 89 cannot 
be found in the secondary target and no purification method has to be developed to 
remove radionuclidic contaminants [4.2]. The only element of mass 89 that will be 
present in the secondary target is yttrium, which is also strontium-89 daughter. 
Nevertheless, the presence of this stable contaminant (89Y) was considered as relevant 
for further 89Sr radiopharmaceutical developments, which do not foresee the use of 
strontium in the form of a chloride, but bound to a chelator. The big advantage of the 
ISOL method for 89Sr is the possibility of producing this radionuclide as carrier-free. In 
this work a method to purify strontium from yttrium was developed.  
Chapter 4 
 
 
76 
An ion exchanger inorganic material, sodium nonatitanate, previously developed for 
nuclear aqueous waste management thanks to its ability to trap strontium [4.5,4.6], was 
synthetized and used for this purpose. Since this material had been described in a patent 
of Sylvester [4.7] for its potential use as a resin for a 90Sr/90Y generator, the synthetized 
resin was also tested for the purification of 90Y from 90Sr and to develop a generator for 
90Sr/90Y loading 90Sr produced with the ISOL technique. 
Sodium nonatitanate (Na4Ti9O20·xH2O), abbreviated as NaTi, structure in figure 4.1, 
was chosen for its very high selectivity and affinity for strontium [4.6,4.8,4.9]. 
Moreover, it is an inorganic material and this guarantees a higher resistance to 
radiations compared to organic resins [4.10].  
 
Figure 4.1. Sodium nonatitanate’s geometry [9]. Red spheres are sodium atoms, 
blue ones are water molecules.  
The synthesis was performed with a hydrothermal method according to previously 
published procedures [4.6,4.11,4.12]. Hydrothermal methodology is characterized by a 
heterogeneous reaction where the solvent, in our case water, at high temperature and 
pressure can dissolve and then recrystallize the starting and target compounds that 
would not be soluble under standard conditions [4.13,4.14]. Hydrothermal synthesis can 
be carried out in two different conditions: supercritical and subcritical. In the first case 
the synthesis is performed above the critical point (Tc=374.1 °C and Pc=22.1 MPa for 
water) and no phase separation between liquid and vapor can be distinguished. On the 
other hand, in subcritical conditions, and above the boiling point of the solvent, the 
solvent and its vapor can coexist in the reaction chamber. The volume occupied by the 
solvent must be in case of water >32% of the total vessel volume. Key feature of the 
system is the fact that it is a closed system: this way the increase in temperature results 
in the rise of pressure. Autoclaves, where temperature and pressure can be controlled 
individually, and “bombs” are systems that can be used for hydrothermal synthesis. The 
latter is the one used for the synthesis of NaTi here reported. A picture of the used bomb 
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and a scheme of it are shown in figure 4.2. Teflon vessel (Volume = 23 mL), where the 
reaction mixture is prepared, is closed inside the metallic container that guarantees the 
safety of the system when the pressure inside increases. 
 
Figure 4.2. Hydrothermal vessel used for the synthesis. 
The increase in temperature of the system turns out in the change of some of the solvent 
characteristics, such as viscosity, dielectric constant and density. The crystallization 
process is the step necessary to pass from particle suspension to crystalline powder. 
This happens through nucleation, aggregation and particle growth [4.13,4.14].  
In the case of sodium nonatitanate the synthesis was carried out at the limit temperature 
of 175 °C, in order to have a semi crystalline structure, ideal for strontium trapping. As 
described by Merceille [4.12] the semi crystalline NaTi has the correct distance between 
its layers. Its structure is not yet fully understood, but it is assumed to be composed of 
TiO6 octahedral chains linked into layers with exchangeable Na
+ cations in between 
[4.12]. The uptake of strontium occurs after the exchange with two Na+ ions.  
In this work NaTi was synthetized at different temperatures 100, 150 and 175 °C, 
characterized and used for strontium and yttrium purifications. The best conditions for 
the purification were studied and experiments with cold strontium and yttrium were 
carried out in order to assess a simple and fast method for ISOL 89Sr and 90Sr/90Y. 
For these tests analytical methods for strontium and yttrium were used. For the first one 
atomic absorption spectroscopy with graphite furnace atomizer was used (GF-AAS) 
adjusting the samples matrix with the addition of HNO3 to maximize the signal [4.15]. 
Yttrium was analyzed with a spectrophotometric technique using the complexant 
Arsenazo (III) [4.16,4.17]. 
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4.2 Materials and Methods 
4.2.1 Materials 
All the reagents were purchased from Sigma Aldrich: sodium hydroxide (≥98%, 
pellets), titanium isopropoxide (≥97%), strontium nitrate (Standard for AAS, 
TraceCERT® 1000 mg/L in nitric acid), yttrium nitrate (Standard for ICP, 
TraceCERT® 1000 mg/L in nitric acid), nitric acid (≥69%, TraceSELECT®), 
hydrochloric acid (≥37%, TraceSELECT®), sodium nitrate (99.995% trace metal 
basis), sodium chloroacetate for synthesis (EMD Millipore), Arsenazo (III) (calcium-
sensitive dye), sodium chloride (TraceSELECT). 
4.2.2 Synthesis of Sodium Nonatitanate (NaTi) 
Sodium nonatitanate (NaTi) was idrothermally synthetized according to a previously 
published procedure [4.6,4.11,4.12]. The reaction involved in the synthesis was (4.1):  
9𝑇𝑖(𝑂𝐶3𝐻7)4 + 4𝑁𝑎𝑂𝐻 → 𝑁𝑎4𝑇𝑖9𝑂6 ∙ 𝑥𝐻2𝑂                                                   (4.1). 
Around 2.5 g of titanium isopropoxide were quickly added to 2.8 g of a solution of 
NaOH (50% w/w in water) previously prepared in a teflon vessel (internal volume 23 
mL). After stirring, 2 mL of deionized water was added to the mixture and the vessel 
was closed inside the synthesis bomb. The bomb was then heated up inside an oven at 
100, 150 and 175 °C for 21 hours. After removing the bomb from the oven, it was 
cooled down and opened. The synthetized NaTi was carefully washed with deionized 
water and dried at 50 °C overnight. After drying, the powder was ground and sieved. 
The powder with a particle size >40 M was used for the tests. 
4.2.3 NaTi characterization 
After the synthesis, NaTi100, NaTi150 and NaTi175 were characterized using different 
techniques: X-ray Powder Diffraction (XRD), physisorption analysis and Scanning 
Electron Microscopy (SEM).  For XRD analysis the D8 Advance (Bruker®) diffract 
meter was used (5-60°, Cu K) = 0.1542 nm); this analysis was useful to 
determine the identity of the material and to verify its degree of crystallinity. The 
interlayer distance was also calculated with the Bragg’s law [4.18], see equation 4.2: 
2𝑑 ∙ 𝑠𝑖𝑛𝜗 = 𝑛𝜆 (4.2), 
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where d is the distance between the layers,  is the reflection angle, n is a positive 
number and  is characteristic of the incident ray. The data were analyzed using Match! 
software and compared with the literature [4.6,4.8,4.9]. To verify how the difference in 
the synthesis temperature could affect the porosity of the material, the physisorption 
analysis was carried out using ASAP 2020 Plus (Micrometrics ®). The powder 
underwent a degassing step of 10 h before analysis at the same temperature of the 
synthesis (100, 150 and 175 °C for NaTi100, NaTi150 and NaTi175, respectively). The 
BET method was used for Surface Area determination. Powder morphologies were 
determined with Vega 3xmh (Tescan) scanning electron microscope. 
4.2.4 Yttrium quantification method 
For yttrium quantification an analytical method via UV-Vis spectroscopy was 
developed. Arsenazo(III) is a bis-azo derivative of chromotropic acid [4.17], see figure 
4.3, and was used in this study for to its ability of forming colored complexes with 
metal ions. Moreover, this reagent allowed selectivity for yttrium analysis even in the 
presence of other metal ions, by adjusting the solution pH [4.16]. For this reason, based 
on previous studies [4.16], the pH was always adjusted to pH 2.1 thanks to the addition 
of the buffer sodium chloroacetate. The Y(III)-Arsenazo (III) complex formed had a 
violet color [4.16], (figure 4.11).  
 
Figure 4.3. Az(III) structure. 
The range of linearity of the method and its reproducibility were tested. The following 
procedure was used for yttrium quantification: 5 mL of the solution to be tested were 
buffered at pH 2.1 with the addition of sodium chloroacetate (0.1456 g) and of diluted 
(1:10) metal free HNO3. This solution was then quantitatively transferred to a 25 mL 
flask and 2.5 mL of Az(III) 0.04% were added; to reach the final volume of 25 mL mQ 
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water was added to the flask. The solution was analyzed using a UV-Vis Cary 50 
spectrophotometer (Varian ®), recording the spectrum in the UV-visible region from 
800 nm to 250 nm. The absorbance for the calibration curve and sample analysis was 
measured at max=654 nm. The baseline for background subtraction was prepared the 
same way as the samples, but without the addition of yttrium. Solutions of yttrium 
between 200 and 800 g/L were prepared for the calibration curve. Depending on the 
sample matrix, different calibration curves were prepared.  
The possible interference of strontium in solution [4.19] was verified analyzing a 
solution containing a high concentration of strontium (10 mg/L in a total volume of 5 
mL) and treating the sample as for the analysis of yttrium. The pH was taken to 2.1 with 
sodium chloroacetate (0.1456 g) and diluted metal free HNO3. 2.5 mL of Az(III) 0.04% 
were added to the solution after transferring it to a 25 mL flask and diluted with mQ 
water to the final volume and the absorbance measured at 654 nm. The same 
experiment was carried out at a slightly higher pH (3.1) treating the sample equally.  
4.2.5 Strontium uptake in the resin depending on the synthesis 
temperature 
The difference in the capabilities of NaTi100, NaTi150 and NaTi175 in up taking Sr2+ 
was tested. Around 50 mg of NaTi were slurried into a 50 mL test tube, together with 
200 g of Sr(NO3)2 in NaOH/NaNO3 0.05 M in a final volume of 5 mL. The test tube 
was gently mixed for 5 minutes and finally filtered on paper. The eluted solution was 
diluted with metal free HNO3 in order to have an acidic concentration equal to 0.3 M, 
ideal for the analysis. The solutions were then analyzed with Graphite Furnace - Atomic 
Absorption Spectroscopy (GF-AAS, Varian®) to determine strontium concentration. A 
standard at the concentration of 100 g/L in HNO3 0.3 M was prepared for the 
calibration curve. 
The uptake of strontium was tested also with a higher sodium chloride concentration. In 
particular, 0.3 M NaCl was used, because these are the conditions expected after 
dissolution of a 13 mm-diameter NaCl secondary target (see chapter 2). 
 
Chemical purification from isobaric contaminants 
 
 
81 
4.2.6 Yttrium behavior at basic, neutral and acidic pH 
NaTi was described as a selective ion exchanger for strontium [4.9]. Anyway other 
phenomena such as ions hydrolysis can lead to the loss in the resin selectivity. This was 
the case of yttrium, that at not-acidic pH forms colloids, which stick in the resin. The 
behavior of NaTi and yttrium was investigated at different pH values, from basic to 
acidic ones.  
The experiments described in this and in the following paragraphs were carried out with 
a 2 mL plastic syringe, serving as a column, equipped with a polyethylene filter (pore 
size 20 M). 10 mg of NaTi150 (grain size >40 m) were loaded in the column and the 
powder wet with mQ water to remove the fines. 
In the first experiments strontium and yttrium (40 g of Sr2+ and 20 g Y3+) were 
loaded on the resin in a solution of NaOH 0.05M/NaNO3 0.05 M. The fractions 
recovered were analyzed to monitor the behavior of yttrium at basic pH. 
After these tests, solutions containing 20 g of yttrium in a total volume of 5 mL at pH 
values ranging from 1 to 7.5 (1.15, 2.20, 3.22, 4.06, 5.08, 6.09, 7.15 and 7.48) were 
passed through a column, where 10 mg of NaTi had been loaded. The pHs were 
obtained with sodium acetate 0.1 M solutions, buffered at the desired pH after the 
addition of few drops of HCl 0.1 M/NaCl 0.1 M. Before loading the solutions 
containing yttrium, the resin was wetted with solutions at the same pH of the 
corresponding yttrium solution, to buffer the resin. The pH of each solution was 
measured before and after the NaTi. The eluted solutions were analyzed to quantify 
yttrium. 
In order to eliminate the precipitation of yttrium, which was identified as the 
responsible for yttrium uptake in the resin, a higher acetate concentration was used. 
Acetate could act as a counter ion for yttrium, able to prevent its hydrolysis. Acetate 
concentration was 0.3 M and the pH ~4.5. Two experimental set up were used: (i) 20 g 
of yttrium were loaded on the resin (10 mg) in NaOH 0.05 M/NaNO3 0.05 M and then 
the resin was washed with 5 mL of the 0.3 M acetate solution, or (ii) yttrium (20 g) 
was diluted in 5 mL of the acetate solution and passed through the resin (10 mg). The 
eluted solutions were analyzed to quantify yttrium. 
Other strategies to prevent yttrium precipitation in the resin were used: first the washing 
of NaTi with ethanol prior to yttrium passage and afterwards diverse resin pre-
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equilibrations with acidic solution. The used solutions were: HNO3 0.1 M, 
HNO3/CH3COONa 0.1 M, HNO3/NaNO3 0.1M. After washing 10 mg of NaTi with one 
of these solutions, 20 g of yttrium in sodium acetate 0.1 M, pH ~6.5, were passed 
through NaTi and analyzed. 
Additionally, the behavior of yttrium was tested after loading 20 g of yttrium at basic 
pH by NaOH 0.05 M/NaNO3 0.05 M, and washing the resin with acidic solutions of 
diluted mineral acids (HCl or HNO3) at pH values ranging from 0 to 4. Finally, the 
release of yttrium from the resin was tested in a solution of diluted nitric acid (0.1 M) 
with the addition of 0.1 M NaNO3. 
4.2.7 Strontium behavior at acidic pH 
The affinity of NaTi for strontium depends strongly on the pH of the solution [4.6]. That 
is why for the sorption experiments, where the efficiency of trapping Sr2+ was 
evaluated, Sr2+ was always prepared in a sodium hydroxide solution. After studying the 
behavior of strontium at basic pH, it was studied at acidic ones. In particular strontium 
was trapped in the NaTi (40 g of Sr2+ in NaOH 0.05 M and NaNO3 0.05 M), and then 
treated with acidic solutions. The resin was washed twice with 5 mL of HNO3 or HCl 
0.05, 0.1, 0.5 or 1 M and with HNO3 0.1 M at increasing Na
+ concentrations (0.1, 0.2, 
0.5 or 1 M). The release was also studied at slightly higher pH values, up to pH 4, with 
diluted HCl solutions. All the solutions were analyzed for yttrium quantification.  
4.2.8 Purification of strontium from yttrium 
Based on the results of NaTi behavior with strontium and yttrium at the different pH 
values and sodium concentrations, the following scheme, figure 4.4, for 89Sr purification 
from the stable yttrium contaminant was hypothesized.  
The developed procedure was divided into three steps: (1) loading of a solution 
containing Sr2+ and Y3+ (40 and 20 g in 5 mL, respectively) in NaOH 0.05 M and NaCl 
0.30 M; (2) elution with HCl 0.01 M and finally (3) the regeneration of the resin with 5 
mL HNO3 and NaNO3 both 0.1 M. All the procedure was in a 2 mL plastic column, 
equipped with a polyethylene filter (PE) (20 m pore size), where 10 mg of NaTi (> 40 
m) were loaded and wetted with water. Prior to the addition of solution 1, the resin 
was preconditioned with 5 mL of NaOH 0.05 M/NaCl 0.30 M.  
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Figure 4.4. Scheme for strontium purification. 
4.2.9 Purification of yttrium from strontium: a possible generator for 
90Y with NaTi 
A purification scheme was developed for mass 90 purification, in particular for 90Y 
decayed from 90Sr, figure 4.5. ~10 mg of NaTi (>40 m) were loaded into a 2 mL-
plastic column, with one PE filter (20 m pore size). In the first step strontium and 
yttrium (40 and 20 g in 5 mL, respectively) in NaOH 0.05 M and NaCl 0.30 M were 
loaded. Immediately after loading, an acidic solution (HNO3 0.1 M) was passed through 
the column. The eluted solution was eventually loaded again in column 1 to minimize 
strontium loss. After the step 2 the column was conditioned with (i) a basic solution of 
NaOH/NaNO3 0.1 M (pH 12), or (ii) a neutral solution (pH 7) of sodium acetate or (iii) 
a slightly acidic solution (pH 4.5) of sodium acetate 0.1 M buffered with few drops of 
NaCl 0.1 M in diluted HCl. After 10-15 days, the time necessary for strontium to decay 
into yttrium, we eluted the grown yttrium with Na+/HCl 0.10 M (passage 3). 
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Figure 4.5. Scheme for yttrium purification 
To simulate passage 3, a column was loaded with only yttrium (NaOH 0.05 M/NaCl 
0.3M) and treated equally to the columns with strontium, but avoiding passage 2, in 
order to avoid the loss of yttrium. In these tests the elutions of yttrium were carried out 
without the addition of sodium (0.1 M), but in future this step will be carried out with 
the addition of sodium (see 4.14 (B)) to increase yttrium recovery. 
4.3 Results 
4.3.1 Synthesis of Sodium Nonatitanate 
Three types of NaTis were created, depending on their synthesis temperature with good 
efficiencies (~1 g each bomb).  XRD patterns, figure 4.6, of the compounds showed low 
crystallinity in all cases, with 4 main reflection peaks that are characteristic of pure 
NaTi; interlayer distances, calculated with Bragg’s law, equation 4.1, are reported in 
table 4.1.  
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Figure 4.6. XRD patterns of synthetized NaTi: 100 °C blu line, 150 °C red line and 
175 °C green line.  
The interlayer distances of the three synthetized NaTis were 9.0, 9.1 and 8.7 A. These 
values were not considered as significantly different.  
Table 4.1. Interlayer distances calculated with Bragg’s law for NaTi 
synthetized at different temperatures. 
Synthesis temperature 
[°C] 
First Reflection Peak  
[°] 
Interlayer Distance  
[A] 
100 9.8 9.0 
150 9.75 9.1 
175 10.2 8.7 
 
The obtainment of a semi crystalline material was regarded as ideal because it gives to 
NaTi the best configuration for Na+/Sr2+ exchange. The semiamorphous nature was 
confirmed also by the SEM images. From these, indeed, a grain shape structure could be 
observed; crystalline NaTi instead is needle shaped [4.12]. In figure 4.7, NaTi SEM 
images are reported. 
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Figure 4.7. NaTi SEM images. In all the samples NaTi100 (A), NaTi150 (B) and 
NaTi175 (C), grains can be observed. No needle structure was present. The sharp 
surfaces that could be seen, especially in (B), were probably due to grain 
fragmentation. The image for the NaTi175 has different magnitude because a good 
resolution could not be obtained at 8.00 kx. 
Synthesis temperature influenced greatly powder porosity, see the isotherm curves of 
the three NaTis, figure 4.8. The specific surface areas, calculated with BET method, of 
NaTi100, 150 and 175 were 4.2, 102 and 226 m2/g, respectively.  
A 
B 
C 
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Figure 4.8. Isotherm curves obtained for NaTi samples. (A) is the curve of NaTi 
synthetized at 100 °C, no final saturation could be observed and small hysteresis 
was present. (B) and (C) are of NaTi synthetized respectively at 150 and 175 °C: 
they had very similar shape, with great absorption at small p/p0 values and large 
hysteresis loops. 
In figure 4.8 the isotherm obtained for each synthesis temperature are reported. NaTi 
100 gave a curve of the III type with a H3 hysteresis loop, associated to slit-shaped 
A 
 
B 
 
C 
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pores, according to IUPAC classification, see figure 2.5, chapter 2. NaTi 150 and 
NaTi175 had IV type curves with H2 hysteresis loops.  
4.3.2 Yttrium quantification method 
The developed quantification UV-Vis method allowed to quantify yttrium in a range 
between 300 and 800 g/L, with the calibration curve method. Good linearity was 
checked by means of the calculation of the R2 values. In figure 4.9 a typical spectrum of 
Az(III) without yttrium is presented. A broad characteristic peak could be observed at 
max= 538 nm [4.17]. The UV-Vis spectrum registered for the solutions containing 
yttrium, figure 4.9 and 4.10 A, had two peaks at =605 and 654 nm. 
  
 
Figure 4.9. Example of a spectrum of a Az(III) solution, pH 2.31, orange line, and of 
a solution containing the complex Az(III)-Y3+.  
The measure of the absorbance values at 654 nm at different yttrium concentrations 
made possible to draw the linearity curve in figure 4.10 (B). The lowest concentration 
of yttrium that gave an absorbance value >0.1 was 300 g/L. Good linearity was 
achieved with R2 values > 0.99. Prior to every yttrium analysis, the calibration curve 
was prepared with freshly prepared standards, due to Az(III) complexes instability. The 
difference in yttrium concentrations could be qualitatively appreciated also with the 
human eye, see picture 4.11, thanks to the different violet intensities. 
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Figure 4.10. (A) UV spectra of Az(III)-Y complexes at increasing yttrium 
concentrations. (B) Calibration line for yttrium quantification. 
When strontium was added to Az(III) at acidic pH (2.3 and 3.1), no Sr(II)-Az(III) was 
formed and no peak was visible, so it was concluded that the presence of strontium 
concomitant to yttrium did not influence yttrium analysis.  
 
Figure 4.11. Yttrium samples, prior to UV analysis. 
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4.3.3 Strontium uptake in the resin 
The three synthetized NaTi were tested for the strontium uptake capacities. The NaTi 
powder was grounded after synthesis and drying, because big grains were produced, 
figure 4.12 and 4.13.  
 
Figure 4.12. NaTi after synthesis, before drying. 
 
 
Figure 4.13. NaTi after drying. 
To avoid the passage of the smallest particles through the filter in the column, the NaTi 
with a particle size > 40 M was used. In all cases, Sr2+ uptake was very high (>99%), 
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proving a strontium up-take capacity >4 g/mg of NaTi. No difference was observed 
when a sodium chloride concentration of 0.3 M was used for the uptake experiments.  
4.3.4 Yttrium behavior at basic, neutral and acidic pH 
After measuring the uptake efficiency of strontium in the resin, the behavior of yttrium 
was investigated. After passing the solution containing strontium and yttrium in the 
resin at basic pH, no yttrium could be detected in any conditions. For this reason, the 
behavior of yttrium at different pH was investigated. First yttrium was passed through 
the resin in solutions at pH values from 1 to 7. Prior to this step the resin was wetted 
with a solution at the same pH to prepare the environment. The pHs of these solutions 
were checked after the passage through the resin. No change in the pH was registered. 
In these preliminary results, we observed that only at acidic pH values, yttrium could be 
recovered. When the pH was > 4, the concentration of yttrium was below the 
quantification limit (300 g/L). At pH 3, ~10 % of the yttrium which was passed 
through the resin could be measured, this quantity was higher at pH 2 ~58% and the 
entire amount of yttrium (100%) was recovered at pH=1. 
All the strategies adopted to avoid yttrium precipitation, including the use of acetate at 
higher molarities (0.3 M) and the pre-washing step of the resin were not successful: 
yttrium in the eluted solutions was always below the quantification limit. 
After these assays, it was decided to focus the attention on the behavior of both ions at 
acidic pH values, see figure 4.14 A.  
At pH 4, we could detect 18.4 ±0.1% of the loaded yttrium, this value was stable also at 
pH 3, when 17.7 ±0.4% was measured. When the pH was 2 and 3, the recovered yttrium 
was 37.4 ±1.5% and 64.8 ±4.5%, respectively.  
In figure 4.14 (B) a comparison was made between the % of yttrium released with and 
without the addition of NaNO3 0.1 M at pH 1 (HNO3 0.1 M). When NaNO3 was added 
to the exchange solution a higher release of yttrium was observed, 85.4 ±5.8% vs 64.8 
±4.5%. 
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Figure 4.14. (A) Release of strontium (green lines) and yttrium (violet) lines at 
acidic pH. (B) Influence of NaNO3 presence for yttrium release at pH=1. 
4.3.5 Strontium behavior at acidic pH 
The release of strontium from the resin at acidic pH by HCl (from 0 to 4), the only 
conditions which allowed the elution of yttrium, was studied. In figure 4.14 (A) the 
amount of strontium released from the resin in the first 5 mL of solution at the various 
pH is reported. At pH 3 and 4 the percentages of recovered strontium were 6.67 ±4.7% 
and 11.56 ±6.1% of the total strontium loaded in the column, respectively. The amount 
released increased tremendously at more acidic pH, being 74.12 ±0.9%, 80.29 ±2.9% 
and 80.99 ±8.7% at pH 2, 1 and 0, respectively.  
When the second 5 mL used for the elution were analyzed no strontium could be 
detected, meaning that after the first washing, no more strontium could be recovered.  
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Afterwards the impact of the use of either HCl or HNO3 on the release of strontium was 
studied. As can be observed from the graphs of figure 4.15, no influence could be 
observed.  
 
Figure 4.15. Release of strontium from NaTi using HNO3 or HCl. 
The amount of strontium released was not significantly different between hydrochloric 
and nitric acid; moreover, the results of these tests confirmed the data reported in figure 
4.14 (A), because the released strontium was ~80% in a pH range between 1.3 (0.05 M) 
and 0 (1 M).  
Finally, the presence of increasing quantity of NaNO3 (0.1, 0.2, 0.5 and 1 M) in the 
acidic solution was evaluated and strontium release quantified. Independently on 
sodium nitrate amount, the release of strontium in the first 5 mL passed through the 
column was always ~60%, while no strontium was present in the solution analyzed after 
the elution with 5 mL more of acidic solution. 
4.3.6 Purification of strontium from yttrium 
The procedure developed for 89Sr purification from the isobaric contaminant 89Y, stable 
contaminant of strontium, is presented in figure 4.4. The process was developed on the 
ground of the behavior of NaTi with strontium and yttrium at the various pH using 
stable solutions of the elements under study. In the first step of the process, the eluted 
solution (E1) had no detectable amounts of strontium and of yttrium. The second eluate 
(E2) was the fraction containing the highest amount of strontium, because the eluent 
HCl 0.01 M (pH 2) allowed to recover ~74% of strontium, while minimizing yttrium 
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(~37% of the loaded), see figure 4.14 (A), discussed later. The third step allowed to 
eliminate all yttrium present in the resin and regenerate the column for further 
purifications.  
4.3.7 Purification of yttrium from strontium: a possible generator for 
90Y with NaTi 
For yttrium purification from strontium the procedure presented in figure 4.5 with NaTi 
was developed. The first step at basic pH, allowed to charge all strontium on the resin. 
The immediate acidic treatment was necessary to eliminate that part of strontium that 
would have been eluted during yttrium recovery. E2 contained 60% of loaded strontium, 
which could be loaded on the column again. After 10-15 days the columns were treated 
with an acidic solution to recover yttrium. No strontium could be detected in the 
solutions coming from the columns where strontium had been loaded. In those where 
only yttrium was loaded, E3 was evaluated.  When a basic solution was passed through 
the column after passage 2, ~35% of yttrium was recovered. The acidic treatment, 
instead, allowed the recovery of ~40% of the loaded amount of yttrium, while the best 
conditions were those where the column was left at neutral pH. In these circumstances 
~50% of yttrium could be recovered.  
4.4 Discussion 
In this chapter the synthesis and use of an inorganic resin, sodium nonatitanate, for 
yttrium and strontium purifications was described. All the tests were carried out with 
the use of stable ions, for this reason the analytical method had to be tuned according to 
the elements’ concentrations and samples matrix. For strontium the analysis could be 
carried out thanks to atomic absorption adjusting the matrix with 0.3 M HNO3 to 
increase the signal [4.15]. For yttrium a spectrophotometric analysis was developed 
with the use of the complexant Az(III) [4.16,4.17]. Thanks to the pH (2.1) it was 
possible to establish an accurate and linear method; this method proved to be selective 
for yttrium even at the presence of a high amount of strontium. The lowest yttrium 
concentration that could be quantified (Abs >0.1) was 300 g/L. This value was in line 
with the literature data [4.16], but somehow limited the possibility of testing the resin 
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with lower amounts of yttrium. For each sample matrix it was possible to build linear 
and reliable calibration curves. 
Sodium nonatitanate could be synthetized with a hydrothermal method at three different 
temperatures (100, 150 and 175 °C). The three types of NaTi, NaTi100, NaTi150 and 
NaTi175, respectively, had similar XRD spectra and showed all a low crystallinity. This 
result was expected, because NaTi can be produced with high crystallinity, only at 
higher temperatures of synthesis (> 180 °C) [4.12]. The morphology of the NaTi (see 
figure 4.7) obtained with SEM confirmed that our NaTis were semi-amorphous. 
Crystalline NaTi, synthesized by Merceille at 200 °C was needle shaped [4.12], while 
the NaTi100, NaTi150 and NaTi175 of this study were all grain-shaped. XRD spectra, 
even if not so clear due to the low crystallinity of NaTi, showed the four characteristic 
peaks of pure NaTi [4.12], confirming the nature of the resin. The interlayer distance of 
~10 Å was typical of NaTi; the layers are made of TiO6 octahedra spaced sodium ions 
and water molecules [4.8]. The BET results were also in line with the literature [4.12], 
the sample synthetized at 100 °C were scarcely porous (BET surface area 4.2 m2/g), 
while highly mesoporous samples could be produced at higher temperature: 102 m2/g 
and 226 m2/g at 150 °C and 175 °C, respectively. These results, together with the 
efficiency in the uptake of strontium in the resin, which was not significantly different 
depending on the synthesis temperature (>99.8%), lead to the conclusion of always 
synthetizing NaTi at higher temperatures. Since the temperature of 175 °C, was at the 
safety limit for the synthesis vessel used in this study, for safety reasons the temperature 
of 150 °C was selected for the following NaTi productions. 
The uptake of strontium in the resin was described as the ionic exchange between two 
Na+ and one Sr2+. Merceille demonstrated that the concentration of Na+ influenced the 
uptake capacities of NaTi [4.6]. For this reason, in all experiments sodium concentration 
was strictly monitored. In particular, [Na+] was kept constant at 0.1 M during the 
strontium sorption step. Since the secondary target developed for the collection of 
strontium ions (Chapter 2 and 3) is made of sodium chloride [4.2], we tested if a 
difference could be seen in the uptake of strontium when the concentration of NaCl was 
0.3 M. This value is the calculated concentration of sodium chloride after dissolving the 
13 mm secondary target in ~10 mL of solvent. In all the experiments the percentage of 
strontium retained in the NaTi was always >99.8%. The solutions to test the uptake of 
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strontium in the resin were always prepared at basic pH, because the affinity increases 
at pH>8 [4.6]. 
Sylvester described in a US patent in 2005 [4.7] the possibility of eluting 90Y with a 
solution of a sodium salt at pH ≥ 7, from a generator made with NaTi, where 90Sr had 
been loaded and let decay. In the tests performed for this PhD thesis yttrium could never 
be quantified after eluting the resin with a neutral or basic solution. Also the use of 
counter ions (as acetate) did not help. This was probably due to yttrium hydrolysis that 
at pH ≥8 forms yttrium hydroxide, a colloid that stuck in the resin. In our conditions it 
was possible to make yttrium go through the column only at acidic pH. When the 
solutions had pH >4 the concentration of yttrium was below the quantification limit 
(300 g/L). At lower pHs: ~10 % of yttrium was measured (pH 3), ~58% at pH 2 and 
the entire amount of yttrium (100%) was recovered at pH=1. When yttrium was 
previously loaded at basic pH and then eluted with acidic solutions, the efficiencies 
were slightly reduced, see figure 4.14 (A). The use of sodium in the solution improved 
the recovery of yttrium from ~65% to ~85% at pH 1 (figure 4.14 (B)). The reason why 
yttrium could be recovered only at strong acidic pH values is that probably yttrium 
undergoes hydrolysis phenomena even at slightly acidic pH, forming colloids that stay 
in the resin. Moreover, NaTi is a resin that keeps a basic behavior because it has high 
affinity for H+, so it exchanges protons for sodium ions, making the solutions more 
basic [4.5] and the pH at the interface with NaTi might be higher and cause yttrium 
precipitation in situ. 
Since no discrimination between yttrium and strontium could be observed at neutral and 
basic pH, the behaviors of both ions were studied at acidic pH, after loading both of 
them on NaTi in a basic medium, and were compared in figure 4.14 (A). The pH which 
showed the highest difference between the two ions and so could be used to separate 
them was pH 2. At this pH the release of strontium was 74.12 ±0.9% and the release of 
yttrium was 37.4 ±1.5%. Thanks to these results the purification set up for 89Sr, figure 
4.4, was hypothesized. According to the suggested process the sodium chloride target 
where 89Sr will be collected, will be dissolved in a basic solution made of NaOH 0.05 
M. The solution will be loaded on the resin (>99.8% of Sr2+ will stay in the NaTi 
together with 89Y). A simple elution with HCl 0.01 M (pH 2) will guarantee to recover 
~80% of 89Sr and ~37% of yttrium. Based on the consideration that very few yttrium 
atoms will be present as contaminants, due to the very low efficiency of its ionization 
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[4.2] and on the fact that it is a stable nuclide, the reduction of ~60% of yttrium could be 
considered satisfactory. 
Regarding the purification of yttrium from strontium, the impossibility of recovering 
yttrium at neutral pH made the use of NaTi for this purification more challenging. The 
possibility of using the resin for the separation of 90Y directly produced with ISOL 
technique from 90Sr was excluded. For this reason, the studies were addressed to the use 
of NaTi for a generator 90Sr/90Y for 90Sr produced with ISOL technique. Based on the 
observation that, after loading Sr2+ on the resin, only in the first passage of the acidic 
solutions strontium was released (74.12%, pH 2), while no Sr2+ could be detected after 
washing again, the procedure described in picture 4.5 was developed. This method 
foresees the loading of 90Sr in NaOH 0.05 M and the washing with HCl 0.01 M, where 
part of 90Sr will be lost, being this the weak point of the method. After waiting for the 
residual 90Sr to decay, yttrium can be eluted with HCl/NaCl 0.1 M. The 90Sr lost in the 
second step can be eventually recovered using a second column or loading the first 
column again. 
4.5 Conclusion 
In this chapter the synthesis and characterization of NaTi was described. This material 
was hydrothermally synthesized and three types of NaTis, depending on the 
temperatures of synthesis, were produced. The NaTi synthetized at 150 °C was then 
used to develop the purification method of strontium and yttrium. All the assays were 
carried out using the cold elements, for this reason analytical methods for strontium 
(GF-AAS) and for yttrium (UV-Vis) were developed. The affinity of NaTi for strontium 
was very high at basic pH, but also yttrium was retained in the resin. Yttrium could be 
recovered from NaTi only at acidic pH (<4), when also strontium was released. For this 
reason, the separation of the two ions turned out to be more challenging. An evaluation 
of the behavior of the two ions in the pH range from 0 to 4 made it possible to find a 
condition where the two ions behaved differently (pH 2). Its use for the purification of 
89Sr from the stable contaminant 89Y, considering the very low amount of 89Y in the 
solution, was satisfactory with a reduction of >60% of the initial amount. NaTi as a 
resin for a 90Sr/90Y generator was also studied and a process developed. In the 
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hypothesized system it will be possible to elute pure 90Y after 90Sr decay. The weak 
point of the system is the loss of 90Sr in the loading process that needs to be optimized.  
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Chapter 5  
Radiolabeling and Characterization of 
Plasma Protein-Binding Ligands 
The work described in this chapter was carried out at the Center for 
Radiopharmaceutical Sciences (CRS) of Paul Scherrer Institute (PSI), in the group of 
PD Dr. Cristina Müller, who kindly gave me the possibility of working on this project. 
Her research focus is the development of small molecular weight radiopharmaceuticals 
for targeting the folate receptor and the prostate specific membrane antigen. The work 
was, recently published in the journal Bionjugate Chemistry: 
http://pubs.acs.org/doi/10.1021/acs.bioconjchem.7b00378. 
5.1 Introduction 
Drug discovery is aimed at the development and selection of drug candidates with 
favorable pharmacokinetic (PK) and pharmacodynamic profiles in order to optimize the 
biological activity and minimize undesired side effects [5.1]. Drug candidates that are 
cleared too fast from the blood circulation require large dosage and/or repeated 
administration which may lead to unwanted toxicity to healthy organs and tissue [5.2]. 
Increasing the half-life of therapeutics in the blood has, therefore, been regarded as a 
valuable means to reduce the number of injections and improve the efficacy of the drug. 
A wide variety of techniques meant to enhance the blood circulation time of drug 
candidates have been proposed and studied [5.3,5.4]. Conjugation of drug molecules 
with high-molecular weight polyethyleneglycole (PEG) or carbohydrate polymers has 
been used to increase the blood permanence by reducing glomerular filtration [5.4]. In 
the case of peptide-based molecules, chemical modification with for instance unnatural 
amino acids have been employed to reduce unwanted enzymatic degradation [5.5]. 
Another strategy to increase the blood circulation time of drugs is to enhance their 
binding capability to blood components with long circulation half-lives, such as the Fc 
region of IgG isotype antibodies, lipoproteins or blood plasma proteins[5.1,5.6]. Indeed, 
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the extent of binding to plasma proteins influences the pharmacokinetic profile of drugs 
which show reduced blood clearance with high binding capability [5.1]. While plasma 
binding properties may reduce the therapeutic effect as only the free fraction can 
penetrate biological barriers and reach the therapeutic target [5.2], it is considered as a 
valuable strategy to avoid undesired side effects of drugs with a narrow therapeutic 
window such as anticancer therapeutics [5.7].  
The most important proteins responsible for drug binding are human serum albumin 
(HSA) and 1-acid glycoprotein (1-AGP) [5.1]. The HSA accounts for 55% of the total 
plasma protein pool (blood plasma concentration: ~700 µM) and is, thus, a major 
protein component of blood plasma [5.8]. It is composed of a single, non-glycosylated 
amino acid chain with a molecular weight of ~66 kDa and a long blood plasma half-life 
of ~19 days [5.1,5.7]. HSA plays an important role in the transport of various 
endogenous and exogenous compounds as it has an extraordinary ligand binding 
capacity and can reversibly bind acidic and neutral compounds [5.1]. It is composed of 
three main domains (I, II, III) which are each divided into two helical subdomains (A 
and B) [5.8]. Two main drug binding sites have been identified: (i) Sudlow’s site I is 
located on the subdomain IIA and binds bulky heterocyclic anions such as the 
anticoagulant warfarin, whereas (ii) Sudlow’s site II is located in the subdomain IIIA 
and binds preferentially extended aromatic carboxylates molecules such as ibuprofen, a 
non-steroidal anti-inflammatory drug [5.8].  
1-AGP is smaller (38-48 kDa) than HSA, highly glycosylated and present at lower 
blood plasma levels (10-30 M) [5.1]. Its blood plasma half-life of ~2-3 days is 
dependent on the extent of glycosylation [5.9]. 1-AGP is responsible for the transport 
of lipophospholipids and biliverdin, but also for exogenous ligands such as antibiotics 
and anticancer drugs. The binding capacity of 1-AGP is lower than of HSA, but the 
binding affinity of its ligands, mostly basic compounds, is commonly higher [5.1].  
Human transthyretin (hTTR)  ̶  originally referred to as pre-albumin  ̶  is a protein (55 
kDa) present in blood plasma at much lower levels (~5 µM) than HSA. It acts as a 
transport molecule for thyroxine hormones and holo-retinol-binding protein [5.10]. 
hTTR is a homo-tetramer and has an in vivo half-life of ~2 days [5.11]. Recently, drug 
binding to hTTR has been demonstrated as a novel strategy to prevent fast clearance of 
therapeutic drugs [5.11].  
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Targeted radionuclide therapy makes use of a tumor targeting agent to deliver the 
therapeutic radionuclide to the tumor site where it acts as a source of radiation to 
damage cancer cells [5.12]. These radiotherapeutic drugs should ideally accumulate 
specifically at diseased sites while sparing healthy tissue from radiotoxic effects [5.13]. 
In recent years, it has been demonstrated pre-clinically that plasma protein binding may 
be of value for the development of radiopharmaceuticals enabling high tumor uptake 
and reducing renal clearance and related toxicities [5.14,5.15]. More recently, a DOTA-
based bisphosphonate as well as PSMA-targeting ligands have been modified with an 
albumin-binding entity to improve their tissue-distribution profile [5.16–5.18].  It is, 
thus, of interest to identify and compare different types of plasma protein binding 
entities to be conjugated with targeting ligands in order to optimize the 
pharmacokinetics of these (radio)therapeutics.  
The aim of this study was to evaluate and compare three different plasma protein 
binders potentially useful in combination with radiopharmaceuticals. Among those was 
a 4-(4-iodophenyl)butyric acid derivative (PPB-01) previously discovered from a DNA-
encoded chemical library by Dumelin et al. [5.19]. This entity was previously used in 
combination with antibody fragments [5.20] as well as with folic acid radioconjugates 
[5.15,5.21] where the desired effect of enhanced blood circulation of the biomolecule 
was successfully demonstrated. The second compound was based on an ethynyl 
benzene entity (PPB-02). The ethynyl moiety served as a bioisosteric replacement of the 
iodine of compound PPB-01 based on a study in which the ethynyl group was evaluated 
as a halogen bioisostere [5.22]. The third entity (PPB-03) was recently reported to 
effectively bind to transthyretin (hTTR) [5.23]. The three entities were functionalized 
with a DOTA chelator via a L-lysine and β-alanine linker moiety using solid phase 
peptide chemistry (Figure 5.1). Radiolabeling was performed with 177Lu (177Lu: T1/2 = 
6.7 d; E-average = 134 keV; E = 113 keV, 208 keV), an established radiometal used in 
clinics for targeted therapy. The three radioligands were investigated extensively in 
vitro and compared with regard to their blood clearance in mice. 
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Figure 5.1. Chemical structures of the investigated plasma protein-binding ligands: 
DOTA-PPB-01, DOTA-PPB-02 and DOTA-PPB-03. 
5.2 Experimental 
All reagents and solvents were purchased from Sigma-Aldrich (Germany), Merck 
(Germany) and Fluka (Switzerland), respectively, and used without further purification 
or drying. All chemicals used for the radiolabeling were metal-free and obtained from 
Sigma-Aldrich (Germany) in Suprapur quality. Analytical radio-HPLC was performed 
on a Merck-Hitachi HPLC equipped with a L-6200A pump, a L-3000 Photo Diode 
Array detector and a Berthold LB 508 radiometric detector. For this purpose, a 
reversed-phase C18 column (5 μm, 4.6 mm x 150 mm, XTerraTM MS, Waters, USA) 
was used. The compounds were synthetized in PD Dr. Müller’s group [5.24]. 
5.2.1 Preparation of 177Lu-DOTA-PPB Ligands and 177Lu-DOTA.  
Each compound, DOTA-PPB-01, DOTA-PPB-02, DOTA-PPB-03 and DOTA, 
respectively, was labeled at the specific activity up to 50 MBq/nmol with 177Lu (Isotope 
Technologies Garching ITG GmbH). The reaction mixture consisted of HCl 0.05 M and 
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Na-acetate 0.5 M (pH 8) at the ratio of 5:1 in order to obtain a solution of pH ~4.5. 
After the addition of the compounds (stock solutions of 1 mM), the reaction mixture 
was incubated at 95 °C for 10 min. The quality control of 177Lu-DOTA-PPB-01, 177Lu-
DOTA-PPB-02 and 177Lu-DOTA-PPB-03 was carried out by reversed-phase high-
performance liquid chromatography (RP-HPLC) analysis (Merck LaChrom HPLC) 
using a C18 column (5 μm, 4.6 mm x 150 mm, XTerraTM MS, Waters USA). The eluent 
consisted of acetonitrile (solvent A) and 0.1% TFA in H2O (solvent B). A gradient of 5-
80% A and 95-20% B was used over 15 min at a flow rate of 1.0 mL/min. The quality 
control of 177Lu-DOTA was carried out via thin layer chromatography (TLC) using 
silica gel plates (~100 x 100 mm2 obtained from commercial plates available at 200 x 
200 mm2, 200 µm, 60Å, VWR, Switzerland). As a liquid phase ammonium acetate 10% 
and methanol (1:1 volume ratio, pH 5.5) was used over a front of 50 mm. The 177Lu-
labeled DOTA complex migrated with the liquid phase (Rf = 0.5) and free 
177Lu 
remained at the starting line (Rf = 0). The TLC plate was exposed to a multisensitive 
medium phosphor screen (Type MS, Perkin Elmer) for 15 s using a Cyclone Plus 
Storage Phosphor System (Perkin Elmer) and analyzed with Optiquant software 
(version 5.0).  
5.2.2 Stability of the radioligands 
The three compounds DOTA-PPB-01, DOTA-PPB-02, DOTA-PPB-03 were labeled at 
a specific activity of 50 MBq/nmol for testing the stability in PBS pH 7.4 and human 
plasma. The radiochemical purity was determined immediately after production (T = 0) 
using HPLC. Dilutions of the labeling solution of each compound were prepared at low 
activity concentration (~10 MBq/500 L) using PBS pH 7.4 with and without the 
addition of ascorbic acid (~120 g). In addition, the stability of the radioligands was 
checked at higher activity concentrations (250 MBq/500 L) with the addition of a 
higher amount of ascorbic acid (3 mg). In the latter case, it was necessary to adjust the 
pH by addition of a solution of sodium acetate (0.5 M, pH 8, 150 µL) to obtain a value 
of 7.0-7.5. The integrity of the radioligands was determined after incubation periods of 
4 h, 24 h and 48 h. 
For the determination of plasma stability, the radioligands were diluted to 30 MBq/500 
L using PBS pH 7.4. An aliquot of the prepared dilutions (50 L, ~3 MBq) were 
incubated in human plasma (Foundation Blood Donation SRK Aargau-Solothurn, 
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Switzerland, ~250 µL) at 37 °C. The compounds’ integrity was determined after 4, 24 
and 48 h. For this purpose, aliquots of the plasma (50 L) were treated with three-fold 
volume of methanol to precipitate plasma proteins. After centrifugation the supernatants 
were filtered and used for analysis using HPLC. 
The HPLC chromatograms were analyzed by determination of the peak area of the 
radioligand and set into relation to the area of the radioligand observed at T = 0 which 
was set to 100%. 
5.2.3 Determination of LogD values 
The n-octanol/PBS distribution coefficients (logD values) of the 177Lu-labeled 
compounds (DOTA-PPB-01, DOTA-PPB-02, DOTA-PPB-03 and DOTA, respectively) 
were determined using a previously published procedure [5.25]. In brief, the compounds 
were labeled at the specific activity of 50 MBq/nmol. A sample of the 177Lu-labeled 
compound (25 µL; ~500 kBq) was mixed with PBS pH 7.4 (1475 µL) and n-octanol 
(1500 µL). The vials were vortexed vigorously for 1 min and then centrifuged (2000 
rpm) for 6 min for phase separation. The activity concentration in a defined volume of 
each layer was measured in a γ-counter (Perkin Elmer, Wallac Wizard 1480). The 
distribution coefficient was expressed as the logarithm of the ratio of counts per minute 
(cpm) measured in equal volumes of the n-octanol phase to the cpm measured in the 
PBS phase. The values reported are the mean (± standard deviation, SD) of the results 
of three independent experiments, each performed with five replicates. Significance of 
the data was determined using a one-way ANOVA with Bonferroni`s multiple 
comparison post-test (GraphPad Prism software, version 5.01). A p-value of <0.05 was 
considered statistically significant. 
5.2.4 Determination of Plasma Protein-Binding Properties 
An ultrafiltration assay was performed for determination of the plasma protein binding 
of the three labeled compounds and of the control 177Lu-DOTA. For this purpose, the 
compounds were labeled at the specific activity of 50 MBq/nmol. The labeling solutions 
were diluted to an activity concentration of 10 MBq in 500 L PBS pH 7.4. Ascorbic 
acid (120 g) was added to these solutions to prevent radiolysis of the radioligands. The 
diluted radioligands (25 L, ~500 kBq, 0.01 nmol) were added to human plasma (250 
L) as well as to solutions of human serum albumin (HSA, Sigma Aldrich, fatty acid-
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free, globulin free, ≥99%, 700 M, 250 L), human 1-acid glycoprotein (hAGP, 
Sigma Aldrich, ≥99%, 30 M, 250 L), human transthyretin (hTTR, Sigma Aldrich, 
≥99%, 5 M, 250 L) diluted in PBS pH 7.4, respectively, and incubated at 37°C for 
30 min. A control experiment was performed using PBS pH 7.4 only. After incubation, 
the samples were loaded onto the ultrafiltration devices (Centrifree ultrafiltration 
devices; 30,000 Da nominal molecular weight limit, methylcellulose micropartition 
membranes, Millipore) and centrifuged at 2000 rpm for 40 min at 20 °C. The filtered 
solutions were measured in a γ-counter. The counts of the filtered solutions were 
calculated as a fraction of the radioactivity in the corresponding loading solutions which 
was set to 100%. The reported values represent the average of three independent 
measurements (± standard deviation), each performed with two replicates. Significance 
of the data was determined using a two-way ANOVA with Bonferroni`s multiple 
comparison post-test (GraphPad Prism software, version 5.01). A p-value of <0.05 was 
considered statistically significant. 
5.2.5 Determination of Relative Binding Affinity to Plasma Proteins 
In order to better understand the binding properties of the radioligands, the percentage 
of bound radioligand to plasma proteins was determined at different plasma 
proteins/radioligand ratios, by means of an ultrafiltration assay. The compounds were 
labeled at a specific activity of 50 MBq/nmol and diluted with PBS (pH 7.4) to 
10 MBq/500 L. Ascorbic acid (120 g) was added to these solutions to prevent 
radiolysis of the radioligands. The diluted radioligands (25 L, 0.01 nmol for 177Lu-
DOTA-PPB-01 and 177Lu-DOTA-PPB-03 and 12.5 L, 0.005 nmol for 177Lu-DOTA-
PPB-02) were added to previously prepared plasma dilutions. Five different plasma 
concentrations were prepared in a volume of 250 L using PBS (pH 7.4) (Table 5.1). 
The samples were incubated for 30 min at 37 °C followed by filtration as described 
above in order to determine the bound fraction. The obtained values were analyzed by a 
semi-logarithmic plot to obtain the IC50 values using the GraphPad Prism software 
(version 5.01). The IC50 value of 
177Lu-DOTA-PPB-01 was set to 1.0. The inverse ratio 
of the IC50 values of the other compounds was calculated to allow comparison of the 
binding affinities of all three radioligands.  
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Table 5.1. Dilutions for determination of relative plasma-proteins-
binding affinity  
Dilution 
HSA concentration in 
plasma 
M] 
[HSA] in plasma-to-[Radioligand] 
ratio 
 
1 700 17500 
2 40 1000 
3 4 100 
4 0.4 10 
5 0.0004 0.01 
 
5.2.6 Determination of the Affinity of the Radioligands to HSA and 
hTTR 
The binding affinity of 177Lu-DOTA-PPB-01 and 177Lu-DOTA-PPB-02 to HSA was 
determined using the ultrafiltration method. A fixed concentration of HSA (35 M) was 
incubated at room temperature for 30 min with increasing amounts of radioligand (10-
150 M), prepared by mixing radiolabeled compound (~10 MBq/nmol) with increasing 
amounts of cold compound and ascorbic acid in PBS pH 7.4. The solutions were then 
incubated at room temperature for 30 min before filtration. The affinity of 177Lu-DOTA-
PPB-03 to hTTR was determined using the same ultrafiltration method. A fixed 
concentration of hTTR (5 M) was incubated at room temperature for 30 min with 
increasing amounts of radioligand (10-1000 nM), prepared by mixing radiolabeled 
compound (~10 MBq/nmol) with increasing amounts of cold compound and ascorbic 
acid in PBS pH 7.4. The amount of free radioligand was determined in the filtrate 
allowing calculation of the bound fraction. The counts of the bound fraction were 
plotted against the concentration of the radioligand with a non-linear fitting of the data 
points using Graph Pad Prism software (version 5.01) for determination of the KD 
values.  
Radiolabeling and characterization of plasma protein-binding ligands 
 
 
109 
5.2.7 Displacement Experiments on HSA using Warfarin and 
Ibuprofen 
To estimate the preferential binding site of the compounds on HSA, displacement 
studies were carried out with warfarin (Sigma-Aldrich) and ibuprofen (Sigma-Aldrich, 
purity ≥98%) respectively, both used as sodium salts. These drugs served as specific 
markers for HSA binding sites Sudlow’s site I (warfarin) and Sudlow’s site II 
(ibuprofen), respectively [5.8]. HSA, warfarin and ibuprofen were dissolved in PBS (pH 
7.4). The concentration of HSA was 70 M for investigating 177Lu-DOTA-PPB-01 and 
140 M for investigating 177Lu-DOTA-PPB-02 and 177Lu-DOTA-PPB-03, respectively. 
In order to saturate the binding sites, warfarin and ibuprofen were added to the HSA in 
10-fold excess, which means at a concentration of 700 M for the investigation of 
177Lu-DOTA-PPB-01 and 1.4 mM for the investigation of 177Lu-DOTA-PPB-02 and 
177Lu-DOTA-PPB-03, respectively. After incubation of the mixtures for 30 min at 37 °C 
the binding was determined using the ultrafiltration assay. In each experiment control 
samples were treated equally but incubated without addition of the competitor. The 
result of the bound fraction in the control sample was set as 100% and the percentage of 
the radioligand bound to HSA in experiments performed with warfarin and ibuprofen, 
respectively, was expressed as a percentage of the control value.  
5.2.8 Displacement Experiments on hTTR using L-Thyroxine 
It is known that hTTR has a binding site for the transport of L-thyroxine in blood. The 
binding entity of 177Lu-DOTA-PPB-03 was previously reported to bind to this binding 
pocket of hTTR [5.11]. A displacement assay was performed using a solution of hTTR 
(5 M) and L-thyroxine (50 µM) in PBS followed by addition of 177Lu-DOTA-PPB-03 
(25 L, ~500 kBq, 0.01 nmol, labeled at ~50 MBq/nmol) in a final volume of 250 L. 
A control experiment was carried in parallel using the same mixture, but without the 
addition of L-thyroxine. The solutions were incubated at 37 °C for 30 min and then 
processed using the ultrafiltration assay. Displacement studies on hTTR were not 
performed for 177Lu-DOTA-PPB-01 and 177Lu-DOTA-PPB-02, respectively, due to the 
lack of binding of these radioligands to this protein (Figure 5.4 A). 
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5.2.9 Displacement Experiments using Plasma Protein-Binding 
Entities 
Competition assays for HSA binding were performed with 177Lu-DOTA-PPB-01, 177Lu-
DOTA-PPB-02 and 177Lu-DOTA-PPB-03 using the respective binding entities PPB-01, 
PPB-02 and *PPB-03, a truncated version of PPB-03 [5.24]. 177Lu-DOTA-PPB-03 was 
additionally tested with regard to hTTR binding using *PPB-03 for displacement. The 
concentrations of HSA and hTTR were 140 M and 5 M, respectively, while the 
binding entities were prepared at a 10-fold increased concentration as compared to the 
protein concentration. The mixed solutions were incubated for 30 min at 37 °C and the 
bound fractions of the respective radioligand were determined using the ultrafiltration 
assay. 
5.2.10 In Vivo Studies 
In vivo experiments were approved by the local veterinarian department and conducted 
in accordance with the Swiss law of animal protection. Female Balb/c mice at the age of 
5 weeks were obtained from Charles River Laboratories (Sulzfeld, Germany). The mice 
received standard rodent chow (Kliba Nafag, Switzerland) ad libitum. For in vivo 
SPECT/CT scans, mice were anesthetized with a mixture of isoflurane (1.5-2.0%) and 
oxygen. 
5.2.11 Blood Clearance 
Blood clearance of the 177Lu-labeled ligands (DOTA-PPB-01, DOTA-PPB-02 and 
DOTA-PPB-03, respectively) was determined in three mice per compound. The 
radioligands were prepared at the specific activity of 10 MBq/nmol. After labeling, 
ascorbic acid (2.4 µg per 10 MBq) was added to avoid radiolysis. Mice were 
intravenously injected with the radioligands diluted in PBS pH 7.4 (10 MBq, 1 nmol, 
100 L per mouse). Blood samples (1 L) were taken in triplicate from the tail vein at 3 
min, 1 h, 2 h, 4 h, 8 h and 24 h after injection of the radioligand, using 1 L-capillaries. 
In the case of 177Lu-DOTA-PPB-01 and 177Lu-DOTA-PPB-03 blood sampling was also 
performed at later time points. The collected blood samples were measured in a -
counter (Perkin Elmer, Wallac Wizard 1480). Assuming that the total blood volume of a 
mouse would be ~2 mL, the results were listed as percentage of injected activity per 2 
mL of blood (% IA/2 mL). The total injected activity was determined by measuring a 
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defined volume of the original injection solution at the same time as the blood samples 
resulting in decay corrected values. The blood concentration values were analyzed and 
fitted with a bi-compartmental model using the PK solver software to obtain an area 
under the curve (AUC) over the time period of interest and extrapolated to infinite (0-∞) 
and the blood half-lives [5.26]. As a control, three mice were injected with 177Lu-DOTA 
(10 MBq, 1 nmol, 100 µL per mouse) and blood samples were taken after 3 min, 15 min 
30 min, 1 h and 2 h.  
5.2.12 SPECT/CT Imaging Studies.  
Imaging studies were performed using a four-head, multiplexing, multipinhole small-
animal SPECT camera (NanoSPECT/CT™, Mediso Medical Imaging Systems, 
Budapest, Hungary). Each head was outfitted with a tungsten-based aperture of nine 1.4 
mm-diameter pinholes and a thickness of 10 mm. The energy peaks for the camera were 
set at 56.1 keV (± 10%), 112.9 keV (± 10%) and 208.4 keV (± 10%). The compounds 
were labeled with 177Lu at the specific activity of 20 MBq/nmol and diluted to 20 
MBq/100 L (~1 nmol injected per mouse). SPECT/CT scans of 40 min duration were 
performed 4 h after injection of mice followed by CT scans which lasted for 7.5 min. 
The images were acquired using the Nucline software (version 1.02, Mediso Ltd., 
Budapest, Hungary). The real-time CT reconstruction used a cone-beam filtered 
backprojection. The reconstruction of SPECT data was performed using the HiSPECT 
software (version 1.4.3049, Scivis GmbH, Göttingen, Germany). Images were prepared 
using the VivoQuant post-processing software (version 2.5, inviCRO Imaging Services 
and Software, Boston, U.S.). A Gauss post-reconstruction filter (full width at half 
maximum = 1 mm) was applied for the presentation of the SPECT image and the scale 
was adjusted to allow the best visualization of the radioligands distribution. 
5.3 Results 
5.3.1 Preparation of 177Lu-Labeled Ligands  
The radiochemical purity of 177Lu-DOTA-PPB-01, 177Lu-DOTA-PPB-02, 177Lu-DOTA-
PPB-03 and 177Lu-DOTA, labeled at a specific activity of 50 MBq/nmol, was ≥97%. 
The HPLC retention times of 177Lu-DOTA-01, 177Lu-DOTA-PPB-02 and 177Lu-DOTA-
Chapter 5 
 
 
112 
PPB-3 were determined as 11.8 min, 11.3 min and 10.1 min respectively (Figure 5.2 
and Table 5.2). 
 
Figure 5.2. HPLC chromatograms of (A) 177Lu-DOTA-PPB-01, (B) 177Lu-DOTA-
PPB-02 and (C) 177Lu-DOTA-PPB-03 with corresponding retention times. 
Table 5.2. Summary of the in Vitro Properties of the 177Lu-Labeled 
Ligands  
 177Lu- 
DOTA- 
PPB-01 
177Lu- DOTA- 
PPB-02 
177Lu- DOTA- 
PPB-03 
177Lu- DOTA 
 
HPLC retention times [min] 11.8 11.3 10.1 0.5** 
LogD value -3.15 ± 0.04 -4.02 ± 0.02 <-5 <-5 
Plasma protein binding [%] 93 ± 1.5 70 ± 0.6 94 ± 0.6 <1 
HSA binding [%] 95 ± 0.6 83 ± 0.6 57 ± 0.6 <1 
Human α1-AGP [%] 39 ± 9.6 13 ± 4.5 4.0 ± 1.1 <1 
Human Transthyretin* [%] 9.0 ± 1.0 7.0 ± 2.1 50 ± 0.6 <1 
* also referred to as prealbumin; ** TLC Rf value 
5.3.2 Stability of 177Lu-Labeled Ligands  
Stability experiments revealed that 177Lu-DOTA-PPB-01 in PBS pH 7.4 (10 MBq/250 
L) was not sufficiently stable as only 88% intact compound were found after 4 h and 
this amount dropped further to 32% intact compound after 48 h. The addition of 
ascorbic acid increased the stability of 177Lu-DOTA-PPB-01 significantly demonstrated 
by 97% completely intact after 4 h and 88% after 48 h. 177Lu-DOTA-PPB-02 (10 
MBq/250 L) showed a similar behavior. Without ascorbic acid the product peak 
quickly decreased to 94% after 4 h and dropped further to 42% after 48 h. Stability was 
increased by addition of ascorbic acid resulting in 97% intact compound after 4 h and 
87% after 48 h. 177Lu-DOTA-PPB-03 (10 MBq/250 L) revealed to be more stable with 
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>98% intact product after 4 h and still >75% after 48 h. The addition of ascorbic acid 
improved the stability allowing to maintain the compound completely intact (>98%) 
over the whole time of investigation (Figure 5.3). 
 
Figure 5.3. Results of the stability experiments performed with (A) 177Lu-DOTA-
PPB-01, (B) 177Lu-DOTA-PPB-02 and (C) 177Lu-DOTA-PPB-03. The stability was 
evaluated for the three radioligands diluted in PBS (10 MBq/250 L), with and 
without the addition of the scavenger ascorbic acid, after incubation of up to 48 h.  
With the addition of ascorbic acid (3 mg) all radioligands were stable even when diluted 
at high activity concentration (250 MBq/500 L). 177Lu-DOTA-PPB-01 and 177Lu-
DOTA-PPB-02 were almost completely intact (>97%) after 4 h and showed only slight 
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degradation after 24 h (>90% and >92% intact radioligand, respectively). Both 
radioligands remained relatively stable showing ~88% intact product at 48 h. Due to the 
high stability shown for 177Lu-DOTA-PPB-03 at low activity concentrations, this 
compound was also evaluated at high activity concentration (250 MBq/500 L) without 
addition of ascorbic acid. It was shown that this radioligand remained largely intact 
(~91%) after 4 h, but after 24 h only ~55% of intact radioligand was determined, 
however, when ascorbic acid was added the radioligand remained intact (>98%) over 48 
h. All the three radioligands were stable (>95%) in human plasma over 24 h and even 
after 48 h, a high fraction of these radioligands were still intact (>93%). 
5.3.3 n-Octanol/PBS Distribution Coefficients  
All radioligands revealed to be hydrophilic as confirmed by the logD values found to be 
below -3 (Table 5.2). 177Lu-DOTA-PPB-01 was the least hydrophilic (-3.15 ± 0.04), 
followed by 177Lu-DOTA-PPB-02 (-4.01 ± 0.03). The logD values of 177Lu-DOTA-
PPB-03 and 177Lu-DOTA could not be determined (<-5) as the radioactivity was only 
detectable in the hydrophilic phase. Based on the statistical analysis the logD values of 
the three radioligands were significantly different (p<0.05). 
5.3.4 Determination of Plasma Protein Binding of the Radioligands 
The binding capacities of the radioligands as well as of the 177Lu-DOTA complex were 
evaluated using total human plasma and solutions of the most important proteins 
including HSA, 1-AGP and hTTR, which are responsible for drug binding (Figure 5.4 
A, Table 5.1). 177Lu-DOTA-PPB-01 bound to a high extent to human plasma (93 ± 
1.5%). It was found by the performance of ultrafiltration assays with a solution of HSA 
(700 µM) only, that the binding to HSA (95 ± 0.6%) was most prominent. 177Lu-DOTA-
PPB-01 bound also to 1-AGP (39 ± 9.6%) as determined by ultrafiltration using an 1-
AGP solution. The binding to hTTR was considered negligible with a bound fraction of 
only 9.0 ± 1.0%. In the case of 177Lu-DOTA-PPB-02, the plasma protein-bound fraction 
was with 70 ± 0.6% clearly lower when using full plasma. The bound fraction was, 
however, increased to 83 ± 0.6% when a HSA solution was used. The binding of 177Lu-
DOTA-PPB-02 to 1-AGP (13 ± 4.5%) and to hTTR (7 ± 2.1%) was very low. 177Lu-
DOTA-PPB-03 showed significant binding to human plasma proteins (94 ± 0.6%) in 
full plasma but when solutions of single plasma proteins were investigated, it was 
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revealed, that the fraction bound to HSA was only 57 ± 0.6%. The fraction bound to 
hTTR was, however, 50 ± 0.6%. Binding to 1-AGP was considered negligible also for 
this radioligand (4.0 ± 1.1%). Plasma protein binding of 177Lu-DOTA was not observed 
(<1%) in plasma. Control experiments of the filter assay were performed after 
incubation of the radioligands in PBS. False positive results due to unspecific binding of 
the radioligands to the filter membrane were excluded by the fact that all the three 
radioligands completely passed through the membrane. 
 
Figure 5.4. (A) Fraction of radioligands bound to proteins in full plasma as well as 
to specific plasma proteins determined by a filter assay. These values were 
calculated based on the measurement of the filtered fraction (i.e. free fraction) and 
expressed as the percentage of the corresponding loading solutions, which were set 
to 100%.  (B) Results of the binding at different ratios between HSA and radioligand 
revealed relative plasma protein-binding affinities of 0.08 for 177Lu-DOTA-PPB-02 
and 0.59 for 177Lu-DOTA-PPB-03 as compared to 177Lu-DOTA-PPB-01 set to 1. 
5.3.5 Relative Binding Affinity to Plasma Proteins 
The percentage of bound radioligand (177Lu-DOTA-PPB-01, 177Lu-DOTA-PPB-02 and 
177Lu-DOTA-PPB-03, respectively) was determined and presented as three different 
semi-log binding plots (Figure 5.4 B). 177Lu-DOTA-PPB-01 and 177Lu-DOTA-PPB-03 
were almost completely bound to plasma proteins (~93% and ~94%, respectively) at the 
highest ratios of [HSA]/[radioligand] when the concentration of HSA was in the 
physiological range of 700 µM. Under the same experimental conditions ~70% of 
177Lu-DOTA-PPB-02 was bound to HSA. When the HSA concentration was lowered so 
that the ratio between HSA and the radioligand was 1000, 177Lu-DOTA-PPB-01 and 
177Lu-DOTA-PPB-03 were still bound with >80% and >65%, respectively. The binding 
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of 177Lu-DOTA-PPB-02 was, however, decreased to <20%. Decreasing the ratio 
between HSA and the radioligand further to 100 resulted in ~30% binding for 177Lu-
DOTA-PPB-01 and ~17% binding for 177Lu-DOTA-PPB-03 whereas the binding of 
177Lu-DOTA-PPB-02 was <5%. The half-maximum binding (50%) was obtained at 
[HSA]/[radioligand] ratios of 234, 3270, and 396 for 177Lu-DOTA-PPB-01, 177Lu-
DOTA-PPB-02 and 177Lu-DOTA-PPB-03, respectively.  The relative plasma protein-
binding affinities of 177Lu-DOTA-PPB-02 and 177Lu-DOTA-PPB-03 were 0.08 and 
0.59, respectively, as compared to 177Lu-DOTA-PPB-01 which was set to 1 (Table 5.3).  
5.3.6 Determination of the Affinity of the Radioligands to HSA and 
hTTR 
The absolute binding affinities (KD values) of 
177Lu-DOTA-PPB-01 and 177Lu-DOTA-
PPB-02 to HSA and the affinity of 177Lu-DOTA-PPB-03 to hTTR were determined 
using an ultrafiltration assay. KD values of 
177Lu-DOTA-PPB-01 (5.0 ± 1.4 µM) and 
177Lu-DOTA-PPB-02 (54.1 ± 19.4 µM) for HSA differed by one order of magnitude, 
however, both values were still in the micromolar range. The KD value of 
177Lu-DOTA-
PPB-03 was in the sub-micromolar range (0.425 ± 0.082 µM) with regard to the binding 
affinity to hTTR. 
Table 5.3. Affinity values for total plasma proteins, HSA and hTTR 
determined by ultrafiltration.  
 DOTA-PPB-
01 
DOTA-PPB-
02 
DOTA-PPB-
03 
Binding to HSA: KD [M] 5.0 ± 1.4 54.1 ± 19.4 - 
Binding to hTTR: KD [M] - - 0.425 ± 0.082 
Relative plasma protein binding 
affinity* 
1 0.08 0.59 
* full plasma involving all plasma proteins 
5.3.7 Displacement Experiments using Warfarin and Ibuprofen 
The binding of 177Lu-DOTA-PPB-01 to HSA was not significantly reduced when 
competed with warfarin as shown by the fact that more than 90% of the radioligand was 
found to be bound (control set as 100%). However, this radioligand was almost 
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completed displaced when competed with ibuprofen resulting in <20% binding to HSA 
binding (Figure 5.5 A). 177Lu-DOTA-PPB-02 was displaced ~50% by warfarin, while 
only ~10% of the compound was bound to HSA when competed with an excess of 
ibuprofen. In the case of 177Lu-DOTA-PPB-03 about ~50% and <30% was bound when 
warfarin and ibuprofen, respectively, were used as competitors (Figure 5.5 A).  
5.3.8 Displacement Experiments on hTTR using L-Thyroxine 
In the absence of L-tyroxine used as a competitor, ~50% of the radioligand was bound 
to hTTR. The addition of L-tyroxine reduced the binding of 177Lu-DOTA-PPB-03 to 
10%. This indicates that 177Lu-DOTA-PPB-03 binds to the same binding pocked of 
hTTR as does L-tyroxine (Figure 5.5 A). 
5.3.9 Displacement Experiments using Plasma Protein-Binding 
Entities 
The 177Lu-DOTA-PPB-01 and 177Lu-DOTA-PPB-02 were displaced from their binding 
site on HSA resulting in only 14% and <10% bound compound when co-incubated with 
excess PPB-01 and PPB-02, respectively (Figure 5.5 B). The binding of 177Lu-DOTA-
PPB-03 to HSA was not reduced by the addition of excess sPPB-03, indicating that 
177Lu-DOTA-PPB-03 does not bind specifically to HSA. However, the binding of 177Lu-
DOTA-PPB-03 to hTTR was displaced when it was co-incubated with sPPB-03. Under 
these conditions less than 10% of the total 177Lu-DOTA-PPB-03 was bound to hTTR 
(Figure 5.5 B). 
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Figure 5.5. Bound fractions of 177Lu-DOTA-PPB-01, 177Lu-DOTA-PPB-02 and 
177Lu-DOTA-PPB-03, respectively, determined after incubation with a 10-fold 
excess of the competitor for 30 min at 37°C followed by a filter assay and calculated 
as the percentage of a control experiment (set to 100%) performed without addition 
of competitor. (A) All three radioligands were incubated with HSA and warfarin and 
ibuprofen, respectively. In addition, 177Lu-DOTA-PPB-03 was incubated with hTTR 
and L-thyroxine. (B) All three radioligands were incubated with HSA and PPB-01, 
PPB-02 and sPPB-03, respectively. In addition, 177Lu-DOTA-PPB-03 was incubated 
with hTTR and *PPB-03. 
5.3.10 In Vivo Blood Clearance 
The pharmacokinetic profile of 177Lu-DOTA-PPB-01, 177Lu-DOTA-PPB-02 and 177Lu-
DOTA-PPB-03 were evaluated and compared to the excretion profile of 177Lu-DOTA 
using normal mice in order to assess how the in vitro properties correlate with the in 
vivo pharmacokinetic properties. All three plasma-binding radioligands showed a 
delayed plasma clearance as compared to 177Lu-DOTA (Figure 5.6). The latter was 
quickly cleared from the blood, being no longer detectable 2 h after administration. The 
blood concentration of 177Lu-DOTA-PPB-01 decreased very slowly, showing biphasic 
pharmacokinetics, well consistent with previous findings [5.19]. Within the first hour 
period, the radioactivity concentration dropped to 54.0 ± 9.8% IA/2 mL and remained 
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constant over a long period, showing still 41.6 ± 3.0% IA/2 mL after 8 h. The activity 
concentration decreased to 19.2 ± 4.1% IA/2 mL and to 7.2 ± 1.0% IA/2 mL after 24 h 
and 48 h, respectively. After 96 h the blood level of 177Lu-DOTA-PPB-01 (1.0 ± 0.2% 
IA/2 mL) was negligible and not significantly above the detection limit of the γ-counter. 
In comparison, 177Lu-DOTA-PPB-02 showed a faster excretion profile over the first 
hour (26.2 ± 5.2% IA/2 mL at 1 h p.i.),  followed by a slow excretion phase resulting in 
almost complete excretion of the radioligand (0.8 ± 0.2% IA/2 mL) after 8 h. 177Lu-
DOTA-PPB-03 was initially cleared very quickly (40.8 ± 5.7% IA/2 mL at 1 h p.i.) 
followed by a moderate excretion profile as compared to 177Lu-DOTA-PPB-02 resulting 
in remaining activity concentrations of 14.1 ± 0.9% IA/2 mL at 4 h p.i. and 4.6 ± 3.1% 
IA/2 mL at 8 h p.i..  
 
 
Figure 5.6. Results of the in vivo clearance of 177Lu-DOTA-PPB-01, 177Lu-DOTA-
PPB-02, 177Lu-DOTA-PPB-03 and 177Lu-DOTA determined over a period of 24 (A) 
and 96 (B) hours. The blood concentration is reported as % of the injected activity 
(%IA). All plasma protein-binding radioligands had significantly longer blood half-
lives as compared to the blood half-life of 177Lu-DOTA.  
 
The acquired data were fitted using the PK solver software. For all the radioligands the 
best fit was obtained with a bi-compartmental model. The pharmacokinetic values, 
AUC0-∞, the T1/2, alpha and the T1/2, beta were extrapolated from the fitting of the 
experimentally obtained plasma clearance data (Table 5.4). The T1/2,alpha of the 
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compounds were not significantly different (<0.05 h for all the radioligands). The 
T1/2,beta of 
177Lu-DOTA-PPB-01 was ~15.8 h, demonstrating a significantly extended 
circulating time as compared to 177Lu-DOTA which showed a T1/2,beta value of ~0.4 h. 
The T1/2, beta values of 
177Lu-DOTA-PPB-02 and 177Lu-DOTA-PPB-03 were ~1.1 h and 
~2.3 h, respectively. As a consequence of these different excretion profiles, the AUC0-∞ 
values were significantly increased in all three cases of plasma protein-binding 
radioligands as compared to 177Lu-DOTA (~0.1 nmol/mL·h). 
Table 5.4. Blood Clearance Parameters Calculated Using PK Solver 
Software.  
Radioligand 
AUC0-∞ 
[nmol/mL·h] 
T1/2, alpha * 
[h] 
T1/2, beta* 
[h] 
177Lu-DOTA-PPB-01 7.13 ± 0.64 0.05 ± 0.02 15.83 ± 2.56 
177Lu-DOTA-PPB-02 0.40 ± 0.07 0.03 ± 0.01 1.14 ± 0.10 
177Lu-DOTA-PPB-03 0.99 ± 0.24 0.01 ± 0.02 2.33 ± 0.44 
177Lu-DOTA 0.09 ± 0.04 0.01 ± 0.202 0.48 ± 0.12 
* T1/2 alpha/beta refers to the biological half-lives of the ligands. 
 
5.3.11 SPECT/CT Imaging Studies 
SPECT scans were performed 4 h after injection of 20 MBq (1 nmol) of the 177Lu-
labeled radioligands (Figure 5.7). The highest retention of activity in the blood pool and 
the heart was visible in the mouse which received 177Lu-DOTA-PPB-01 (Fig. 5.7 A). 
177Lu-DOTA-PPB-02 (Fig. 5.7 B) and 177Lu-DOTA-PPB-03 (Fig. 5.7 C) showed clearly 
less retention in the blood which was in agreement with the quantitative investigation of 
the clearance. In contrast to compound 177Lu-DOTA-PPB-03 which was almost entirely 
excreted 4 h after injection, there was activity visible in the intestinal tract in mice 
which were injected with 177Lu-DOTA-PPB-02. 
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Figure 5.7. Maximal intensity projections (MIPs) of SPECT/CT scans obtained of 
Balb/c mice 4 h after injection of (A) 177Lu-DOTA-PPB-01, (B) 177Lu-DOTA-PPB-02 
and (C) 177Lu-DOTA-PPB-03, respectively. (H: heart; BP: blood pool; Bl: urinary 
bladder; Int: intestinal tract; F: feces) 
5.4 Discussion 
In this study, we investigated three different plasma protein-binding entities in vitro and 
in vivo. The aim was to compare their characteristics in view of their use for 
modification of radiopharmaceuticals in order to enhance the blood circulation time.  
The radiolabeling of the three DOTA-functionalized plasma protein-binding ligands 
was achieved at a high specific activity (50 MBq/nmol) with high radiochemical purity 
(>98%). The stability of the radioligands up to 48 hours was guaranteed when ascorbic 
acid was added. Based on the in vitro results, it appeared that the 4-iodo-phenyl butyric 
acid group rendered the 177Lu-DOTA-PPB-01 slightly more lipophilic than the other 
plasma protein binders (Table 5.2). 177Lu-DOTA-PPB-01, carrying the HSA binding 
entity developed by Dumelin et al. [5.19], proved to bind to a large extent to HSA 
(~95%) and binding to 1-AGP (~40%) was also observed. 177Lu-DOTA-PPB-02 bound 
to a lesser extent to HSA (~84%) and 1-AGP (~13%), respectively, indicating that the 
iodine substituent in the aromatic ring is responsible for the enhanced plasma protein 
binding properties of 177Lu-DOTA-PPB-01. These findings are in agreement with a 
study in which the replacement of the iodine by an ethynyl group reduced the affinity to 
the protein of interest significantly even though the ethynyl group was thought to act as 
a halogen bioisostere [5.22].  
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The higher extent of binding of 177Lu-DOTA-PPB-02 to pure HSA if compared to full 
plasma (~83% and ~70%, respectively) could be due to the presence of endogenous 
ligands in plasma, which can compete and cooperate with drug binding altering binding 
capacity of HSA [5.27] and to the different HSA concentration that can be in the range 
of 600 M to 700 M in plasma. The binding of 177Lu-DOTA-PPB-03 to full plasma 
was similar to that of 177Lu-DOTA-PPB-01, however, in this case about 50% of the 
binding could be ascribed to specific interaction with hTTR whereas the remaining 
fraction was due to the unspecific interaction with HSA, as discussed later.  
Investigations using variable dilutions of full plasma and a fixed amount of radioligand 
allowed comparison of the three radioligands by presenting the relative affinities 
(Figure 5.4 B, Table 5.3). 177Lu-DOTA-PPB-01 showed the highest plasma protein 
binding (relative binding 1.0) whereas the binding affinity of 177Lu-DOTA-PPB-03 
(relative binding 0.59) and 177Lu-DOTA-PPB-02 (relative binding 0.08) was clearly 
reduced as compared to 177Lu-DOTA-PPB-01. These experiments demonstrate that the 
percentage of plasma protein-bound radioligands is critically dependent on the amount 
of radioligand as shown in Figure 5.4 B. This should be kept in mind when using 
radioligands with plasma protein binding entities in vivo.  
Determination of KD values using a filter assay revealed a KD value of 5.0 ± 1.4 µM for 
177Lu-DOTA-PPB-01 (Table 5.3), similar to what was determined by Dumelin et al. 
[5.19] who used the method of Isothermal Titration Calorimetry (ITC) for determination 
of the KD value of the same albumin-binding entity coupled to acetic acid or 5-
carboxyfluoroscein instead of a DOTA chelator. The KD value of
 177Lu-DOTA-PPB-02 
for HSA was 10-fold increased (54.2 ± 19.4 µM, Table 5.3) indicating significantly 
lower binding affinity.  
The affinity of 177Lu-DOTA-PPB-03 for hTTR was, however, very high (KD = 425 ± 
82.4 nM, Table 5.3). This value was in line with the literature in which this binding 
entity was proposed for the first time [5.11]. These findings indicate why the relative 
binding of 177Lu-DOTA-PPB-03 to plasma proteins (0.59) was higher than for 177Lu-
DOTA-PPB-02 (0.08) even though its binding to HSA was weak (~50%; Table 5.3) and 
unspecific. 
The displacement of the radioligands from HSA after the addition of warfarin or 
ibuprofen, respectively, allowed identification of the preferential Sudlow’s binding site 
I and II, respectively. 177Lu-DOTA-PPB-01 and 177Lu-DOTA-PPB-02 were both 
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displaced (>90%) by ibuprofen, coherent with extended aromatic conformation of the 
compounds [5.8]. 177Lu-DOTA-PPB-03 was partially displaced by both warfarin and 
ibuprofen. Both 177Lu-DOTA-PPB-01 and 177Lu-DOTA-PPB-02 were displaced (>90%) 
from HSA by their respective binding entities, while 177Lu-DOTA-PPB-03 was only 
marginally displaced (<20%) by *PPB-03. These findings confirmed that the binding of 
177Lu-DOTA-PPB-03 to HSA is mostly due to unspecific interactions. On the contrary 
177Lu-DOTA-PPB-03 was, indeed, displaced from hTTR by its binding entity *PPB-03 
and by the site-marker thyroxine (>80 and >60%, respectively).  
The in vitro findings correlated well with the in vivo data which showed an enhanced 
blood clearance for all plasma protein binding compounds as compared to 177Lu-DOTA. 
177Lu-DOTA-PPB-01 showed the slowest kinetics in line with the tightest plasma 
protein-binding properties followed by 177Lu-DOTA-PPB-03 and 177Lu-DOTA-PPB-02. 
All three plasma protein-binding entities are promising to be used in combination with 
radiopharmaceuticals and may be employed dependent on the desired modulation of the 
kinetics. 
5.5 Conclusion  
Three plasma protein-binding radioligands, potentially useful for modification of 
radiopharmaceuticals, were evaluated in this study. Our results confirmed the 
exceptionally high affinity of the 4-iodo-phenyl-butyric acid entity (PPB-01) to HSA 
while replacement of the halogen by an ethynyl entity (PPB-02) reduced the plasma 
protein binding significantly. A promising approach is the application of PPB-03 which 
binds with high affinity to hTTR. The fact that the concentration of plasma proteins may 
vary between different species and under conditions of inflammation, infection and 
cancer, should be kept in mind, however, when developing plasma-binding 
radiopharmaceuticals. This is particularly important for hTTR- and α1-AGP-binding 
compounds since these proteins are present at significantly lower concentrations as 
compared to HSA. Future studies in PD Dr. Cristina Müller’s laboratory will be focused 
on the application of these binding entities in combination with clinically relevant 
targeting agents for diagnostic and therapeutic purposes in nuclear medicine.  
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Chapter 6  
Preliminary in vitro evaluation of TKIs-
177Lu-folate combination therapy in FR-
positive cancer cells 
6.1 Introduction 
Cancer onset, progression and metastasis can be due to alterations in the cell cycle [6.1], 
and it is nowadays known that a key role in cell cycle regulation is played by tyrosine 
kinases (TKs) [6.2,6.3]. These proteins act as catalyzers of reaction where a phosphate 
molecule is transferred from an ATP molecule to a tyrosine residue of a target protein, 
thus leading to signal transduction. They can be receptor TKs (RTKs), as the epidermal 
growth factor receptor (EGFR), the fibroblast growth factor receptor 1 (FGFR-1), the 
vascular endothelial growth factor receptor 1 and 2 (VEGFR-1 and 2) and the platelet-
derived growth factor receptor  (PDGFR-, and cytoplasmic TKs, as Src, Abl and Lck 
[6.4]. The final effect of RTKs activation is cell growth stimulation and division [6.5]. 
While in healthy cells TKs activity is strictly regulated so that cell proliferation and 
apoptosis are balanced, in several cancer tissues TKs are up-regulated or undergo gain-
of-function mutations [6.6,6.7]. For these reasons, TKs have been regarded as suitable 
molecular targets for cancer treatment and several inhibitors have been developed. They 
can be classified into two classes: (i) small organic compounds (TKIs) that act as ATP-
mimicking inhibitors or growth factors binders, inhibiting this way the binding of ATP; 
(ii) monoclonal antibodies (mAbs) that act as growth factor-mimicking inhibitors and 
preventing this way RTK activation [6.8,6.9]. 
The blockage of tyrosine kinases signal has been reviewed as a valuable strategy for 
enhancing external beam radiotherapy efficacy in tumors [6.10]. In particular it was 
shown in previous studies that combination of EGFR inhibitors could enhance 
radiotherapeutic effect [6.11]. It is known that EGFR overexpression generally 
correlates with decreased survival, resistance to radiotherapy and treatment failure 
[6.12]. It was also demonstrated that the downstream signal of EGFR directly increases 
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radiation resistance in tumor cells, because radiation induces the release of EGFR 
ligands and thus the signaling that results in the activation of transcription factors 
responsible for enhanced tumor survival and DNA repair [6.13–6.15]. Going more into 
detail, the mechanism of EGFR inhibition and the possible mechanism underlying the 
radio sensitizing effect has been reviewed by Zheng et al. [6.16]. The cell response to 
radiation can be summarized in the 4Rs: repair of radiation damage, redistribution, 
reoxygenation, and repopulation [6.17]. EGFR inhibitors have been suggested to play a 
role in all these 4 mechanisms: (i) inhibition of DNA damage repair, (ii) blocking the 
cell in the G1 phase, not allowing redistribution, and prolongation in the radiation-
induced G2 phase, (iii) inhibition of pro-survival downstream pathways PI3K/AKT and 
RAS/RAF/MEK/MAPK, and (iv) inhibition of reoxygenation through the blocking of 
tumor neo-angiogenesis [6.18].  
Inhibition of PDGFR, another RTK, was also demonstrated to specifically increase 
cytotoxicity in glioblastoma cells treated with external radiations. The downstream 
mechanisms underlying this effect are unknown, but a possible way is the activation by 
PDGFR of Stat5 which is implicated in radioresistance in Bcr-Abl-expressing cells 
[6.19,6.20]. 
Radiosensitivity depends on intrinsic and extrinsic factors to cancer cells [6.21] and the 
modulation of tumor microenvironment is a strategy to increase radiation 
responsiveness [6.22]. Inhibition of PDGFR- for example is related to the decrease in 
the interstitial pressure in solid tumors, thus facilitating the cellular up-take of cytotoxic 
agents, including for example radiopharmaceuticals [6.23,6.24]. 
For all the aforementioned reasons, it is rational to develop a combination therapy using 
TKIs and internal radiation therapy. Moreover, the use of combined-modality regimens 
in cancer therapy is a valuable strategy to overcome the emergence of resistance to 
therapy [6.25]. Targeting the cancer cell on diverse molecular path mechanisms makes 
the cell less prone to developing survival mechanisms. At the same time, the use of 
multimodality therapies allows to decrease the dosage of single therapies, thus reducing 
side-effects. 
In this study, in particular, we preliminarily investigated the combination of two TKIs, 
imatinib and G475, with a therapeutic radiofolate, 177Lu-cm10 [6.26]. The combination 
was tested on folate positive tumor cells, namely KB and IGROV-1, cervical and 
ovarian cancer cell lines, respectively.  
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Imatinib, structure in figure 6.1, is a small molecule that selectively inhibits the catalytic 
action of c-Abl kinase, stem cell factor receptor (c-Kit) and PDGFR tyrosine kinase. Its 
use is approved in the clinics for the treatment of patients suffering from chronic 
myeloid leukemia and gastrointestinal stromal tumors, where its targets are 
constitutively activated [6.27]. Since protein kinases are frequently deregulated in 
several tumor types, its use is currently under investigation in other tumor types. In 
particular PDGF family members play an important role in meningiomas, gliomas, 
melanomas, neuroendocrine tumors, sarcomas and ovarian, pancreatic, gastric, lung 
breast and prostate carcinomas [6.28–6.30].  
 
Figure 6.1. Chemical structure of imatininb. 
G475, figure 6.2, is a novel quinazoline-based multi-tyrosine kinase inhibitor, 
developed by a team of the Department of Pharmaceutical and Pharmacological 
Sciences of the University of Padova [6.9]. This compound was selected as one of the 
most promising ones for its multi-targeting capacity and cell-death induction on a panel 
of cells. In particular, G475 targets EGFR, FGFR-1, PDGFR- and Abl [6.9]. Its IC50 
values on a panel of tumor cell lines derived from breast (MCF-7) and colon (HT-29) 
carcinomas, cervical cancer (HeLa), and from murine hepatocellular carcinoma (BNL 1 
ME A.7R.1), were in the low micromolar range.  
 
 
Figure 6.2. Chemical structure of G475 [6.9]. 
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177Lu-cm10, figure 6.3, is a therapeutic radiofolate developed in the group of PD Dr. 
Cristina Müller  [6.26] for the treatment of folate receptor α (FR) positive cancer cells. 
The FR is expressed on a variety of tumor types (e.g. ovarian, endometrial, lung cancer, 
etc. [6.31]) and for this reason it is regarded as a promising tumor target in targeted  
therapy (TRT).  
 
Figure 6.3. Chemical structure of cm10 [6.26]. 
The vitamin, folic acid, has been derivatized and used as a diagnostic tool with 
radionuclides in the clinics and as therapeutic probe in preclinical studies 
[6.26,6.32,6.33]. The translation to the clinics of radiofolate therapy has been hindered 
by the nephrotoxicity of this therapy, due to the overexpression of the FR in the kidneys 
and its renal clearance [6.34]. Several strategies are under development to overcome 
this issue, one of these is the development of combination therapies, which could allow 
the administration of a lower dose of radionuclides to patients, thus reducing side 
effects.   
The cell lines used in this study, KB and IGROV-1, overexpressing the folic acid 
receptor, were extensively studied and characterized, and they were proved to be 
suitable for preclinical investigations in FR-targeting research over a panel of FR 
positive cell lines [6.35]. 
The TKs overexpression of the tested cell lines, KB and IGROV-1, was checked using 
the database GENEVESTIGATOR, which allows to check the gene overexpression 
profile in several cell types [6.36]. This allowed to verify if the molecular targets of 
imatinib and G475 were overexpressed on the tested cell lines. KB cells were found to 
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highly overexpress EGFR and Abl, and had a medium expression of PDGFR-, FGFR1 
and c-Kit. IGROV-1 cells have a high expression of EGFR, FGFR-1 and Abl, and a 
medium expression of PDGFR-and c-Kit. 
In this very preliminary study we tested first the single agents, imatinib, G475 and 
177Lu-cm10, on the selected cell lines, KB and IGROV-1, and afterwards we combined 
the TKIs and radionuclide therapy. For the evaluation of cells viability, we used a 
colorimetric (MTT) assay. 
6.2 Materials and Methods 
All reagents and solvents were purchased from Sigma-Aldrich. All chemicals used for 
the radiolabeling were metal-free and obtained from Sigma-Aldrich (Germany) in 
Suprapur quality. Analytical radio-HPLC was performed on a Merck-Hitachi HPLC 
equipped with a L-6200A pump, a L-3000 Photo Diode Array detector and a Berthold 
LB 508 radiometric detector. For this purpose, a reversed-phase C18 column (5 μm, 4.6 
mm x 150 mm, XTerraTM MS, Waters, USA) was used. The ligand cm10 was 
synthetized in the group of PD Dr. Cristina Müller, while imatinib and G475 were 
synthetized in the group of Prof. Giovanni Marzaro (UniPD). The experiments with the 
cells were performed in duplicates, with the exception of the combination therapy, 
which were performed only once and for this reason the results are given as indicative 
values only. 
6.2.1 Preparation of radioligands 
Radiolabeling of cm10 was performed at a specific activity (Sp. Act.) of 50 MBq/nmol. 
177Lu in HCl 0.05 M, obtained from Isotope Technologies Garching ITG GmbH, was 
added to sodium acetate 0.5 M, pH 8.0, in a ratio of 5:1, to a final pH of ~4.5. After 
mixing, the folate was added (1 mM stock solution) and the reaction vial was incubated 
for 10 minutes, 95 °C. Quality control of 177Lu-cm10 was carried out by reversed-phase 
high-performance liquid chromatography (RP-HPLC) analysis (Merck LaChrom 
HPLC) using a C18 column (5 μm, 4.6 mm x 150 mm, XTerraTM MS, Waters USA). 
The eluent consisted of acetonitrile (solvent A) and 0.1% TFA in H2O (solvent B). A 
gradient of 5-80% A and 95-20% B was used over 15 min at a flow rate of 1.0 mL/min. 
5 L of Na-DTPA (5 mM), for the complexation of unreacted 177Lu, were added to the 
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radioligand, before dilutions for cell experiments. Radiolabeling of 177Lu-DTPA was 
carried out as for cm10, but after preparing the reaction mixture (177Lu in HCl 0.05 M 
and Na-Acetate 0.5 M) Na-DTPA 5 mM was added in a ligand/radionuclide ratio of 
~150.  
6.2.2 Cell lines and cell culture 
FR-overexpressing cell lines (KB and IGROV-1) were cultured in folate-deficient 
RPMI medium (FFRPMI, Cell Culture Technologies GmbH, Gravesano, Switzerland) 
supplemented with 10% fetal calf serum, L-glutamine, and antibiotics. Routine cell 
culture was performed twice a week using trypsin for detachment of the cells. 
KB cells (cervical carcinoma cell line, subclone of HeLa cells, ACC-136) were 
purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, 
Germany). IGROV-1 cells (human ovarian carcinoma cell line) were a kind gift of Dr. 
Gerrit Jansen (Department of Rheumatology, Free University Medical Center, 
Amsterdam, The Netherlands).  
6.2.3 Dilutions of imatinib and G475 
Stock solutions of imatinib and G475 were prepared weekly at the concentration of 50 
mM in dimethyl sulfoxide (DMSO). For cell experiments the stock solutions were 
diluted to 500 M (dilution 1:100) in water with the addition of DMSO to avoid the 
compounds precipitation. Briefly, 40 L of stock solution were diluted with 60 L of 
DMSO and then 3.9 mL of water were slowly added, mixing the solution with the tip. 
These solutions were then filtered through 0.22 m sterile filters and thus sterilized. 
Further dilutions were then performed with sterile medium to the desired 
concentrations.  
6.2.4 Evaluation of anti-proliferative activity of TKIs 
Cells were seeded into 96-well plates (2500 cells per well in a volume of 200 L). After 
24 h of incubation, the medium was removed and replaced with various concentrations 
of the tested compounds, 1 and 10 M for G475 and 1, 10, 50 and 100 M for imatinib, 
diluted in medium. Control cells were supplemented with fresh medium. The 
compounds were left on the cells for 1, 2, 3, 4, 5 and 6 days, incubating the plates at 37 
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°C, 5% CO2. In each plate also blank wells, where no cells were added, were treated 
equally to control wells.  
After the incubation period, 30 L of thiazolyl blue tetrazolium bromide (MTT) reagent 
(5 mg/mL, Sigma Aldrich) were added to each well and incubated for 3-5 hours, 37 °C, 
5% CO2. The supernatant was removed, and the crystals dissolved adding 200 L of 
DMSO. Color intensity was measured in a microplate reader, =560 nm (PerkinElmer, 
VICTOR X).  Blank absorbance was subtracted from test wells intensities and control 
set as 100 %. 
6.2.5 Evaluation of anti-proliferative activity of 177Lu-cm10 and 177Lu-
DTPA 
The cells (KB and IGROV-1) were seeded out in the same conditions as described in 
6.2.3. The radioligands were prepared as described in 6.2.1 and diluted before 
incubation on the cells. For KB cells 177Lu-cm10 and 177Lu-DTPA were diluted in 
medium without additives and incubated on the cells at an activity concentration of 
0.01, 0.05 and 0.15 MBq/mL. For IGROV-1 they were diluted to 5, 15 and 30 
MBq/mL.  
After removing the medium, the cells were washed with 200 L PBS and the diluted 
radioligands were added and incubated for 4 hours at 37 °C, 5% CO2. After the 
incubation period, the cells supernatant was removed, the cells washed with PBS (200 
L) and finally fresh medium (200 L) was added. The cells were then incubated for 4 
days, 37 °C, 5% CO2. The MTT reagent was then added and the plates developed as 
described in paragraph 6.2.3 for cell viability measurements. 
6.2.6 Evaluation of 177Lu-cm10-TKIs combination 
To evaluate the synergistic effect of 177Lu-cm10 and imatinib or G475 therapy, KB and 
IGROV-1 cells were seeded out as previously described (§ 6.2.3). Activity was 
incubated and left on the cells for 4 hours, 0.10 MBq/mL and 5 MBq/mL on KB and 
IGROV-1, respectively. After washing the cells, imatinib or G475 were incubated in a 
range of concentrations from 1-100 M and 1-1000 nM, respectively, and left for 4 
days. After the period of incubation, the cells were treated as described in § 6.2.3 for 
MTT development.  
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6.2.7 Cell-uptake studies 
KB and IGROV-1 cells were seeded out into 12-well plates (700’000 cells per well) and 
let to grow overnight. After removing the medium, the cells were washed with PBS and 
G475 or imatinib were added to the cells (975 L, 0.1-10 M and 50-100 M, 
respectively) and incubated for 10 min. 975 L of medium were added to control wells. 
Finally, 177Lu-cm10 (25 L, 1.5 MBq/mL, Sp. Act. 50 MBq/nmol) was added to each 
well and plates were incubated at 37 °C, 5% CO2. After 1 or 4 hours the supernatant 
was discarded, cells washed with cold PBS (3x), lysed with NaOH (1 M, 1 mL) and 
transferred to RIA tubes for measurement in a -counter (PerkinElmer Wallac Wizard 
1480). After homogenization of the cell suspensions by vortexing, the concentration of 
proteins was determined for each sample using a Micro BCA Protein Assay Kit (Pierce, 
Thermo Scientific) in order to standardize the measured radioactivity to the average 
content of protein (0.3 mg) in a single well. The results were expressed as the 
percentage of total added radioactivity.  
6.3 Results 
6.3.1 Preparation of radioligand 
177Lu-cm10 could be prepared with high radiochemical purity (>99.5%). The 
radioligand was eluted with a retention time of 9.6 min,  and no scavenger was added to 
guarantee stability, as it was previously demonstrated that it was stable (>95%) over 4 
hours [6.26].  
6.3.2 Evaluation of anti-proliferative activity of TKIs 
Anti-proliferative activity was evaluated with MTT assay on both cell lines with 
imatinib and G475, alone. The inhibitors were left on the cells from 1 to 6 days, in order 
to evaluate the time necessary to induce cell death. Both inhibitors were initially tested 
at 1 and 10 M concentration, and afterwards imatinib was tested at 50 and 100 M, as 
well, since the lower concentrations were not effective (figure 6.4).  
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Figure 6.4 Results of MTT assay on KB (A) and IGROV-1 (B) cells after treatment 
with imatinib and G475. 
KB cells were not affected by imatinib when its concentration was 1 or 10 M, with % 
of viable cells not distinguishable from controls. When the imatinib concentration was 
increased to 50 and 100 M, ~70 and 35% of cells, respectively, were alive after 1 day 
of treatment. When the treatment was imatinib 50 M, ~50% of cells was still alive 
after 2 days, and this percentage increased after 3, 4, and 5 days with a percentage of 
viable cells of 55.07 ± 3.5%, 73.57 ± 3.6% and 75.49 ± 10.8%, respectively. In the 
plates treated with imatinib 100 M, the cell number was drastically decreased after two 
and three days (7.69 ± 0.3% and <1%, respectively). A weak recovery could be 
observed after day 5 and 6 (3.48 ± 0.8% and 5.42 ± 0.6%). 
IGROV-1 cells were more sensitive to imatinib than KB when the same inhibitor 
concentrations were applied. At 50 M after 1 day of treatment 70% of cells were alive, 
but this number decreased dramatically to 25.9 ± 2.9% and 7.86 ± 2.9% after 2 and 3 
days of treatment. In this case no cell recovery was observed. The highest concentration 
of imatinib (100 M) killed irreversibly all the cells after 2 and 3 days 4.82 ± 0.2% and 
0.09 ± 0.1%.  
Both cell lines proved to be very sensitive to G475, with ~50% of survived cells after 1 
day of treatment, independently on the applied concentration (1 or 10 M). ~20% of KB 
cells were alive after 3 days, with this value slowly decreasing to 1.90 ±1.3% after 6 
days of treatment with G475 1 M. The same trend was observed with the highest 
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concentration, with only ~12% of cells alive after 2 days and <1% after 4 days.  Cell 
survival for IGROV-1 was <5% after 3 days of treatment with G475 10 M, while a 
slow recovery was observed with 1 M treatment: 10.2 ± 10.5%, 30.3 ± 4.4%, 27.1 ±2 
% and 44.5 ±3.7 % after 3, 4, 5 and 6 days, respectively. 
The values of absorbance of control wells were measured in time, in order to check their 
growth, figure 6.5. After 4 days from the seeding out, the cells reached the plateau; for 
this reason, for IC50 determination, plates were measured after 4 days of incubation. 
 
Figure 6.5. Control cells growth. 
The IC50 of imatinib could not be accurately defined, because in these assays even when 
the highest concentration of compound was applied on the cells (100 M), ~40% of the 
cells were still alive. Higher concentrations of the compound were not prepared to avoid 
the precipitation in the medium. For IGROV-1, instead, the value was determined and 
was found to be 64.63 ±8.4 M. The IC50 of G475 on KB and IGROV-1 was in the low 
micromolar range, ~0.16 and 0.26 M, respectively. 
6.3.3 Evaluation of anti-proliferative activity of 177Lu-cm10 and 177Lu-
DTPA 
To evaluate the proper radioactivity concentration to incubate with cells in the 
combination therapy, a preliminary assay with 177Lu-cm10 alone was carried out. The 
use of the radioligand 177Lu-cm10, which is known to be internalized into the FR+ cells 
[6.26], was also compared to 177Lu-DTPA, which is not internalized (figure 6.6).  
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Figure 6.6. Results of MTT assays on KB (A) and IGROV-1 (B) cells after 
incubation of cells with 177Lu-cm10 or 177Lu-DTPA. 
KB cells were incubated with 177Lu-cm10 or 177Lu-DTPA at the concentrations of 0.01, 
0.05 and 0.15 MBq/mL. At the lowest radioactivity concentration, no cell death was 
observed in the cells treated with either 177Lu-cm10 or 177Lu-DTPA. 177Lu-DTPA was 
not able to induce cell death even at the highest activity concentration (0.15 MBq/mL), 
conditions that enabled 177Lu-cm10 to kill ~55% of cells. 
IGROV-1 cells were incubated with 177Lu-cm10 or 177Lu-DTPA at the concentration of 
5, 15 and 30 MBq/mL of activity. When the lowest concentration was applied, ~65% of 
cells were alive if the radiofolate was used, while no cell death was observed with 
177Lu-DTPA. At 15 and 30 MBq/mL of radiofolate only 17.1 ± 4.9% and 1.1 ± 0.4%, 
respectively, survived. A higher survival rate at these concentrations was observed for 
cells treated with 177Lu-DTPA, 73.6 ± 9.5% and 37.8 ± 5.9%. 
6.3.4 Combination therapy 
The effect after combining 177Lu-cm10 and one of the two inhibitors was evaluated. In 
all cases a sum effect was observed. In particular, for IGROV-1 we could measure a 
change in the IC50 values with both compounds. IC50 of imatinib on IGROV-1 was ~64 
M, this value was reduced, even if not significantly, to 50.70 ±17.0 M, when also 
177Lu-cm10 was applied on the cells, see figure 6.7. 
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Figure 6.7. Curve of cell survival for IGROV-1 with imatinib alone and in 
combination with 177Lu-cm10. 
In the case of G475 on IGROV-1 cells the value was changed from ~260 nM to ~215 
nM. On KB cells the use of both agents on the cells was influenced by the strong effect 
of radiation that in these experiments caused the death of ~70% of cells, differently 
from what was expected. For this reason, it was not possible to determine accurately the 
new IC50 values. Nevertheless, it was observed that when imatinib was 1 M only 
~9.8% of cells were alive, so the effect was summed to that of radiation alone. 
Moreover, at this concentration imatinib alone was not effective.  G475 combined with 
177Lu-cm10, caused the death of >90% of KB cells when the inhibitor was applied at the 
concentration of 100 nM. This concentration of inhibitor alone was not able to induce 
significantly different cell death from untreated wells.  
6.3.5 Cell-uptake studies 
To verify that no interference in the cell-uptake of the radiofolate could happen because 
of the presence of either imatinib or G475 on the cells, uptake studies were carried out 
comparing cells where only the radiofolate was added, with cells where imatinib (50 or 
100 M) or G475 (0.1 or 10 M) was previously added, figure 6.8.  
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Figure 6.8. Results of the up-take studies on KB (upper part) and IGROV-1 (on the 
bottom) cells.  
The uptake of 177Lu-cm10 on both KB and IGROV-1 cells was not influenced when 
imatinib was added. No significant difference could be observed between control and 
treated cells after 1 and 4 hours of incubation. G475 did not influence the uptake of the 
radiofolate on IGROV-1 cells, while a slight decrease was observed in KB cells at the 
higher inhibitor concentration (10 M), ~58 and 63% of controls after 1 and 4 hours, 
respectively.   
6.4 Discussion  
Small molecule-based radionuclide therapy is a valuable tool for the delivery of 
cytotoxic doses of radiations selectively to tumor tissues [6.37]. The success of the 
therapy can be limited by the accumulation of radioactivity into undesired tissues, like 
the kidneys as in the case of folic acid [6.34]. The development of combined regimens 
therapy is a valuable tool to decrease the single agent amounts, thus reducing side 
effects.  
In this study we preliminary evaluated in vitro the combination therapy of a therapeutic 
radiofolate, 177Lu-cm10, with two multi-tyrosine kinases inhibitors, imatinib and G475 
on KB and IGROV-1 cells. We first evaluated the efficacy of the single agents on the 
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cells. Imatinib was found to be effective at concentrations >50 M, while G475 had 
IC50 values in the low micromolar range, in agreement with previously published data. 
The difference between the potency of the two agents might be due to the different 
overexpression of the molecular targets of the two inhibitors. Further studies in our 
laboratory will be dedicated to the accurate study of the tyrosine kinases overexpression 
of the cells lines. Further investigations will also be carried out to study the cell cycle 
arrest, in order to determine the mechanism of action of the compounds on these 
peculiar cell lines. The cell cycle arrest studies will also be useful to understand the 
possible synergistic effect with radiations.  
Very preliminary assays, where imatinib or G475 and 177Lu-cm10 were both incubated 
on the cells, were carried out. These assays could not give a quantitative value of the 
synergistic effect of the two therapeutic agents, because a more extensive in vitro 
evaluation should be performed, which was not the aim of this preliminary study. 
Nevertheless, an encouraging trend could be observed, because in all the cases as 
described in the results, a sum effect was observed. The IC50 of imatinib used alone had 
an IC50 of ~64 M, while the combination of imatinib with 177Lu-cm10 (5 MBq/mL) 
had a lower IC50 value of ~50 M) and made possible to kill >90% of KB cells when 
imatinib was 1 M and radioactivity alone induced ~70% of cell death. Normally this 
concentration of imatinib induced no cell death (100 % of survival).  When we 
combined G475 with 177Lu-cm10 (5 MBq/mL) the IC50 of IGROV-1 was 215 nM, while 
the inhibitor alone, which was already very potent, had an IC50 of 260 nM. Also on KB 
cells a sum effect was observed: at a concentration of G475 of 100 nM with 177Lu-cm10 
(0.10 MBq/mL) >90% of KB cells were dead, when 177Lu-cm10 alone induced 70% of 
cell death and G475 100 nM alone did not induce any cell death (100% of cells alive).  
Cell uptake studies were also carried out to exclude a possible influence in the uptake of 
the radiofolate from the cells when also the inhibitors were present. Imatinib did not 
influence the uptake at all, as no significant difference was visible between controls and 
cells where imatinib (50 or 100 M) was added. The same was observed for G475 on 
IGROV-1. This was not true for KB cells which, when the highest concentration of 
G475 was added (10 M), had a significantly lower uptake of the radiofolate, 58 and 
63% of controls after 1 and 4 hours, respectively (see figure 6.8). This was probably due 
to the decreased cell activity after the addition of a toxic amount of the compound (IC50 
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value was in the low micromolar range). Such a high concentration will not be used in 
further combination studies. 
On the ground of these data, further in vitro studies will be carried out. In particular, 
more combination experiments will be carried out to clearly define IC50 values; 
furthermore, a study to understand how the agents cooperate in inducing cell death will 
be carried out in our laboratory. If further in vitro studies will confirm this trend, in vivo 
studies will be carried out. In this context it will be possible to observe not only the 
intrinsic synergistic effect, but also the extrinsic one [6.22], which is believed to play a 
crucial role in the radiosensitivity of cells to radiation [6.21].   
6.5 Conclusion 
In this study two multi-tyrosine kinase inhibitors were tested alone and in combination 
with a therapeutic radiofolate, 177Lu-cm10, on FR-positive cell lines. The tested 
compounds were imatinib, a clinically established inhibitor, and a novel compound 
G475, synthetized at the Department of Pharmaceutical and Pharmacological Sciences 
at the University of Padova. With cells survival assays (MTT) we could demonstrate 
that both compounds could induce cell death with different effectiveness and potency, 
with G475 being the most potent. The combination of the agents had a sum effect in 
inducing cell death. Further in vitro studies will be carried out to confirm these 
preliminary results and to study the mechanisms on interaction of the agents.  
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Conclusions 
In the first part of this thesis project a new method for the production of carrier-free 
radionuclides was studied in order to make the production of radionuclides for medical 
use possible at the ISOL facility under construction at LNL-INFN.  
Secondary targets for the ion beams deposition were produced. Two target materials 
were chosen, sodium chloride and activated carbon. The materials were transformed 
into solid discs thanks to powder compression, with the help of the binder PVA in the 
case of activated carbon and without any additive for sodium chloride. The discs were 
characterized and proved to have good mechanical and superficial properties. These 
substrates could be used for the deposition of stable accelerated yttrium, copper and 
iodine. The test-bench of the SPES project, named Front End (FE), was used for the 
production of stable beams. All three elements under test, yttrium, iodine and copper, 
could be ionized, collected on the secondary targets, and detected after dissolution, even 
if with difficult repeatability caused by instability of the FE. These results however 
represent a very positive starting point for the validation of the “ISOL” part of the 
ISOLPHARM project, making available secondary targets in which desired isotopes are 
collected. 
In chapter 4 the chemical purification process for yttrium and strontium, developed to 
get rid of isobaric contaminants, was described. NaTi, an inorganic material could be 
synthetized and three types of NaTis were produced, depending on the temperatures of 
synthesis (100, 150 and 175 °C). The resin was tested using the cold elements, for this 
reason analytical methods for strontium (GF-AAS) and for yttrium (UV-Vis) were 
developed. The affinity of NaTi for strontium was very high at basic pH, but also 
yttrium was retained in the resin. Yttrium could be recovered from NaTi only at acidic 
pH (<4), when also strontium was released. For this reason, the separation of the two 
ions turned out to be more challenging. An evaluation of the behavior of the two ions in 
the pH range from 0 to 4 made it possible to find a condition where the two ions 
behaved differently (pH 2). Its use for the purification of 89Sr from the stable 
contaminant 89Y, considering the very low amount of 89Y in the solution, was 
satisfactory with a reduction of >60% of the initial amount. NaTi as a resin for a 
90Sr/90Y generator was also studied and a process developed. In the hypothesized system 
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it will be possible to elute pure 90Y after 90Sr decay. The weak point of the system is the 
loss of 90Sr in the loading process that needs to be optimized.  
In the second part of this thesis, two different strategies to improve TRT were studied: 
firstly, a set of serum protein binders were radiolabeled and characterized in vitro and in 
vivo, secondly a preliminary study for the combination therapy of TKIs with TRT was 
carried out. 
The evaluation of three plasma protein-binding radioligand was described in chapter 5. 
It was demonstrated that PPB-01 had extraordinary binding properties to HSA while 
PPB-02, where a halogen was replaced by an ethynyl entity, had reduced plasma 
proteins binding affinity. The third entity PPB-03 was found to bind with high affinity 
to hTTR and has a very promising pharmacokinetic properties. Future studies in PD Dr. 
Cristina Müller’s laboratory will be focused on the application of these binding entities 
in combination with clinically relevant targeting agents for diagnostic and therapeutic 
purposes in nuclear medicine.  
Finally, two multi-tyrosine kinase inhibitors were tested alone and in combination with 
a therapeutic radiofolate, 177Lu-cm10, on FR-positive cell lines. The compounds chosen 
for the project were imatinib, a clinically established inhibitor, and a novel compound 
G475, synthetized at the Department of Pharmaceutical and Pharmacological Sciences 
at the University of Padova. MTT assays proved that both compounds could induce cell 
death with different effectiveness and potency, with G475 being the most potent. The 
combination of the agents with 177Lu-cm10 had a sum effect in inducing cell death. 
Further in vitro studies will be carried out to confirm these preliminary results and to 
study the mechanisms of interaction of the agents.  
